<!DOCTYPE html>
<html><head><meta charset="UTF-8">
<title>Earnings Call ë²ˆì—­</title>
<style>
    body { font-family: Arial; margin: 40px; background-color: #fdfdfd; }
    h1 { text-align: center; }
    h2 { margin-top: 50px; color: #003366; }
    h3 { color: #333; }
    table { border: 1px solid #ddd; width: 100%; border-collapse: collapse; }
    th { background: #f0f0f0; padding: 10px; border-bottom: 2px solid #ccc; }
    td { padding: 10px; border-bottom: 1px dotted #ccc; vertical-align: top; }
    p { line-height: 1.6; }
    hr { margin: 50px 0; border: none; border-top: 1px solid #ccc; }
    .back-button {
        display: inline-block;
        background-color: #5f5f5f;
        color: white;
        padding: 10px 16px;
        border-radius: 6px;
        text-decoration: none;
        font-weight: 500;
        box-shadow: 0 2px 6px rgba(0,0,0,0.1);
        margin-bottom: 30px;
    }
</style>
</head><body>
<a href="../../index.html" class="back-button">â†</a>
<h1>ğŸ“„ Earnings Call Transcript ë²ˆì—­ ê²°ê³¼</h1>

    <h2>ğŸ“Š Presentation</h2>
    <table style="width:100%; border-collapse:collapse; margin-bottom: 40px;">
        <tr>
            <th style="width:50%; border-bottom: 2px solid #333;">Original</th>
            <th style="width:50%; border-bottom: 2px solid #333;">Translation</th>
        </tr>
        <tr><td>Abbott Laboratories (ABT) Q4 2025 Earnings Call January 22, 2026 9:00 AM EST<br><br>Company Participants<br><br>Michael Comilla - Vice President of Investor Relations.</td><td># Abbott Laboratories (ABT) 2025ë…„ 4ë¶„ê¸° ì‹¤ì  ë°œí‘œ ì»¨í¼ëŸ°ìŠ¤ ì½œ<br><br>**ì¼ì‹œ:** 2026ë…„ 1ì›” 22ì¼ ì˜¤ì „ 9ì‹œ (ë¯¸êµ­ ë™ë¶€ í‘œì¤€ì‹œ)<br><br>## íšŒì‚¬ ì°¸ì„ì<br><br>**Michael Comilla** - íˆ¬ìì ê´€ê³„ ë‹´ë‹¹ ë¶€ì‚¬ì¥<br><br>---<br><br>*[ì°¸ê³ : ì œê³µëœ í…ìŠ¤íŠ¸ì—ëŠ” íšŒì‚¬ ì°¸ì„ì ì†Œê°œ ë¶€ë¶„ë§Œ í¬í•¨ë˜ì–´ ìˆìŠµë‹ˆë‹¤. ì „ì²´ ì»¨í¼ëŸ°ìŠ¤ ì½œ ë‚´ìš©ì´ ì œê³µë˜ë©´ ê³„ì†í•´ì„œ ë²ˆì—­í•´ ë“œë¦¬ê² ìŠµë‹ˆë‹¤.]*</td></tr>
<tr><td>Robert Ford - Chairman, President & CEO<br>Philip Boudreau - CFO & Executive VP of Finance<br><br>Conference Call Participants<br><br>Larry Biegelsen - Wells Fargo Securities, LLC, Research Division<br>David Roman - Goldman Sachs Group, Inc., Research Division<br>Robert Marcus - JPMorgan Chase & Co, Research Division<br>Vijay Kumar - Evercore ISI Institutional Equities, Research Division<br>Danielle Antalffy - UBS Investment Bank, Research Division<br>Matthew Taylor - Jefferies LLC, Research Division<br>Travis Steed - BofA Securities, Research Division<br>Joanne Wuensch - Citigroup Inc., Research Division<br>Joshua Jennings - TD Cowen, Research Division<br><br>Presentation<br><br>Operator<br><br>Good morning, and thank you for standing by.</td><td># ì‹¤ì  ë°œí‘œ ì»¨í¼ëŸ°ìŠ¤ ì½œ ì°¸ì„ì<br><br>## íšŒì‚¬ ì¸¡ ì°¸ì„ì<br>- Robert Ford - íšŒì¥, ì‚¬ì¥ ê²¸ CEO<br>- Philip Boudreau - CFO ê²¸ ì¬ë¬´ ë‹´ë‹¹ ë¶€ì‚¬ì¥<br><br>## ì• ë„ë¦¬ìŠ¤íŠ¸ ì°¸ì„ì<br>- Larry Biegelsen - Wells Fargo Securities, LLC, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>- David Roman - Goldman Sachs Group, Inc., ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>- Robert Marcus - JPMorgan Chase & Co, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>- Vijay Kumar - Evercore ISI Institutional Equities, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>- Danielle Antalffy - UBS Investment Bank, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>- Matthew Taylor - Jefferies LLC, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>- Travis Steed - BofA Securities, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>- Joanne Wuensch - Citigroup Inc., ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>- Joshua Jennings - TD Cowen, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br><br>---<br><br>## ë°œí‘œ<br><br>**ì‚¬íšŒì**<br><br>ì¢‹ì€ ì•„ì¹¨ì…ë‹ˆë‹¤. ì°¸ì„í•´ ì£¼ì…”ì„œ ê°ì‚¬í•©ë‹ˆë‹¤.</td></tr>
<tr><td>Welcome to Abbott's Fourth Quarter 2025 Earnings Conference Call. [Operator Instructions]<br><br>This call is being recorded by Abbott. With the exception of any participants' questions asked during the question-and-answer session, the entire call, including the question-and-answer session, is material copyrighted by Abbott. It cannot be recorded or rebroadcast without Abbott's expressed written permission. I would now like to introduce Mr. Mike Comilla, Vice President, Investor Relations. Michael Comilla<br>Vice President of Investor Relations. Good morning, and thank you for joining us.</td><td># Abbott 2025ë…„ 4ë¶„ê¸° ì‹¤ì  ë°œí‘œ ì»¨í¼ëŸ°ìŠ¤ ì½œ<br><br>**ìš´ì˜ì:**<br>Abbottì˜ 2025ë…„ 4ë¶„ê¸° ì‹¤ì  ë°œí‘œ ì»¨í¼ëŸ°ìŠ¤ ì½œì— ì˜¤ì‹  ê²ƒì„ í™˜ì˜í•©ë‹ˆë‹¤. [ìš´ì˜ì ì•ˆë‚´ì‚¬í•­]<br><br>ë³¸ ì»¨í¼ëŸ°ìŠ¤ ì½œì€ Abbottì— ì˜í•´ ë…¹ìŒë˜ê³  ìˆìŠµë‹ˆë‹¤. ì§ˆì˜ì‘ë‹µ ì„¸ì…˜ ì¤‘ ì°¸ê°€ìë“¤ì˜ ì§ˆë¬¸ì„ ì œì™¸í•œ ì§ˆì˜ì‘ë‹µ ì„¸ì…˜ì„ í¬í•¨í•œ ì „ì²´ ì»¨í¼ëŸ°ìŠ¤ ì½œì€ Abbottì˜ ì €ì‘ê¶Œìœ¼ë¡œ ë³´í˜¸ë˜ëŠ” ìë£Œì…ë‹ˆë‹¤. Abbottì˜ ëª…ì‹œì  ì„œë©´ í—ˆê°€ ì—†ì´ëŠ” ë…¹ìŒí•˜ê±°ë‚˜ ì¬ë°©ì†¡í•  ìˆ˜ ì—†ìŠµë‹ˆë‹¤. <br><br>ì´ì œ íˆ¬ìì ê´€ê³„ ë‹´ë‹¹ ë¶€ì‚¬ì¥ì´ì‹  Mike Comilla ì”¨ë¥¼ ì†Œê°œí•´ ë“œë¦¬ê² ìŠµë‹ˆë‹¤.<br><br>**Michael Comilla (íˆ¬ìì ê´€ê³„ ë‹´ë‹¹ ë¶€ì‚¬ì¥):**<br>ì¢‹ì€ ì•„ì¹¨ì…ë‹ˆë‹¤. ì°¸ì„í•´ ì£¼ì…”ì„œ ê°ì‚¬í•©ë‹ˆë‹¤.</td></tr>
<tr><td>With me today are Robert Ford, Chairman and Chief Executive Officer; and Phil Boudreau, Executive Vice President, Finance, and Chief Financial Officer. Robert and Phil will provide opening remarks. Following their comments, we'll take your questions. Before we get started, some statements made today may be forward-looking for purposes of the Private Securities Litigation Reform Act of 1995, including the expected results for 2026. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements.</td><td>ì €ì™€ í•¨ê»˜ Robert Ford íšŒì¥ ê²¸ ìµœê³ ê²½ì˜ìì™€ Phil Boudreau ì¬ë¬´ë‹´ë‹¹ ë¶€ì‚¬ì¥ ê²¸ ìµœê³ ì¬ë¬´ì±…ì„ìê°€ ì°¸ì„í–ˆìŠµë‹ˆë‹¤. Robertì™€ Philì´ ëª¨ë‘ë°œì–¸ì„ í•˜ê³ , ì´í›„ ì§ˆì˜ì‘ë‹µ ì‹œê°„ì„ ê°–ê² ìŠµë‹ˆë‹¤. ì‹œì‘í•˜ê¸° ì „ì—, ì˜¤ëŠ˜ ì¼ë¶€ ë°œì–¸ì€ 1995ë…„ ì¦ê¶Œì†Œì†¡ê°œí˜ë²•ì— ë”°ë¥¸ ë¯¸ë˜ì˜ˆì¸¡ì§„ìˆ ì— í•´ë‹¹í•  ìˆ˜ ìˆìœ¼ë©°, ì—¬ê¸°ì—ëŠ” 2026ë…„ ì˜ˆìƒ ì‹¤ì ì´ í¬í•¨ë©ë‹ˆë‹¤. AbbottëŠ” ì´ëŸ¬í•œ ë¯¸ë˜ì˜ˆì¸¡ì§„ìˆ ì´ ì‹¤ì œ ê²°ê³¼ê°€ ë¯¸ë˜ì˜ˆì¸¡ì§„ìˆ ì— ëª…ì‹œëœ ë‚´ìš©ê³¼ ì¤‘ëŒ€í•˜ê²Œ ë‹¤ë¥¼ ìˆ˜ ìˆëŠ” ìœ„í—˜ê³¼ ë¶ˆí™•ì‹¤ì„±ì˜ ì˜í–¥ì„ ë°›ì„ ìˆ˜ ìˆìŒì„ ì•Œë ¤ë“œë¦½ë‹ˆë‹¤.</td></tr>
<tr><td>Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, Risk Factors to our annual report on Form 10-K for the year ended December 31, 2024. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law. On today's conference call, as in the past, non-GAAP financial measures will be used to help investors understand Abbott's ongoing business performance.</td><td>ì• ë³´íŠ¸ì˜ ì‚¬ì—… ìš´ì˜ì— ì˜í–¥ì„ ë¯¸ì¹  ìˆ˜ ìˆëŠ” ê²½ì œì , ê²½ìŸì , ì •ë¶€ ê·œì œ, ê¸°ìˆ ì  ë° ê¸°íƒ€ ìš”ì¸ë“¤ì€ 2024ë…„ 12ì›” 31ì¼ ì¢…ë£Œëœ íšŒê³„ì—°ë„ì˜ Form 10-K ì—°ì°¨ë³´ê³ ì„œ ì¤‘ í•­ëª© 1A, ìœ„í—˜ìš”ì¸(Risk Factors)ì—ì„œ ë…¼ì˜ë˜ê³  ìˆìŠµë‹ˆë‹¤. ì• ë³´íŠ¸ëŠ” ë²•ë¥ ì—ì„œ ìš”êµ¬í•˜ëŠ” ê²½ìš°ë¥¼ ì œì™¸í•˜ê³ ëŠ” í›„ì† ì‚¬ê±´ì´ë‚˜ ìƒí™© ë³€í™”ë¡œ ì¸í•œ ë¯¸ë˜ì˜ˆì¸¡ì§„ìˆ ì˜ ìˆ˜ì •ì‚¬í•­ì„ ê³µê°œì ìœ¼ë¡œ ë°œí‘œí•  ì˜ë¬´ë¥¼ ì§€ì§€ ì•ŠìŠµë‹ˆë‹¤. ì˜¤ëŠ˜ ì»¨í¼ëŸ°ìŠ¤ ì½œì—ì„œëŠ” ê³¼ê±°ì™€ ë§ˆì°¬ê°€ì§€ë¡œ, íˆ¬ììë“¤ì´ ì• ë³´íŠ¸ì˜ ì§€ì†ì ì¸ ì‚¬ì—… ì„±ê³¼ë¥¼ ì´í•´í•˜ëŠ” ë° ë„ì›€ì„ ë“œë¦¬ê³ ì ë¹„-GAAP ì¬ë¬´ì§€í‘œë¥¼ ì‚¬ìš©í•  ì˜ˆì •ì…ë‹ˆë‹¤.</td></tr>
<tr><td>These non-GAAP financial measures are reconciled with the comparable GAAP financial measures in our earnings news release and regulatory filings from today, which are available on our website at abbott.com. Note that Abbott has not provided the related GAAP financial measures on a forward-looking basis for the non-GAAP financial measures for which it is providing guidance because the company is unable to predict, with reasonable certainty and without unreasonable effort, the timing and impact of certain items, which could significantly impact Abbott's results in accordance with GAAP.</td><td>ì´ëŸ¬í•œ ë¹„-GAAP ì¬ë¬´ ì§€í‘œëŠ” ì˜¤ëŠ˜ ë°œí‘œëœ ì‹¤ì  ë³´ë„ìë£Œ ë° ê·œì œ ì œì¶œ ì„œë¥˜ì—ì„œ ë¹„êµ ê°€ëŠ¥í•œ GAAP ì¬ë¬´ ì§€í‘œì™€ ì¡°ì •ë˜ì–´ ìˆìœ¼ë©°, ì´ëŠ” ë‹¹ì‚¬ ì›¹ì‚¬ì´íŠ¸ abbott.comì—ì„œ í™•ì¸í•˜ì‹¤ ìˆ˜ ìˆìŠµë‹ˆë‹¤. AbbottëŠ” ê°€ì´ë˜ìŠ¤ë¥¼ ì œê³µí•˜ëŠ” ë¹„-GAAP ì¬ë¬´ ì§€í‘œì— ëŒ€í•´ ì „ë§ ê¸°ì¤€ì˜ ê´€ë ¨ GAAP ì¬ë¬´ ì§€í‘œë¥¼ ì œê³µí•˜ì§€ ì•Šì•˜ìŒì„ ìœ ì˜í•˜ì‹œê¸° ë°”ëë‹ˆë‹¤. ì´ëŠ” íšŒì‚¬ê°€ í•©ë¦¬ì ì¸ í™•ì‹¤ì„±ì„ ê°€ì§€ê³ , ê·¸ë¦¬ê³  ê³¼ë„í•œ ë…¸ë ¥ ì—†ì´ëŠ” íŠ¹ì • í•­ëª©ë“¤ì˜ ì‹œê¸°ì™€ ì˜í–¥ì„ ì˜ˆì¸¡í•  ìˆ˜ ì—†ê¸° ë•Œë¬¸ì´ë©°, ì´ëŸ¬í•œ í•­ëª©ë“¤ì€ GAAP ê¸°ì¤€ì— ë”°ë¥¸ Abbottì˜ ì‹¤ì ì— ì¤‘ëŒ€í•œ ì˜í–¥ì„ ë¯¸ì¹  ìˆ˜ ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Unless otherwise noted, our commentary on sales growth refers to organic sales growth, which is defined in the press release issued earlier today. With that, I will now turn the call over to Robert. Robert Ford<br>Chairman, President & CEO<br><br>Thanks, Mike. Good morning, everyone, and thank you for joining us. Before discussing our fourth quarter results, I want to take a moment to reflect on 2025, a year that demonstrated Abbott's leadership in innovation, disciplined execution and strategic actions taken to position the company for sustainable long-term growth. Innovation continues to be the foundation of our success.</td><td>ë³„ë„ë¡œ ì–¸ê¸‰í•˜ì§€ ì•ŠëŠ” í•œ, ë§¤ì¶œ ì„±ì¥ì— ëŒ€í•œ ë…¼ì˜ëŠ” ì˜¤ëŠ˜ ì´ˆ ë°œí‘œëœ ë³´ë„ìë£Œì— ì •ì˜ëœ ìœ ê¸°ì  ë§¤ì¶œ ì„±ì¥ì„ ì˜ë¯¸í•©ë‹ˆë‹¤. ê·¸ëŸ¼ ì´ì œ Robertì—ê²Œ ë§ˆì´í¬ë¥¼ ë„˜ê¸°ê² ìŠµë‹ˆë‹¤.<br><br>Robert Ford<br>íšŒì¥, ì‚¬ì¥ ê²¸ CEO<br><br>Mike, ê°ì‚¬í•©ë‹ˆë‹¤. ì—¬ëŸ¬ë¶„ ì•ˆë…•í•˜ì‹­ë‹ˆê¹Œ, ì°¸ì„í•´ ì£¼ì…”ì„œ ê°ì‚¬í•©ë‹ˆë‹¤. 4ë¶„ê¸° ì‹¤ì ì„ ë…¼ì˜í•˜ê¸°ì— ì•ì„œ, 2025ë…„ì„ ì ì‹œ ë˜ëŒì•„ë³´ê³ ì í•©ë‹ˆë‹¤. ì´ëŠ” Abbottì˜ í˜ì‹  ë¦¬ë”ì‹­, ê·œìœ¨ ìˆëŠ” ì‹¤í–‰ë ¥, ê·¸ë¦¬ê³  ì§€ì† ê°€ëŠ¥í•œ ì¥ê¸° ì„±ì¥ì„ ìœ„í•œ íšŒì‚¬ì˜ í¬ì§€ì…”ë‹ì„ ìœ„í•´ ì·¨í•œ ì „ëµì  ì¡°ì¹˜ë“¤ì„ ì…ì¦í•œ í•œ í•´ì˜€ìŠµë‹ˆë‹¤. í˜ì‹ ì€ ê³„ì†í•´ì„œ ìš°ë¦¬ ì„±ê³µì˜ ê¸°ë°˜ì´ ë˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>In 2025, we achieved several important milestones that strengthen our position for the future, including regulatory approvals for our Volt and TactiFlex Duo PFA products, a new indication for our Navitor TAVR valve, CMS national coverage for TriClip and CardioMEMS, completing enrollment in our pivotal trial to bring a new LAA device to market, filing for FDA approval for our dual glucose-ketone sensor, initiating the pivotal trial of our coronary IVL device, starting the launch sequence in EPD to bring biosimilars to emerging markets and recently starting the launch sequence in Nutrition to bring new products to market that meet evolving consumer preferences.</td><td>2025ë…„ì— ìš°ë¦¬ëŠ” ë¯¸ë˜ë¥¼ ìœ„í•œ ì…ì§€ë¥¼ ê°•í™”í•˜ëŠ” ëª‡ ê°€ì§€ ì¤‘ìš”í•œ ì´ì •í‘œë¥¼ ë‹¬ì„±í–ˆìŠµë‹ˆë‹¤. ì—¬ê¸°ì—ëŠ” Volt ë° TactiFlex Duo PFA ì œí’ˆì— ëŒ€í•œ ê·œì œ ìŠ¹ì¸, Navitor TAVR íŒë§‰ì— ëŒ€í•œ ìƒˆë¡œìš´ ì ì‘ì¦, TriClip ë° CardioMEMSì— ëŒ€í•œ CMS ì „êµ­ ë³´í—˜ ì ìš©, ìƒˆë¡œìš´ LAA ê¸°ê¸°ë¥¼ ì‹œì¥ì— ì¶œì‹œí•˜ê¸° ìœ„í•œ í”¼ë²— ì„ìƒì‹œí—˜ ë“±ë¡ ì™„ë£Œ, ì´ì¤‘ í¬ë„ë‹¹-ì¼€í†¤ ì„¼ì„œì— ëŒ€í•œ FDA ìŠ¹ì¸ ì‹ ì²­, ê´€ìƒë™ë§¥ IVL ê¸°ê¸°ì˜ í”¼ë²— ì„ìƒì‹œí—˜ ê°œì‹œ, ì‹ í¥ ì‹œì¥ì— ë°”ì´ì˜¤ì‹œë°€ëŸ¬ë¥¼ ì¶œì‹œí•˜ê¸° ìœ„í•œ EPD ë¶€ë¬¸ì˜ ì¶œì‹œ ì ˆì°¨ ì‹œì‘, ê·¸ë¦¬ê³  ìµœê·¼ ì§„í™”í•˜ëŠ” ì†Œë¹„ì ì„ í˜¸ë„ë¥¼ ì¶©ì¡±í•˜ëŠ” ì‹ ì œí’ˆì„ ì‹œì¥ì— ì¶œì‹œí•˜ê¸° ìœ„í•œ ì˜ì–‘ ë¶€ë¬¸ì˜ ì¶œì‹œ ì ˆì°¨ ì‹œì‘ì´ í¬í•¨ë©ë‹ˆë‹¤.</td></tr>
<tr><td>2025 was also a year of disciplined execution. We delivered top-tier margin expansion and achieved our original target of double-digit earnings growth in earnings per share despite implementation of new tariffs and heightened market challenges in China. Finally, in 2025, we made important strategic moves to shape Abbott's future. Our announced acquisition of Exact Sciences will allow Abbott to enter and lead in the fast-growing cancer diagnostics market and adds a new high-growth business with an attractive pipeline to the Abbott portfolio. We expect 2026 to be another year powered by innovation, operational excellence and strategic execution.</td><td>2025ë…„ì€ ë˜í•œ ê·œìœ¨ ìˆëŠ” ì‹¤í–‰ì˜ í•œ í•´ì˜€ìŠµë‹ˆë‹¤. ìš°ë¦¬ëŠ” ìµœê³  ìˆ˜ì¤€ì˜ ë§ˆì§„ í™•ëŒ€ë¥¼ ë‹¬ì„±í–ˆìœ¼ë©°, ìƒˆë¡œìš´ ê´€ì„¸ ì‹œí–‰ê³¼ ì¤‘êµ­ ì‹œì¥ì˜ ë†’ì•„ì§„ ë„ì „ ê³¼ì œì—ë„ ë¶ˆêµ¬í•˜ê³  ì£¼ë‹¹ìˆœì´ìµì—ì„œ ë‘ ìë¦¿ìˆ˜ ì„±ì¥ì´ë¼ëŠ” ë‹¹ì´ˆ ëª©í‘œë¥¼ ë‹¬ì„±í–ˆìŠµë‹ˆë‹¤. ë§ˆì§€ë§‰ìœ¼ë¡œ 2025ë…„ì—ëŠ” Abbottì˜ ë¯¸ë˜ë¥¼ í˜•ì„±í•˜ê¸° ìœ„í•œ ì¤‘ìš”í•œ ì „ëµì  ì¡°ì¹˜ë“¤ì„ ì·¨í–ˆìŠµë‹ˆë‹¤. ë°œí‘œëœ Exact Sciences ì¸ìˆ˜ë¥¼ í†µí•´ AbbottëŠ” ë¹ ë¥´ê²Œ ì„±ì¥í•˜ëŠ” ì•” ì§„ë‹¨ ì‹œì¥ì— ì§„ì…í•˜ê³  ì„ ë„í•  ìˆ˜ ìˆê²Œ ë  ê²ƒì´ë©°, ë§¤ë ¥ì ì¸ íŒŒì´í”„ë¼ì¸ì„ ë³´ìœ í•œ ìƒˆë¡œìš´ ê³ ì„±ì¥ ì‚¬ì—…ì„ Abbott í¬íŠ¸í´ë¦¬ì˜¤ì— ì¶”ê°€í•˜ê²Œ ë©ë‹ˆë‹¤. ìš°ë¦¬ëŠ” 2026ë…„ì´ í˜ì‹ , ìš´ì˜ ìš°ìˆ˜ì„±, ê·¸ë¦¬ê³  ì „ëµì  ì‹¤í–‰ìœ¼ë¡œ ì¶”ì§„ë˜ëŠ” ë˜ ë‹¤ë¥¸ í•œ í•´ê°€ ë  ê²ƒìœ¼ë¡œ ê¸°ëŒ€í•©ë‹ˆë‹¤.</td></tr>
<tr><td>As we announced this morning, we forecast the midpoint of our 2026 organic sales growth range to be 7% and the midpoint of our adjusted earnings per share range to reflect 10% growth. I'll now summarize the fourth quarter results in more detail. I'll start with Nutrition, where sales declined in the quarter. Abbott has been in Nutrition business for more than 60 years. And with that history comes experience, not just in times of growth but in times that require navigating challenges. And as I mentioned last quarter, the U.S. pediatric business is seeing an impact from market share loss, partly due to the loss of a large WIC contract last year.</td><td>ì˜¤ëŠ˜ ì•„ì¹¨ ë°œí‘œí•œ ë°”ì™€ ê°™ì´, ë‹¹ì‚¬ëŠ” 2026ë…„ ìœ ê¸°ì  ë§¤ì¶œ ì„±ì¥ë¥  ë²”ìœ„ì˜ ì¤‘ê°„ê°’ì„ 7%ë¡œ, ì¡°ì • ì£¼ë‹¹ìˆœì´ìµ ë²”ìœ„ì˜ ì¤‘ê°„ê°’ì€ 10% ì„±ì¥ì„ ë°˜ì˜í•  ê²ƒìœ¼ë¡œ ì „ë§í•©ë‹ˆë‹¤. ì´ì œ 4ë¶„ê¸° ì‹¤ì ì„ ë³´ë‹¤ ìƒì„¸íˆ ìš”ì•½í•˜ê² ìŠµë‹ˆë‹¤. ë¨¼ì € ì˜ì–‘ ì‚¬ì—…ë¶€í„° ë§ì”€ë“œë¦¬ê² ëŠ”ë°, ì´ë²ˆ ë¶„ê¸°ì— ë§¤ì¶œì´ ê°ì†Œí–ˆìŠµë‹ˆë‹¤. AbbottëŠ” 60ë…„ ì´ìƒ ì˜ì–‘ ì‚¬ì—…ì„ ì˜ìœ„í•´ ì™”ìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì´ëŸ¬í•œ ì—­ì‚¬ì™€ í•¨ê»˜ ì„±ì¥ê¸°ë¿ë§Œ ì•„ë‹ˆë¼ ë„ì „ ê³¼ì œë¥¼ í—¤ì³ë‚˜ê°€ì•¼ í•˜ëŠ” ì‹œê¸°ì— ëŒ€í•œ ê²½í—˜ë„ ì¶•ì ë˜ì–´ ìˆìŠµë‹ˆë‹¤. ì§€ë‚œ ë¶„ê¸°ì— ë§ì”€ë“œë¦° ë°”ì™€ ê°™ì´, ë¯¸êµ­ ì†Œì•„ ì˜ì–‘ ì‚¬ì—…ì€ ì‘ë…„ ëŒ€ê·œëª¨ WIC ê³„ì•½ ìƒì‹¤ë¡œ ì¸í•´ ë¶€ë¶„ì ìœ¼ë¡œ ì‹œì¥ ì ìœ ìœ¨ í•˜ë½ì˜ ì˜í–¥ì„ ë°›ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>But our results this quarter underscore a broader challenge, which is the need to reignite volume growth, a challenge many consumer goods businesses face today. Over the last several years, we've seen manufacturing costs in Nutrition rise, in part due to a post-pandemic-driven surge in commodity cost that remains in our cost base today. We've increased prices to help mitigate the impact of higher manufacturing costs, but those price increases in the current economic environment have become a factor in constraining volume growth. Many consumer goods businesses are facing this dynamic.</td><td>ê·¸ëŸ¬ë‚˜ ì´ë²ˆ ë¶„ê¸° ì‹¤ì ì€ ë” ê´‘ë²”ìœ„í•œ ê³¼ì œë¥¼ ë¶€ê°ì‹œí‚¤ê³  ìˆìŠµë‹ˆë‹¤. ë°”ë¡œ ë§¤ì¶œ ìˆ˜ëŸ‰ ì„±ì¥ì„ ì¬ì í™”í•´ì•¼ í•  í•„ìš”ì„±ì´ë©°, ì´ëŠ” ì˜¤ëŠ˜ë‚  ë§ì€ ì†Œë¹„ì¬ ê¸°ì—…ë“¤ì´ ì§ë©´í•œ ê³¼ì œì…ë‹ˆë‹¤. ì§€ë‚œ ëª‡ ë…„ê°„ ì˜ì–‘ ë¶€ë¬¸ì˜ ì œì¡° ì›ê°€ê°€ ìƒìŠ¹í–ˆëŠ”ë°, ë¶€ë¶„ì ìœ¼ë¡œëŠ” íŒ¬ë°ë¯¹ ì´í›„ ê¸‰ë“±í•œ ì›ìì¬ ë¹„ìš©ì´ í˜„ì¬ê¹Œì§€ë„ ìš°ë¦¬ì˜ ì›ê°€ êµ¬ì¡°ì— ë‚¨ì•„ìˆê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. ìš°ë¦¬ëŠ” ë†’ì•„ì§„ ì œì¡° ì›ê°€ì˜ ì˜í–¥ì„ ì™„í™”í•˜ê¸° ìœ„í•´ ê°€ê²©ì„ ì¸ìƒí–ˆì§€ë§Œ, í˜„ì¬ì˜ ê²½ì œ í™˜ê²½ì—ì„œ ì´ëŸ¬í•œ ê°€ê²© ì¸ìƒì´ ë§¤ì¶œ ìˆ˜ëŸ‰ ì„±ì¥ì„ ì œì•½í•˜ëŠ” ìš”ì¸ì´ ë˜ê³  ìˆìŠµë‹ˆë‹¤. ë§ì€ ì†Œë¹„ì¬ ê¸°ì—…ë“¤ì´ ì´ëŸ¬í•œ ì—­í•™ ê´€ê³„ì— ì§ë©´í•´ ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Higher manufacturing costs led to higher prices, which in turn are suppressing demand as consumers become increasingly more price sensitive. Path is not sustainable in the long term, so we began to make changes in the fourth quarter. Our goal is to transition our business back to one with a more balanced growth profile with volume growth playing a greater role going forward. In the fourth quarter, we began implementing price and promotion initiatives to help start the process of reigniting volume growth.</td><td>ì œì¡° ì›ê°€ ìƒìŠ¹ìœ¼ë¡œ ì¸í•œ ê°€ê²© ì¸ìƒì€ ì†Œë¹„ìë“¤ì˜ ê°€ê²© ë¯¼ê°ë„ê°€ ë†’ì•„ì§€ë©´ì„œ ìˆ˜ìš”ë¥¼ ì–µì œí•˜ëŠ” ê²°ê³¼ë¥¼ ì´ˆë˜í–ˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ê²½ë¡œëŠ” ì¥ê¸°ì ìœ¼ë¡œ ì§€ì† ê°€ëŠ¥í•˜ì§€ ì•Šê¸° ë•Œë¬¸ì—, ì €í¬ëŠ” 4ë¶„ê¸°ë¶€í„° ë³€í™”ë¥¼ ì‹œì‘í–ˆìŠµë‹ˆë‹¤. ì €í¬ì˜ ëª©í‘œëŠ” í–¥í›„ ë¬¼ëŸ‰ ì„±ì¥ì´ ë” í° ì—­í• ì„ í•˜ëŠ”, ë³´ë‹¤ ê· í˜• ì¡íŒ ì„±ì¥ í”„ë¡œí•„ì„ ê°€ì§„ ì‚¬ì—…ìœ¼ë¡œ ì „í™˜í•˜ëŠ” ê²ƒì…ë‹ˆë‹¤. 4ë¶„ê¸°ì— ì €í¬ëŠ” ë¬¼ëŸ‰ ì„±ì¥ì„ ì¬ì í™”í•˜ëŠ” í”„ë¡œì„¸ìŠ¤ë¥¼ ì‹œì‘í•˜ê¸° ìœ„í•´ ê°€ê²© ë° í”„ë¡œëª¨ì…˜ ì´ë‹ˆì…”í‹°ë¸Œë¥¼ ì‹¤í–‰í•˜ê¸° ì‹œì‘í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>To further drive volume growth, we are increasing our focus on innovation, which is an area that was deprioritized for the last few years given the necessary heavy focus on production and supply chain management in this business. Following the launch of 2 new versions of Ensure late last year, we expect to launch at least 8 new products over the course of the next 12 months. We expect performance in the Nutrition to remain challenged in the first half of the year with a return to growth in the second half.</td><td>ë³¼ë¥¨ ì„±ì¥ì„ ë”ìš± ì´‰ì§„í•˜ê¸° ìœ„í•´, ìš°ë¦¬ëŠ” í˜ì‹ ì— ëŒ€í•œ ì§‘ì¤‘ë„ë¥¼ ë†’ì´ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŠ” ì§€ë‚œ ëª‡ ë…„ê°„ ì´ ì‚¬ì—…ë¶€ì—ì„œ ìƒì‚°ê³¼ ê³µê¸‰ë§ ê´€ë¦¬ì— í•„ìˆ˜ì ìœ¼ë¡œ ì§‘ì¤‘í•´ì•¼ í–ˆê¸° ë•Œë¬¸ì— ìš°ì„ ìˆœìœ„ì—ì„œ ë°€ë ¤ë‚¬ë˜ ì˜ì—­ì…ë‹ˆë‹¤. ì‘ë…„ ë§ 2ê°€ì§€ ìƒˆë¡œìš´ ë²„ì „ì˜ ì¸ìŠˆì–´(Ensure) ì œí’ˆ ì¶œì‹œì— ì´ì–´, í–¥í›„ 12ê°œì›” ë™ì•ˆ ìµœì†Œ 8ê°œì˜ ì‹ ì œí’ˆì„ ì¶œì‹œí•  ê³„íšì…ë‹ˆë‹¤. ì˜ì–‘(Nutrition) ì‚¬ì—…ë¶€ì˜ ì‹¤ì ì€ ìƒë°˜ê¸°ì—ëŠ” ê³„ì† ì–´ë ¤ì›€ì„ ê²ªì„ ê²ƒìœ¼ë¡œ ì˜ˆìƒë˜ë©°, í•˜ë°˜ê¸°ì— ì„±ì¥ì„¸ë¡œ ë³µê·€í•  ê²ƒìœ¼ë¡œ ì „ë§í•©ë‹ˆë‹¤.</td></tr>
<tr><td>While this transition back to a more sustainable volume-driven business has consequences on our near-term results, these are the right steps to take to better position the business for long-term success. Moving to Diagnostics, where sales declined 3.5% due to the anticipated year-over-year decline in COVID testing sales. Core Lab Diagnostics grew 3.5%, achieving a third consecutive quarter of accelerating growth and building steady momentum as we enter 2026. For the full year, excluding China, growth in Core Lab Diagnostics was 7%, reflecting durable demand in markets around the world.</td><td>ì´ëŸ¬í•œ ì§€ì† ê°€ëŠ¥í•œ ë³¼ë¥¨ ì¤‘ì‹¬ ì‚¬ì—…ìœ¼ë¡œì˜ ì „í™˜ì´ ë‹¨ê¸° ì‹¤ì ì— ì˜í–¥ì„ ë¯¸ì¹˜ê³  ìˆì§€ë§Œ, ì´ëŠ” ì¥ê¸°ì ì¸ ì„±ê³µì„ ìœ„í•´ ì‚¬ì—…ì„ ë” ë‚˜ì€ ìœ„ì¹˜ì— ì˜¬ë ¤ë†“ê¸° ìœ„í•œ ì˜¬ë°”ë¥¸ ì¡°ì¹˜ì…ë‹ˆë‹¤. ì§„ë‹¨(Diagnostics) ë¶€ë¬¸ìœ¼ë¡œ ë„˜ì–´ê°€ë©´, ì˜ˆìƒí–ˆë˜ ëŒ€ë¡œ ì „ë…„ ëŒ€ë¹„ COVID ê²€ì‚¬ ë§¤ì¶œ ê°ì†Œë¡œ ì¸í•´ ë§¤ì¶œì´ 3.5% ê°ì†Œí–ˆìŠµë‹ˆë‹¤. í•µì‹¬ ì„ìƒê²€ì‚¬(Core Lab Diagnostics) ë¶€ë¬¸ì€ 3.5% ì„±ì¥í•˜ë©° 3ë¶„ê¸° ì—°ì† ê°€ì†í™”ëœ ì„±ì¥ì„ ë‹¬ì„±í–ˆê³ , 2026ë…„ ì§„ì…ì„ ì•ë‘ê³  ê¾¸ì¤€í•œ ëª¨ë©˜í…€ì„ êµ¬ì¶•í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì—°ê°„ ê¸°ì¤€ìœ¼ë¡œ ì¤‘êµ­ì„ ì œì™¸í•œ í•µì‹¬ ì„ìƒê²€ì‚¬ ë¶€ë¬¸ì˜ ì„±ì¥ë¥ ì€ 7%ë¡œ, ì „ ì„¸ê³„ ì‹œì¥ì—ì„œì˜ ì§€ì†ì ì¸ ìˆ˜ìš”ë¥¼ ë°˜ì˜í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>In Point of Care Diagnostics, sales grew 7% in the quarter, driven by adoption of our high-sensitivity troponin test, which allows for earlier and more accurate detection of heart attack. Turning to EPD, where sales increased 7% in the quarter. Growth was well balanced across the markets and therapeutic areas that we participate in, including double-digit growth in India and several countries across Latin America and the Middle East. By focusing on high-demand therapies in faster-growing markets, EPD delivered its fifth consecutive year of sales growth exceeding 7%. And I'll wrap up with Medical Devices, where sales grew 10.5%.</td><td>í˜„ì¥ì§„ë‹¨(Point of Care Diagnostics) ë¶€ë¬¸ì—ì„œëŠ” ë§¤ì¶œì´ 7% ì„±ì¥í–ˆìŠµë‹ˆë‹¤. ì´ëŠ” ì‹¬ê·¼ê²½ìƒ‰ì„ ë” ì¡°ê¸°ì— ì •í™•í•˜ê²Œ ê°ì§€í•  ìˆ˜ ìˆëŠ” ê³ ê°ë„ íŠ¸ë¡œí¬ë‹Œ ê²€ì‚¬ì˜ ì±„íƒ ì¦ê°€ì— í˜ì…ì€ ê²ƒì…ë‹ˆë‹¤. EPD ë¶€ë¬¸ìœ¼ë¡œ ë„˜ì–´ê°€ë©´, ë¶„ê¸° ë§¤ì¶œì´ 7% ì¦ê°€í–ˆìŠµë‹ˆë‹¤. ì„±ì¥ì€ ìš°ë¦¬ê°€ ì°¸ì—¬í•˜ëŠ” ì‹œì¥ê³¼ ì¹˜ë£Œ ì˜ì—­ ì „ë°˜ì— ê±¸ì³ ê· í˜•ìˆê²Œ ì´ë£¨ì–´ì¡Œìœ¼ë©°, ì¸ë„ì™€ ë¼í‹´ì•„ë©”ë¦¬ì¹´ ë° ì¤‘ë™ì˜ ì—¬ëŸ¬ êµ­ê°€ì—ì„œ ë‘ ìë¦¿ìˆ˜ ì„±ì¥ì„ ê¸°ë¡í–ˆìŠµë‹ˆë‹¤. ë¹ ë¥´ê²Œ ì„±ì¥í•˜ëŠ” ì‹œì¥ì—ì„œ ìˆ˜ìš”ê°€ ë†’ì€ ì¹˜ë£Œì œì— ì§‘ì¤‘í•¨ìœ¼ë¡œì¨, EPDëŠ” 5ë…„ ì—°ì† 7%ë¥¼ ì´ˆê³¼í•˜ëŠ” ë§¤ì¶œ ì„±ì¥ì„ ë‹¬ì„±í–ˆìŠµë‹ˆë‹¤. ë§ˆì§€ë§‰ìœ¼ë¡œ ì˜ë£Œê¸°ê¸°(Medical Devices) ë¶€ë¬¸ì—ì„œëŠ” ë§¤ì¶œì´ 10.5% ì„±ì¥í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>In Diabetes Care, sales of continuous glucose monitors grew 12% in the fourth quarter and 17% for the year, with sales in 2025 exceeding $7.5 billion. This marks the third consecutive year that our CGM sales have grown by more than $1 billion. Our success in CGM continues to be driven by strong underlying market fundamentals, a leading position in cost and scale and an unwavering commitment for market-leading innovation. These factors have led to a continued increase in adoption across all of the various user groups. In Electrophysiology, sales grew double digits in the U.S. and internationally.</td><td>ë‹¹ë‡¨ë³‘ ê´€ë¦¬ ë¶€ë¬¸ì—ì„œ ì—°ì†í˜ˆë‹¹ì¸¡ì •ê¸°(CGM) ë§¤ì¶œì€ 4ë¶„ê¸°ì— 12%, ì—°ê°„ 17% ì„±ì¥í–ˆìœ¼ë©°, 2025ë…„ ë§¤ì¶œì€ 75ì–µ ë‹¬ëŸ¬ë¥¼ ì´ˆê³¼í–ˆìŠµë‹ˆë‹¤. ì´ëŠ” CGM ë§¤ì¶œì´ 3ë…„ ì—°ì† 10ì–µ ë‹¬ëŸ¬ ì´ìƒ ì„±ì¥í•œ ê²ƒì…ë‹ˆë‹¤. CGM ë¶€ë¬¸ì˜ ì„±ê³µì€ ê²¬ê³ í•œ ì‹œì¥ í€ë”ë©˜í„¸, ë¹„ìš©ê³¼ ê·œëª¨ ì¸¡ë©´ì—ì„œì˜ ì„ ë„ì  ì§€ìœ„, ê·¸ë¦¬ê³  ì‹œì¥ì„ ì„ ë„í•˜ëŠ” í˜ì‹ ì— ëŒ€í•œ í™•ê³ í•œ ì˜ì§€ì— ì˜í•´ ì§€ì†ì ìœ¼ë¡œ ê²¬ì¸ë˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ìš”ì¸ë“¤ì€ ëª¨ë“  ì‚¬ìš©ì ê·¸ë£¹ì—ì„œ ì§€ì†ì ì¸ ì±„íƒ ì¦ê°€ë¡œ ì´ì–´ì¡ŒìŠµë‹ˆë‹¤. ì „ê¸°ìƒë¦¬í•™(Electrophysiology) ë¶€ë¬¸ì—ì„œëŠ” ë¯¸êµ­ê³¼ í•´ì™¸ì—ì„œ ë‘ ìë¦¿ìˆ˜ ì„±ì¥ì„ ê¸°ë¡í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>In December, we announced FDA approval of our Volt PFA catheter, which represents our first PFA product offering in the United States. And earlier this week, we announced that we obtained CE Mark for our new TactiFlex Duo Ablation Catheter, which offers both RF and PFA energy to treat patients battling AFib. In Structural Heart, growth was driven by double-digit growth in Navitor, double-digit growth in TriClip, double-digit growth in MitraClip. In the coming weeks, we'll achieve an important milestone by completing enrollment in our CATALYST trial. This trial is evaluating the performance of Amulet left atrial appendage device compared to oral anticoagulants in patients with AFib.</td><td>12ì›”ì— ìš°ë¦¬ëŠ” Volt PFA ì¹´í…Œí„°ì˜ FDA ìŠ¹ì¸ì„ ë°œí‘œí–ˆìœ¼ë©°, ì´ëŠ” ë¯¸êµ­ ì‹œì¥ì—ì„œ ìš°ë¦¬ì˜ ì²« ë²ˆì§¸ PFA ì œí’ˆì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì´ë²ˆ ì£¼ ì´ˆì— ìš°ë¦¬ëŠ” ì‹¬ë°©ì„¸ë™ í™˜ì ì¹˜ë£Œë¥¼ ìœ„í•´ RFì™€ PFA ì—ë„ˆì§€ë¥¼ ëª¨ë‘ ì œê³µí•˜ëŠ” ìƒˆë¡œìš´ TactiFlex Duo ì ˆì œ ì¹´í…Œí„°ì— ëŒ€í•œ CE ë§ˆí¬ë¥¼ íšë“í–ˆë‹¤ê³  ë°œí‘œí–ˆìŠµë‹ˆë‹¤. êµ¬ì¡°ì  ì‹¬ì¥ì§ˆí™˜ ë¶€ë¬¸ì—ì„œëŠ” Navitorì˜ ë‘ ìë¦¿ìˆ˜ ì„±ì¥, TriClipì˜ ë‘ ìë¦¿ìˆ˜ ì„±ì¥, MitraClipì˜ ë‘ ìë¦¿ìˆ˜ ì„±ì¥ì— í˜ì…ì–´ ì„±ì¥ì„ ë‹¬ì„±í–ˆìŠµë‹ˆë‹¤. ì•ìœ¼ë¡œ ëª‡ ì£¼ ì•ˆì— ìš°ë¦¬ëŠ” CATALYST ì„ìƒì‹œí—˜ì˜ ë“±ë¡ì„ ì™„ë£Œí•¨ìœ¼ë¡œì¨ ì¤‘ìš”í•œ ì´ì •í‘œë¥¼ ë‹¬ì„±í•  ê²ƒì…ë‹ˆë‹¤. ì´ ì„ìƒì‹œí—˜ì€ ì‹¬ë°©ì„¸ë™ í™˜ìì—ì„œ Amulet ì¢Œì‹¬ë°©ì´ íì‡„ ì¥ì¹˜ì˜ ì„±ëŠ¥ì„ ê²½êµ¬ìš© í•­ì‘ê³ ì œì™€ ë¹„êµ í‰ê°€í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>This trial is designed to generate the evidence to demonstrate the clinical benefits of Amulet, which could lead to broader adoption and expansion of the addressable market. In Heart Failure, growth of 12% was driven by growth across our market-leading portfolio of ventricular assist devices, which offer treatment for chronic and temporary conditions and growth in CardioMEMS, our implantable sensor used for the early detection of heart failure. Our investment strategy in Medical Devices is based upon a two-pronged approach.</td><td>ì´ ì„ìƒì‹œí—˜ì€ Amuletì˜ ì„ìƒì  ì´ì ì„ ì…ì¦í•˜ëŠ” ê·¼ê±°ë¥¼ ìƒì„±í•˜ë„ë¡ ì„¤ê³„ë˜ì—ˆìœ¼ë©°, ì´ëŠ” ë” ê´‘ë²”ìœ„í•œ ì±„íƒê³¼ ì ì¬ ì‹œì¥ì˜ í™•ëŒ€ë¡œ ì´ì–´ì§ˆ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì‹¬ë¶€ì „ ë¶€ë¬¸ì—ì„œëŠ” 12%ì˜ ì„±ì¥ì„ ê¸°ë¡í–ˆëŠ”ë°, ì´ëŠ” ë§Œì„± ë° ì¼ì‹œì  ì§ˆí™˜ ì¹˜ë£Œë¥¼ ì œê³µí•˜ëŠ” ì‹œì¥ ì„ ë„ì ì¸ ì‹¬ì‹¤ ë³´ì¡° ì¥ì¹˜ í¬íŠ¸í´ë¦¬ì˜¤ ì „ë°˜ì˜ ì„±ì¥ê³¼, ì‹¬ë¶€ì „ì˜ ì¡°ê¸° ë°œê²¬ì— ì‚¬ìš©ë˜ëŠ” ì´ì‹í˜• ì„¼ì„œì¸ CardioMEMSì˜ ì„±ì¥ì— í˜ì…ì€ ê²ƒì…ë‹ˆë‹¤. ì˜ë£Œê¸°ê¸° ë¶€ë¬¸ì—ì„œ ìš°ë¦¬ì˜ íˆ¬ì ì „ëµì€ ë‘ ê°€ì§€ ì ‘ê·¼ë²•ì„ ê¸°ë°˜ìœ¼ë¡œ í•©ë‹ˆë‹¤.</td></tr>
<tr><td>We invest to sustain strong performance in high-growth segments like Diabetes, Structural Heart, Electrophysiology and Heart Failure, and we invest to increase the growth outlook in more foundational segments like Rhythm Management and Vascular. While the investments in traditionally high-growth segments tend to get more attention, the investments we've made in our foundational businesses are generating very impressive returns. In Rhythm Management, growth of 12% was led by continued strong uptake of our leadless pacemaker AVEIR. For the full year, growth of 10% in Rhythm Management represents the third consecutive year of significantly outperforming the market.</td><td>ìš°ë¦¬ëŠ” ë‹¹ë‡¨ë³‘, êµ¬ì¡°ì  ì‹¬ì¥ì§ˆí™˜, ì „ê¸°ìƒë¦¬í•™ ë° ì‹¬ë¶€ì „ê³¼ ê°™ì€ ê³ ì„±ì¥ ë¶€ë¬¸ì—ì„œ ê°•ë ¥í•œ ì‹¤ì ì„ ìœ ì§€í•˜ê¸° ìœ„í•´ íˆ¬ìí•˜ê³  ìˆìœ¼ë©°, ë¦¬ë“¬ ê´€ë¦¬ ë° í˜ˆê´€ ì‚¬ì—…ê³¼ ê°™ì€ ë³´ë‹¤ ê¸°ë°˜ì ì¸ ë¶€ë¬¸ì˜ ì„±ì¥ ì „ë§ì„ ë†’ì´ê¸° ìœ„í•´ íˆ¬ìí•˜ê³  ìˆìŠµë‹ˆë‹¤. ì „í†µì ìœ¼ë¡œ ê³ ì„±ì¥ ë¶€ë¬¸ì— ëŒ€í•œ íˆ¬ìê°€ ë” ë§ì€ ì£¼ëª©ì„ ë°›ëŠ” ê²½í–¥ì´ ìˆì§€ë§Œ, ìš°ë¦¬ê°€ ê¸°ë°˜ ì‚¬ì—…ì— íˆ¬ìí•œ ê²ƒë“¤ì€ ë§¤ìš° ì¸ìƒì ì¸ ìˆ˜ìµì„ ì°½ì¶œí•˜ê³  ìˆìŠµë‹ˆë‹¤. ë¦¬ë“¬ ê´€ë¦¬ ë¶€ë¬¸ì—ì„œëŠ” ë¬´ì„  ì‹¬ë°•ì¡°ìœ¨ê¸° AVEIRì˜ ì§€ì†ì ì¸ ê°•ë ¥í•œ ì±„íƒì— í˜ì…ì–´ 12% ì„±ì¥í–ˆìŠµë‹ˆë‹¤. ì—°ê°„ ê¸°ì¤€ìœ¼ë¡œ ë¦¬ë“¬ ê´€ë¦¬ ë¶€ë¬¸ì˜ 10% ì„±ì¥ì€ 3ë…„ ì—°ì† ì‹œì¥ì„ í¬ê²Œ ìƒíšŒí•˜ëŠ” ì„±ê³¼ë¥¼ ë‚˜íƒ€ëƒ…ë‹ˆë‹¤.</td></tr>
<tr><td>With AVEIR and the investments we're making in conduction system pacing and other novel technologies, we see the $10 billion Rhythm Management market as a great opportunity to capture market share and drive sustainable growth for years to come. In Vascular, growth of 6.5% was led by double-digit growth in vessel closure products and growth from Esprit, our below-the-knee resorbable stent. For the full year, Vascular sales grew 5%, making this the second consecutive year Vascular has delivered mid-single-digit growth. With the expected approval of our coronary IVL device next year, we expect growth in Vascular to follow a similar pattern of acceleration that we've seen in Rhythm Management.</td><td>AVEIRì™€ ì „ë„ê³„ í˜ì´ì‹±(conduction system pacing) ë° ê¸°íƒ€ í˜ì‹  ê¸°ìˆ ì— ëŒ€í•œ íˆ¬ìë¥¼ í†µí•´, ìš°ë¦¬ëŠ” 100ì–µ ë‹¬ëŸ¬ ê·œëª¨ì˜ ë¦¬ë“¬ ê´€ë¦¬(Rhythm Management) ì‹œì¥ì„ ì‹œì¥ì ìœ ìœ¨ì„ í™•ë³´í•˜ê³  í–¥í›„ ìˆ˜ë…„ê°„ ì§€ì†ê°€ëŠ¥í•œ ì„±ì¥ì„ ê²¬ì¸í•  ìˆ˜ ìˆëŠ” í›Œë¥­í•œ ê¸°íšŒë¡œ ë³´ê³  ìˆìŠµë‹ˆë‹¤. í˜ˆê´€(Vascular) ë¶€ë¬¸ì€ 6.5% ì„±ì¥í–ˆìœ¼ë©°, ì´ëŠ” í˜ˆê´€ íì‡„ ì œí’ˆì˜ ë‘ ìë¦¿ìˆ˜ ì„±ì¥ê³¼ ë¬´ë¦ ì•„ë˜ ë¶€ìœ„ìš© í¡ìˆ˜ì„± ìŠ¤í…íŠ¸ì¸ Espritì˜ ì„±ì¥ì´ ì£¼ë„í–ˆìŠµë‹ˆë‹¤. ì—°ê°„ ê¸°ì¤€ìœ¼ë¡œ í˜ˆê´€ ë¶€ë¬¸ ë§¤ì¶œì€ 5% ì„±ì¥í–ˆìœ¼ë©°, ì´ëŠ” í˜ˆê´€ ë¶€ë¬¸ì´ ì¤‘ê°„ í•œ ìë¦¿ìˆ˜ ì„±ì¥ë¥ ì„ ë‹¬ì„±í•œ ë‘ ë²ˆì§¸ ì—°ì† í•´ì…ë‹ˆë‹¤. ë‚´ë…„ ê´€ìƒë™ë§¥ IVL ê¸°ê¸°ì˜ ìŠ¹ì¸ì´ ì˜ˆìƒë¨ì— ë”°ë¼, ìš°ë¦¬ëŠ” í˜ˆê´€ ë¶€ë¬¸ì´ ë¦¬ë“¬ ê´€ë¦¬ ë¶€ë¬¸ì—ì„œ ëª©ê²©í•œ ê²ƒê³¼ ìœ ì‚¬í•œ ì„±ì¥ ê°€ì†í™” íŒ¨í„´ì„ ë³´ì¼ ê²ƒìœ¼ë¡œ ê¸°ëŒ€í•©ë‹ˆë‹¤.</td></tr>
<tr><td>And lastly, in Neuromodulation, growth of 5.5% was led by strong international growth of Eterna, our rechargeable spinal cord stimulation device. So in summary, despite facing some challenges in 2025, we achieved our original target of double-digit earnings per share growth. Our new product pipeline continues to be highly productive. And combined with the strategic steps we took to shape the company for the future, we're well positioned for accelerating growth in 2026. I'll now turn over the call to Phil. Philip Boudreau<br>CFO & Executive VP of Finance<br><br>Thanks, Robert.</td><td>ë§ˆì§€ë§‰ìœ¼ë¡œ ì‹ ê²½ì¡°ì ˆ(Neuromodulation) ë¶€ë¬¸ì—ì„œëŠ” 5.5%ì˜ ì„±ì¥ì„ ê¸°ë¡í–ˆìœ¼ë©°, ì´ëŠ” ì¬ì¶©ì „ ê°€ëŠ¥í•œ ì²™ìˆ˜ ìê·¹ ì¥ì¹˜ì¸ Eternaì˜ ê°•ë ¥í•œ í•´ì™¸ ì„±ì¥ì´ ì£¼ë„í–ˆìŠµë‹ˆë‹¤. ìš”ì•½í•˜ìë©´, 2025ë…„ ëª‡ ê°€ì§€ ì–´ë ¤ì›€ì— ì§ë©´í–ˆìŒì—ë„ ë¶ˆêµ¬í•˜ê³ , ìš°ë¦¬ëŠ” ë‘ ìë¦¿ìˆ˜ ì£¼ë‹¹ìˆœì´ìµ(EPS) ì„±ì¥ì´ë¼ëŠ” ë‹¹ì´ˆ ëª©í‘œë¥¼ ë‹¬ì„±í–ˆìŠµë‹ˆë‹¤. ì‹ ì œí’ˆ íŒŒì´í”„ë¼ì¸ì€ ê³„ì†í•´ì„œ ë†’ì€ ìƒì‚°ì„±ì„ ë³´ì´ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ë¯¸ë˜ë¥¼ ìœ„í•´ íšŒì‚¬ë¥¼ ì¬í¸í•˜ê¸° ìœ„í•´ ì·¨í•œ ì „ëµì  ì¡°ì¹˜ë“¤ê³¼ ê²°í•©í•˜ì—¬, ìš°ë¦¬ëŠ” 2026ë…„ ê°€ì†í™”ëœ ì„±ì¥ì„ ìœ„í•œ ì¢‹ì€ ìœ„ì¹˜ì— ìˆìŠµë‹ˆë‹¤. ì´ì œ Philì—ê²Œ ë°œí‘œë¥¼ ë„˜ê¸°ê² ìŠµë‹ˆë‹¤.<br><br>Philip Boudreau<br>ìµœê³ ì¬ë¬´ì±…ì„ì(CFO) ê²¸ ì¬ë¬´ ë¶€ë¬¸ ì „ë¬´ì´ì‚¬<br><br>ê°ì‚¬í•©ë‹ˆë‹¤, Robert.</td></tr>
<tr><td>As Mike mentioned earlier, please note that all references to sales growth rates, unless otherwise noted, are on an organic basis. Turning to our fourth quarter results. Sales increased 3.8% when excluding COVID testing sales. Adjusted earnings per share of $1.50 reflects growth of 12% compared to the prior year. Foreign exchange had a favorable year-over-year impact of 1.4% on fourth quarter sales, which was in line with our expectations at the time of our earnings call in October. Regarding other aspects of the P&L, the adjusted gross margin profile was 57.1% of sales, which, despite the impact of tariffs, increased 20 basis points compared to the prior year.</td><td>ë§ˆì´í¬ê°€ ì•ì„œ ì–¸ê¸‰í–ˆë“¯ì´, ë³„ë„ë¡œ ëª…ì‹œí•˜ì§€ ì•ŠëŠ” í•œ ëª¨ë“  ë§¤ì¶œ ì„±ì¥ë¥ ì€ ìœ ê¸°ì  ì„±ì¥ ê¸°ì¤€ì„ì„ ìœ ì˜í•´ ì£¼ì‹œê¸° ë°”ëë‹ˆë‹¤. 4ë¶„ê¸° ì‹¤ì ìœ¼ë¡œ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤. COVID ê²€ì‚¬ ë§¤ì¶œì„ ì œì™¸í•œ ë§¤ì¶œì€ 3.8% ì¦ê°€í–ˆìŠµë‹ˆë‹¤. ì¡°ì • ì£¼ë‹¹ìˆœì´ìµì€ 1.50ë‹¬ëŸ¬ë¡œ ì „ë…„ ëŒ€ë¹„ 12% ì„±ì¥ì„ ë‚˜íƒ€ëƒˆìŠµë‹ˆë‹¤. ì™¸í™˜ì€ 4ë¶„ê¸° ë§¤ì¶œì— ì „ë…„ ëŒ€ë¹„ 1.4%ì˜ ê¸ì •ì ì¸ ì˜í–¥ì„ ë¯¸ì³¤ìœ¼ë©°, ì´ëŠ” 10ì›” ì‹¤ì  ë°œí‘œ ë‹¹ì‹œ ìš°ë¦¬ì˜ ì˜ˆìƒê³¼ ì¼ì¹˜í•˜ëŠ” ìˆ˜ì¤€ì…ë‹ˆë‹¤. ì†ìµê³„ì‚°ì„œì˜ ë‹¤ë¥¸ í•­ëª©ë“¤ê³¼ ê´€ë ¨í•˜ì—¬, ì¡°ì • ë§¤ì¶œì´ì´ìµë¥ ì€ ë§¤ì¶œì˜ 57.1%ë¥¼ ê¸°ë¡í–ˆìœ¼ë©°, ê´€ì„¸ì˜ ì˜í–¥ì—ë„ ë¶ˆêµ¬í•˜ê³  ì „ë…„ ëŒ€ë¹„ 20bp ì¦ê°€í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Adjusted R&D was 6.2% of sales and adjusted SG&A was 25.1% of sales. Adjusted operating margin was 25.8% of sales, which reflects an increase of 150 basis points compared to the prior year. Turning to our outlook for 2026. Today, we issued guidance for full year adjusted earnings per share of $5.55 to $5.80, which reflects 10% growth at the midpoint of the range and contemplates an adjusted earnings per share forecast of $1.12 to $1.18 for the first quarter. For the year, we forecast organic sales growth to be in the range of 6.5% to 7.5%.</td><td>ì¡°ì • R&DëŠ” ë§¤ì¶œì˜ 6.2%ì˜€ê³ , ì¡°ì • SG&AëŠ” ë§¤ì¶œì˜ 25.1%ì˜€ìŠµë‹ˆë‹¤. ì¡°ì • ì˜ì—…ì´ìµë¥ ì€ ë§¤ì¶œì˜ 25.8%ë¡œ, ì „ë…„ ëŒ€ë¹„ 150bp(ë² ì´ì‹œìŠ¤ í¬ì¸íŠ¸) ì¦ê°€í•œ ìˆ˜ì¹˜ì…ë‹ˆë‹¤. 2026ë…„ ì „ë§ìœ¼ë¡œ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤. ì˜¤ëŠ˜ ìš°ë¦¬ëŠ” ì—°ê°„ ì¡°ì • ì£¼ë‹¹ìˆœì´ìµ ê°€ì´ë˜ìŠ¤ë¥¼ $5.55ì—ì„œ $5.80ìœ¼ë¡œ ì œì‹œí–ˆìœ¼ë©°, ì´ëŠ” ê°€ì´ë˜ìŠ¤ ì¤‘ê°„ê°’ ê¸°ì¤€ 10% ì„±ì¥ì„ ë°˜ì˜í•˜ê³  ìˆìœ¼ë©°, 1ë¶„ê¸° ì¡°ì • ì£¼ë‹¹ìˆœì´ìµ ì „ë§ì¹˜ëŠ” $1.12ì—ì„œ $1.18ì…ë‹ˆë‹¤. ì—°ê°„ ê¸°ì¤€ìœ¼ë¡œ, ìš°ë¦¬ëŠ” ìœ ê¸°ì  ë§¤ì¶œ ì„±ì¥ë¥ ì´ 6.5%ì—ì„œ 7.5% ë²”ìœ„ê°€ ë  ê²ƒìœ¼ë¡œ ì „ë§í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Based on current rates, we expect exchange to have a favorable impact of around 1% on full year reported sales, which includes an expected favorable impact of around 3% on first quarter reported sales. And we forecast our adjusted tax rate to be in the range of 15% to 16%. With that, we'll now open the call for questions.</td><td>í˜„ì¬ í™˜ìœ¨ ê¸°ì¤€ìœ¼ë¡œ, ì—°ê°„ ë³´ê³  ë§¤ì¶œì— ì•½ 1%ì˜ ê¸ì •ì ì¸ í™˜ìœ¨ íš¨ê³¼ê°€ ìˆì„ ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ë©°, ì´ëŠ” 1ë¶„ê¸° ë³´ê³  ë§¤ì¶œì— ì•½ 3%ì˜ ê¸ì •ì ì¸ ì˜í–¥ì„ í¬í•¨í•©ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì¡°ì • ì„¸ìœ¨ì€ 15%ì—ì„œ 16% ë²”ìœ„ê°€ ë  ê²ƒìœ¼ë¡œ ì „ë§í•©ë‹ˆë‹¤. ì´ì œ ì§ˆì˜ì‘ë‹µ ì‹œê°„ì„ ê°–ë„ë¡ í•˜ê² ìŠµë‹ˆë‹¤.</td></tr>
    </table>
    <h3>ğŸ“Œ ìš”ì•½</h3>
    <p style="background:#f0f0f0; padding:15px; border-left: 5px solid #333;"># Abbott Laboratories Q4 2025 ì‹¤ì  ë°œí‘œ ìš”ì•½<br><br>â€¢ **2026ë…„ ê°€ì´ë˜ìŠ¤**: ìœ ê¸°ì  ë§¤ì¶œ ì„±ì¥ë¥  ì¤‘ê°„ê°’ 7%, ì¡°ì • ì£¼ë‹¹ìˆœì´ìµ(EPS) ì¤‘ê°„ê°’ 10% ì„±ì¥ ì „ë§. 1ë¶„ê¸° ì¡°ì • EPSëŠ” $1.12~$1.18 ì˜ˆìƒ. í™˜ìœ¨ì€ ì—°ê°„ ë§¤ì¶œì— ì•½ 1% ê¸ì •ì  ì˜í–¥ ì˜ˆìƒ.<br><br>â€¢ **ì˜ì–‘ì‚¬ì—… ë¶€ì§„ ë° êµ¬ì¡°ì¡°ì •**: ì˜ì–‘ì‚¬ì—…ì´ 4ë¶„ê¸° ì—­ì„±ì¥í•˜ë©° ì£¼ìš” ì•½ì ìœ¼ë¡œ ë¶€ê°. ì›ìì¬ ë¹„ìš© ìƒìŠ¹ìœ¼ë¡œ ì¸í•œ ê°€ê²© ì¸ìƒì´ ìˆ˜ìš”ë¥¼ ì–µì œí•˜ë©´ì„œ ì‹œì¥ì ìœ ìœ¨ ì†ì‹¤ ë°œìƒ(WIC ê³„ì•½ ìƒì‹¤ í¬í•¨). ê²½ì˜ì§„ì€ ê°€ê²©/í”„ë¡œëª¨ì…˜ ì¡°ì •ê³¼ ì‹ ì œí’ˆ ì¶œì‹œ(í–¥í›„ 12ê°œì›”ê°„ ìµœì†Œ 8ê°œ)ë¥¼ í†µí•´ ë³¼ë¥¨ ì„±ì¥ íšŒë³µ ì¶”ì§„ ì¤‘ì´ë‚˜, ìƒë°˜ê¸° ì‹¤ì ì€ ê³„ì† ë¶€ì§„í•  ê²ƒìœ¼ë¡œ ì˜ˆìƒ.<br><br>â€¢ **ì˜ë£Œê¸°ê¸° ë¶€ë¬¸ ê°•ì„¸ ì§€ì†**: ì˜ë£Œê¸°ê¸° ë§¤ì¶œ 10.5% ì„±ì¥. ì—°ì†í˜ˆë‹¹ì¸¡ì •ê¸°(CGM) ë§¤ì¶œì´ 4ë¶„ê¸° 12%, ì—°ê°„ 17% ì„±ì¥í•˜ë©° $75ì–µ ëŒíŒŒ(3ë…„ ì—°ì† $10ì–µ ì´ìƒ ì¦ê°€). ì „ê¸°ìƒë¦¬í•™, êµ¬ì¡°ì‹¬ì¥, ì‹¬ë¶€ì „ ë¶„ì•¼ ëª¨ë‘ ë‘ ìë¦¿ìˆ˜ ì„±ì¥. Volt PFA ì¹´í…Œí„° FDA ìŠ¹ì¸ ë° TactiFlex Duo CE ë§ˆí¬ íšë“ ë“± í˜ì‹  íŒŒì´í”„ë¼ì¸ ê°•í™”.<br><br>â€¢ **ìˆ˜ìµì„± ê°œì„  ë°</p>
    <hr style="margin:50px 0;">
    

    <h2>â“ Q&A</h2>
    <table style="width:100%; border-collapse:collapse; margin-bottom: 40px;">
        <tr>
            <th style="width:50%; border-bottom: 2px solid #333;">Original</th>
            <th style="width:50%; border-bottom: 2px solid #333;">Translation</th>
        </tr>
        <tr><td>Operator: [Operator Instructions] And our first question will come from Larry Biegelsen from Wells Fargo.</td><td>**Operator:** [ì§ˆë¬¸ ì ‘ìˆ˜ ì•ˆë‚´] ì²« ë²ˆì§¸ ì§ˆë¬¸ì€ Wells Fargoì˜ Larry Biegelsenì´ í•˜ì‹œê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Larry Biegelsen: Wells Fargo Securities, LLC, Research Division So Robert, on the last call, you seemed comfortable with consensus revenue growth, but you're guiding a little bit lower today. I assume that's related to Nutrition. Can you talk about what's changed since the last call and how you're thinking about the year playing out from a cadence standpoint? I assume you would expect growth to accelerate through the year given your comments on Nutrition and some of the launches. And I'll leave it at that.</td><td>**Larry Biegelsen:** ì§€ë‚œ ì»¨í¼ëŸ°ìŠ¤ ì½œì—ì„œëŠ” ì»¨ì„¼ì„œìŠ¤ ë§¤ì¶œ ì„±ì¥ë¥ ì— ëŒ€í•´ í¸ì•ˆí•˜ê²Œ ìƒê°í•˜ì‹œëŠ” ê²ƒ ê°™ì•˜ëŠ”ë°, ì˜¤ëŠ˜ì€ ì¡°ê¸ˆ ë‚®ê²Œ ê°€ì´ë˜ìŠ¤ë¥¼ ì œì‹œí•˜ì…¨ìŠµë‹ˆë‹¤. ë‰´íŠ¸ë¦¬ì…˜ ë¶€ë¬¸ê³¼ ê´€ë ¨ì´ ìˆë‹¤ê³  ìƒê°ë˜ëŠ”ë°ìš”. ì§€ë‚œ ì»¨í¼ëŸ°ìŠ¤ ì½œ ì´í›„ ë¬´ì—‡ì´ ë‹¬ë¼ì¡ŒëŠ”ì§€, ê·¸ë¦¬ê³  ì˜¬í•´ ì „ë§ì„ ì–´ë–»ê²Œ ë³´ê³  ê³„ì‹ ì§€ ë§ì”€í•´ ì£¼ì‹œê² ìŠµë‹ˆê¹Œ? ë‰´íŠ¸ë¦¬ì…˜ ë¶€ë¬¸ì— ëŒ€í•œ ì½”ë©˜íŠ¸ì™€ ì‹ ì œí’ˆ ì¶œì‹œ ê³„íšì„ ê³ ë ¤í•˜ë©´, ì—°ì¤‘ ì„±ì¥ì„¸ê°€ ê°€ì†í™”ë  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ì‹œëŠ” ê²ƒ ê°™ì€ë°ìš”. ì¼ë‹¨ ì—¬ê¸°ê¹Œì§€ ì§ˆë¬¸ë“œë¦¬ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Robert Ford: Chairman, President & CEO Thanks, Larry. I think if I remember, you're the one who asked that question back in October. And when I answered that question, I think consensus was 7.5% top line. EPS was 10%. So today, we guided the midpoint at 7% on top line, 10% on the bottom. So midpoint here is 0.5% lower than what was consensus. But other than that, nothing has really changed. The EPS is in line with consensus, expecting healthy margin expansions. I'm sure we're going to talk a lot about the pipeline, which is either on target or ahead of schedule in certain products. Balance sheet is in great shape. We feel good about us closing Exact. So the 0.5 point change on the top line is, as you pointed out, is really the change in the near-term outlook, I'd say, of our Nutrition business. You saw in our quarter, in our Q4, we had a negative quarter. And as I said in my comments, there's a component of this business -- it's a health care-driven product portfolio, but there's a component of it, a dynamic of it that is very much aligned with consumer packaged goods. And I'd say the challenges that CPG businesses have been facing are pretty well known following pandemic, pretty significant surge in costs between 2022 and 2024 to offset that. I think we all went ahead and try to mitigate it with price increases that obviously drove top line, but more importantly, I would say, improved or didn't allow the economics and the profitability of the businesses to deteriorate. If you look at our profitability in that business, 2024, 2025, where it was -- back in 2022, it had that impact. But the higher prices though have resulted now in what I see as kind of suppressing demand and lowering the volume growth. And the pressure on the volume growth accelerated, I'd say, as we moved throughout Q4 and consumers became increasingly more price sensitive. So as I said in my comment, it's not a sustainable path. You'll get down into the spiral. If you keep increasing prices, you'll keep on driving volume down. So we could have gone a couple more quarters, maybe 9 more months doing this, but it would not be sustainable. And at some point, something fundamentally has to change here. And I just felt that the long we took to make this change, the more painful it would be. If I look at the strength of the portfolio right now and the growth, all the growth prospects we have, the ability to add a whole new growth vertical, I just thought that the timing was right to do this and do this as quickly as possible to get through it. So we began implementing price promotion initiatives that are going to help invigorate growth. I think early signs right now, Larry, are encouraging. Obviously, we're going to have to keep monitoring that. And then we're also launching a lot of new products to be able to kind of support that volume growth. We haven't had to reallocate R&D resources to be able to do that. This is a business that operates around 2%, 2.2% of R&D. So we just reallocated within that budget to focus on new product development. So we'll have a couple of quarters here where growth in Nutrition is going to be challenged. And then in the second half, we'll return to positive growth. And I got confidence in the team that's in place today that we can execute this transition back to more of a volume base -- more of a volume-driven growth business. If you look at what we did back in 2022, when we had the supply disruption, it took us about 9 to 12 months to get our share back. I don't think it's going to take that long. So I think it's about a 6-month process here of reshifting that. And that's really what's creating, I would say -- part of it what's creating a little bit of this first half, second half dynamic in our growth forecast. But outside of that, Larry, versus where we were in October, nothing has really changed. In fact, I'd say a significant majority of the company here is either maintaining high single-digit top-line growth or low-teens growth or they're accelerating their growth versus 2025, whether it's our cardiovascular franchise, our diabetes products, EPD, our pharma business. We're going to be lapping the core diagnostic headwinds that we faced last year. If you remember, we had about $1 billion of headwind that we faced last year in our Diagnostic business, whether it was COVID and the China challenges. That's mostly going to be behind us. We're going to be adding another high-growth vertical with Exact Sciences. So I think there's a lot to like here. I think there's a lot of growth here. And while we know we've got some work to do in Nutrition, I can guarantee you that we're not distracted by that from all the great opportunities that we have here. So like I said, I think we've got a good setup for 2026, a lot of accelerating growth as we progress through the year.</td><td>**Robert Ford:** ê°ì‚¬í•©ë‹ˆë‹¤, Larry. 10ì›”ì— ì´ ì§ˆë¬¸ì„ í•˜ì…¨ë˜ ë¶„ì´ ë§ìœ¼ì‹œì£ . ê·¸ë•Œ ì œê°€ ë‹µë³€ë“œë ¸ì„ ë•Œ ì»¨ì„¼ì„œìŠ¤ê°€ ë§¤ì¶œ 7.5%, EPSê°€ 10%ì˜€ìŠµë‹ˆë‹¤. ì˜¤ëŠ˜ ì €í¬ëŠ” ë§¤ì¶œ ì¤‘ê°„ê°’ì„ 7%, ìˆœì´ìµì€ 10%ë¡œ ê°€ì´ë˜ìŠ¤ë¥¼ ì œì‹œí–ˆìŠµë‹ˆë‹¤. ê·¸ëŸ¬ë‹ˆê¹Œ ì¤‘ê°„ê°’ ê¸°ì¤€ìœ¼ë¡œ ì»¨ì„¼ì„œìŠ¤ ëŒ€ë¹„ 0.5% ë‚®ì•„ì§„ ê²ƒì…ë‹ˆë‹¤. í•˜ì§€ë§Œ ê·¸ ì™¸ì—ëŠ” ì‹¤ì§ˆì ìœ¼ë¡œ ë³€í•œ ê²Œ ì—†ìŠµë‹ˆë‹¤. EPSëŠ” ì»¨ì„¼ì„œìŠ¤ì™€ ì¼ì¹˜í•˜ê³ , ê²¬ê³ í•œ ë§ˆì§„ í™•ëŒ€ë¥¼ ì˜ˆìƒí•˜ê³  ìˆìŠµë‹ˆë‹¤. íŒŒì´í”„ë¼ì¸ì— ëŒ€í•´ì„œë„ ë§ì€ ì´ì•¼ê¸°ë¥¼ ë‚˜ëˆ„ê²Œ ë  ê²ƒ ê°™ì€ë°, ëª©í‘œë¥¼ ë‹¬ì„±í–ˆê±°ë‚˜ íŠ¹ì • ì œí’ˆë“¤ì€ ì¼ì •ë³´ë‹¤ ì•ì„œ ìˆìŠµë‹ˆë‹¤. ì¬ë¬´ìƒíƒœí‘œë„ ë§¤ìš° ì–‘í˜¸í•©ë‹ˆë‹¤. Exact ì¸ìˆ˜ ë§ˆë¬´ë¦¬ì— ëŒ€í•´ì„œë„ ìì‹ ê°ì„ ê°–ê³  ìˆìŠµë‹ˆë‹¤. ë§ì”€í•˜ì‹  ëŒ€ë¡œ ë§¤ì¶œ ì¸¡ë©´ì˜ 0.5%í¬ì¸íŠ¸ ë³€í™”ëŠ” ì˜ì–‘(Nutrition) ì‚¬ì—…ì˜ ë‹¨ê¸° ì „ë§ ë³€í™”ì— ê¸°ì¸í•œ ê²ƒì…ë‹ˆë‹¤. 4ë¶„ê¸°ì— ë§ˆì´ë„ˆìŠ¤ ì‹¤ì ì„ ê¸°ë¡í–ˆìŠµë‹ˆë‹¤. ì œê°€ ë§ì”€ë“œë¦° ê²ƒì²˜ëŸ¼, ì´ ì‚¬ì—…ì€ í—¬ìŠ¤ì¼€ì–´ ì¤‘ì‹¬ì˜ ì œí’ˆ í¬íŠ¸í´ë¦¬ì˜¤ì´ì§€ë§Œ, ì†Œë¹„ì¬(CPG) ì‚°ì—…ê³¼ ë§¤ìš° ìœ ì‚¬í•œ íŠ¹ì„±ì„ ê°€ì§„ ë¶€ë¶„ì´ ìˆìŠµë‹ˆë‹¤. íŒ¬ë°ë¯¹ ì´í›„ ì†Œë¹„ì¬ ì—…ê³„ê°€ ì§ë©´í•œ ì–´ë ¤ì›€ì€ ì˜ ì•Œë ¤ì ¸ ìˆì£ . 2022ë…„ë¶€í„° 2024ë…„ ì‚¬ì´ì— ìƒë‹¹í•œ ë¹„ìš© ê¸‰ì¦ì´ ìˆì—ˆê³ , ì´ë¥¼ ìƒì‡„í•˜ê¸° ìœ„í•´ ìš°ë¦¬ë¥¼ í¬í•¨í•œ ëª¨ë“  ê¸°ì—…ë“¤ì´ ê°€ê²© ì¸ìƒìœ¼ë¡œ ëŒ€ì‘í–ˆìŠµë‹ˆë‹¤. ì´ëŠ” ë§¤ì¶œ ì¦ëŒ€ë¡œ ì´ì–´ì¡Œì§€ë§Œ, ë” ì¤‘ìš”í•œ ê²ƒì€ ì‚¬ì—…ì˜ ìˆ˜ìµì„±ê³¼ ê²½ì œì„±ì´ ì•…í™”ë˜ì§€ ì•Šë„ë¡ ì§€ì¼œëƒˆë‹¤ëŠ” ì ì…ë‹ˆë‹¤. í•´ë‹¹ ì‚¬ì—…ì˜ ìˆ˜ìµì„±ì„ ë³´ë©´, 2024ë…„, 2025ë…„ì€ 2022ë…„ ë‹¹ì‹œ ì˜í–¥ì„ ë°›ì•˜ë˜ ìˆ˜ì¤€ìœ¼ë¡œ ëŒì•„ì™”ìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ ë†’ì•„ì§„ ê°€ê²©ì´ ì´ì œëŠ” ìˆ˜ìš”ë¥¼ ì–µì œí•˜ê³  ë¬¼ëŸ‰ ì„±ì¥ì„ ë‘”í™”ì‹œí‚¤ê³  ìˆìŠµë‹ˆë‹¤. ë¬¼ëŸ‰ ì„±ì¥ì— ëŒ€í•œ ì••ë°•ì€ 4ë¶„ê¸° ë‚´ë‚´ ê°€ì†í™”ë˜ì—ˆê³ , ì†Œë¹„ìë“¤ì˜ ê°€ê²© ë¯¼ê°ë„ê°€ ì ì  ë” ë†’ì•„ì¡ŒìŠµë‹ˆë‹¤. ì œê°€ ë§ì”€ë“œë¦° ê²ƒì²˜ëŸ¼, ì´ê²ƒì€ ì§€ì† ê°€ëŠ¥í•œ ë°©í–¥ì´ ì•„ë‹™ë‹ˆë‹¤. ì•…ìˆœí™˜ì— ë¹ ì§€ê²Œ ë©ë‹ˆë‹¤. ê°€ê²©ì„ ê³„ì† ì˜¬ë¦¬ë©´ ë¬¼ëŸ‰ì€ ê³„ì† ê°ì†Œí•  ìˆ˜ë°–ì— ì—†ìŠµë‹ˆë‹¤. ëª‡ ë¶„ê¸°, ì•„ë§ˆ 9ê°œì›” ì •ë„ëŠ” ë” ì´ë ‡ê²Œ ê°ˆ ìˆ˜ë„ ìˆì—ˆê² ì§€ë§Œ, ì§€ì† ê°€ëŠ¥í•˜ì§€ ì•ŠìŠµë‹ˆë‹¤. ì–´ëŠ ì‹œì ì—ì„œëŠ” ê·¼ë³¸ì ì¸ ë³€í™”ê°€ í•„ìš”í•©ë‹ˆë‹¤. ì´ëŸ¬í•œ ë³€í™”ë¥¼ ëŠ¦ì¶œìˆ˜ë¡ ë” ê³ í†µìŠ¤ëŸ¬ì›Œì§ˆ ê²ƒì´ë¼ê³  íŒë‹¨í–ˆìŠµë‹ˆë‹¤. í˜„ì¬ í¬íŠ¸í´ë¦¬ì˜¤ì˜ ê°•ì ê³¼ ì„±ì¥ì„±, ê·¸ë¦¬ê³  ìš°ë¦¬ê°€ ê°€ì§„ ëª¨ë“  ì„±ì¥ ì „ë§, ì™„ì „íˆ ìƒˆë¡œìš´ ì„±ì¥ ì¶•ì„ ì¶”ê°€í•  ìˆ˜ ìˆëŠ” ì—­ëŸ‰ì„ ê³ ë ¤í–ˆì„ ë•Œ, ì§€ê¸ˆì´ ì´ë¥¼ ì‹¤í–‰í•˜ê³  ê°€ëŠ¥í•œ í•œ ë¹ ë¥´ê²Œ ì¶”ì§„í•  ì ê¸°ë¼ê³  íŒë‹¨í–ˆìŠµë‹ˆë‹¤. ê·¸ë˜ì„œ ì„±ì¥ì„ í™œì„±í™”í•  ìˆ˜ ìˆëŠ” ê°€ê²© í”„ë¡œëª¨ì…˜ ì´ë‹ˆì…”í‹°ë¸Œë¥¼ ì‹œí–‰í•˜ê¸° ì‹œì‘í–ˆìŠµë‹ˆë‹¤. í˜„ì¬ ì´ˆê¸° ì‹ í˜¸ëŠ” ê³ ë¬´ì ì´ë¼ê³  ìƒê°í•©ë‹ˆë‹¤. ë¬¼ë¡  ê³„ì† ëª¨ë‹ˆí„°ë§í•´ì•¼ í•˜ê² ì§€ë§Œìš”. ê·¸ë¦¬ê³  ë³¼ë¥¨ ì„±ì¥ì„ ë’·ë°›ì¹¨í•˜ê¸° ìœ„í•´ ë§ì€ ì‹ ì œí’ˆë„ ì¶œì‹œí•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ë¥¼ ìœ„í•´ R&D ìì›ì„ ì¬ë°°ë¶„í•  í•„ìš”ëŠ” ì—†ì—ˆìŠµë‹ˆë‹¤. ì´ ì‚¬ì—…ì€ R&Dê°€ ë§¤ì¶œì˜ ì•½ 2%, 2.2% ìˆ˜ì¤€ì—ì„œ ìš´ì˜ë˜ê³  ìˆê¸° ë•Œë¬¸ì—, í•´ë‹¹ ì˜ˆì‚° ë‚´ì—ì„œ ì‹ ì œí’ˆ ê°œë°œì— ì§‘ì¤‘í•˜ë„ë¡ ì¬ë°°ë¶„ë§Œ í–ˆìŠµë‹ˆë‹¤. ì˜ì–‘ ë¶€ë¬¸ì—ì„œëŠ” ì•ìœ¼ë¡œ ëª‡ ë¶„ê¸° ë™ì•ˆ ì„±ì¥ì— ì–´ë ¤ì›€ì„ ê²ªì„ ê²ƒì…ë‹ˆë‹¤. ê·¸ëŸ¬ë‹¤ê°€ í•˜ë°˜ê¸°ì—ëŠ” ë‹¤ì‹œ í”ŒëŸ¬ìŠ¤ ì„±ì¥ìœ¼ë¡œ ëŒì•„ì„¤ ê²ƒì…ë‹ˆë‹¤. í˜„ì¬ íŒ€ì´ ë¬¼ëŸ‰ ê¸°ë°˜ ì„±ì¥ ì‚¬ì—…ìœ¼ë¡œì˜ ì „í™˜ì„ ì„±ê³µì ìœ¼ë¡œ ì‹¤í–‰í•  ìˆ˜ ìˆë‹¤ê³  í™•ì‹ í•©ë‹ˆë‹¤. 2022ë…„ ê³µê¸‰ ì°¨ì§ˆì´ ìˆì—ˆì„ ë•Œë¥¼ ë³´ë©´, ì‹œì¥ ì ìœ ìœ¨ì„ íšŒë³µí•˜ëŠ” ë° ì•½ 9ê°œì›”ì—ì„œ 12ê°œì›”ì´ ê±¸ë ¸ìŠµë‹ˆë‹¤. ì´ë²ˆì—ëŠ” ê·¸ë§Œí¼ ì˜¤ë˜ ê±¸ë¦¬ì§€ ì•Šì„ ê²ƒìœ¼ë¡œ ë´…ë‹ˆë‹¤. ì•½ 6ê°œì›” ì •ë„ì˜ ì¬ì¡°ì • ê³¼ì •ì´ ë  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•©ë‹ˆë‹¤. ì´ê²ƒì´ ë°”ë¡œ ìš°ë¦¬ ì„±ì¥ ì „ë§ì—ì„œ ìƒë°˜ê¸°ì™€ í•˜ë°˜ê¸°ì˜ ì°¨ì´ë¥¼ ë§Œë“œëŠ” ìš”ì¸ ì¤‘ í•˜ë‚˜ì…ë‹ˆë‹¤. í•˜ì§€ë§Œ ê·¸ ì™¸ì—ëŠ” ë˜ë¦¬, 10ì›”ê³¼ ë¹„êµí•´ì„œ ì‹¤ì œë¡œ ë‹¬ë¼ì§„ ê²ƒì´ ì—†ìŠµë‹ˆë‹¤. ì‚¬ì‹¤ íšŒì‚¬ì˜ ìƒë‹¹ ë¶€ë¶„ì´ ë†’ì€ í•œ ìë¦¿ìˆ˜ ë§¤ì¶œ ì„±ì¥ë¥ ì´ë‚˜ ë‚®ì€ 10ëŒ€ ì´ˆë°˜ ì„±ì¥ë¥ ì„ ìœ ì§€í•˜ê³  ìˆê±°ë‚˜, 2025ë…„ ëŒ€ë¹„ ì„±ì¥ì„ ê°€ì†í™”í•˜ê³  ìˆë‹¤ê³  ë§ì”€ë“œë¦´ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì‹¬í˜ˆê´€ í”„ëœì°¨ì´ì¦ˆë“ , ë‹¹ë‡¨ë³‘ ì œí’ˆì´ë“ , EPDë“ , ì œì•½ ì‚¬ì—…ì´ë“  ë§ˆì°¬ê°€ì§€ì…ë‹ˆë‹¤. ì‘ë…„ì— ì§ë©´í–ˆë˜ í•µì‹¬ ì§„ë‹¨ ì‚¬ì—…ì˜ ì—­í’ë„ ì´ì œ ê·¹ë³µí•˜ê²Œ ë  ê²ƒì…ë‹ˆë‹¤. ê¸°ì–µí•˜ì‹œê² ì§€ë§Œ, ì‘ë…„ ì§„ë‹¨ ì‚¬ì—…ì—ì„œ ì½”ë¡œë‚˜ì™€ ì¤‘êµ­ ë¬¸ì œë¡œ ì•½ 10ì–µ ë‹¬ëŸ¬ì˜ ì—­í’ì„ ê²ªì—ˆìŠµë‹ˆë‹¤. ì´ì œ ê·¸ê²ƒì€ ëŒ€ë¶€ë¶„ ìš°ë¦¬ ë’¤ì— ìˆê²Œ ë©ë‹ˆë‹¤. ì—¬ê¸°ì— Exact Sciencesë¼ëŠ” ë˜ ë‹¤ë¥¸ ê³ ì„±ì¥ ë¶„ì•¼ë¥¼ ì¶”ê°€í•˜ê²Œ ë©ë‹ˆë‹¤. ê·¸ë˜ì„œ ì—¬ê¸°ì—ëŠ” ê¸ì •ì ì¸ ìš”ì†Œê°€ ë§ë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. ì„±ì¥ ë™ë ¥ì´ ë§ì´ ìˆìŠµë‹ˆë‹¤. ì˜ì–‘ ë¶€ë¬¸ì—ì„œ í•´ì•¼ í•  ì¼ë“¤ì´ ìˆë‹¤ëŠ” ê²ƒì„ ì•Œê³  ìˆì§€ë§Œ, ê·¸ê²ƒ ë•Œë¬¸ì— ìš°ë¦¬ê°€ ê°€ì§„ í›Œë¥­í•œ ê¸°íšŒë“¤ë¡œë¶€í„° ì£¼ì˜ê°€ ë¶„ì‚°ë˜ì§€ëŠ” ì•Šì„ ê²ƒì„ì„ í™•ì‹ í•©ë‹ˆë‹¤. ë§ì”€ë“œë¦° ê²ƒì²˜ëŸ¼, 2026ë…„ì„ ìœ„í•œ ì¢‹ì€ ê¸°ë°˜ì„ ë§ˆë ¨í–ˆë‹¤ê³  ìƒê°í•˜ë©°, ì—°ì¤‘ ì§„í–‰ë˜ë©´ì„œ ë§ì€ ì„±ì¥ ê°€ì†í™”ê°€ ìˆì„ ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Our next question will come from David Roman from Goldman Sachs.</td><td>**Operator:** ë‹¤ìŒ ì§ˆë¬¸ì€ ê³¨ë“œë§Œì‚­ìŠ¤ì˜ David Romanìœ¼ë¡œë¶€í„° ë°›ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>David Roman: Goldman Sachs Group, Inc., Research Division I did want to start, Robert, on the pipeline and then maybe just ask a follow-up question if we have time on the guidance and the outlook. You did talk about some of the approvals in the EP business. And most specifically, can you help us sort of frame the Abbott portfolio in EP? Maybe looking back 6 months, where we are today, where you are then 6 to 12 months from now and contextualize kind of the portfolio relative to competition and where you see the biggest opportunities to accelerate growth there with Volt, TactiFlex Duo, TactiFlex VT, I think even next-gen Agilis, EnSite X, et cetera.</td><td>**David Roman:** íŒŒì´í”„ë¼ì¸ì— ëŒ€í•´ ë¨¼ì € ë§ì”€ë“œë¦¬ê³ , ì‹œê°„ì´ ë˜ë©´ ê°€ì´ë˜ìŠ¤ì™€ ì „ë§ì— ëŒ€í•œ ì¶”ê°€ ì§ˆë¬¸ë„ ë“œë¦¬ê³  ì‹¶ìŠµë‹ˆë‹¤. EP ì‚¬ì—… ë¶€ë¬¸ì˜ ìŠ¹ì¸ ê±´ë“¤ì— ëŒ€í•´ ë§ì”€í•˜ì…¨ëŠ”ë°ìš”. íŠ¹íˆ EP ë¶„ì•¼ì—ì„œ Abbott í¬íŠ¸í´ë¦¬ì˜¤ë¥¼ ì–´ë–»ê²Œ í‰ê°€í•´ì•¼ í• ì§€ ë„ì›€ì„ ì£¼ì‹¤ ìˆ˜ ìˆì„ê¹Œìš”? 6ê°œì›” ì „ì„ ëŒì•„ë³´ê³ , í˜„ì¬ ìƒí™©, ê·¸ë¦¬ê³  ì•ìœ¼ë¡œ 6~12ê°œì›” í›„ë¥¼ ì „ë§í•˜ë©´ì„œ, ê²½ìŸì‚¬ ëŒ€ë¹„ í¬íŠ¸í´ë¦¬ì˜¤ë¥¼ ì–´ë–»ê²Œ í‰ê°€í•˜ì‹œëŠ”ì§€, ê·¸ë¦¬ê³  Volt, TactiFlex Duo, TactiFlex VT, ì°¨ì„¸ëŒ€ Agilis, EnSite X ë“±ì„ í†µí•´ ì„±ì¥ì„ ê°€ì†í™”í•  ìˆ˜ ìˆëŠ” ê°€ì¥ í° ê¸°íšŒê°€ ì–´ë””ì— ìˆë‹¤ê³  ë³´ì‹œëŠ”ì§€ ë§ì”€í•´ ì£¼ì‹œê² ìŠµë‹ˆê¹Œ?</td></tr>
<tr><td>Robert Ford: Chairman, President & CEO Sure. I mean I think that -- I do have to put that into context though. I mean if you go back 3 years, David, there was a lot of concern about our franchise that was growing double digits, that was going to be flat or even negative because we didn't have a PFA catheter. We developed a strategy. The team put together a strategy. We presented to our Board 3 years ago in terms of what we were going to do. And over the last couple of years, even without PFA products, we've been able to actually sustain our double-digit growth rate '24 and 2025 without a PFA catheter. So the strategy that you're now referencing about our PFA products, that's just part of our strategy that we presented 3 years ago and laid out here. So we began launching the PFA product line in a much larger installed base of capital and mapping systems. The launch of Volt in Europe has gone very well. I'd say when we talked about developing Volt, we said, let's look at where some of the shortcomings of our first-generation products are and can we build those into Volt. And the feedback that I continue to see from the European market and quite frankly, through the last couple of weeks as we began our limited market release here in the U.S. is, 2 things keep jumping out pretty continuously is: one, the elegance, the ease and the smoothness and the predictability of the mapping integrated with the catheter, the visualization, all of that, that we spend a lot of time putting together. I continue to hear very positive feedback on that. And then the ability to potentially do these procedures with sedation versus general anesthesia, that is a recurring theme that I keep on hearing here. So I'd say the Volt launch has gone very much aligned to what we expected as we were putting the program together. This year, we'll have the launch of Volt here in the U.S. and TactiFlex Duo internationally. I think it comes down to -- we always wanted to make sure that we had a toolbox approach here for the physicians so they can have choice and they can have greater flexibility about how they use these products. I'm sure that there will be cases and types of patients and patient profiles that will lend itself more to a balloon and basket Volt-type design, and there are going to be types of patients and situations where TactiFlex Duo with its dual energy source will be preferred. And ultimately, it's going to be up to the physician to make those decisions, but I like the fact that the team as they put the strategy together that we would have both these products. I think you raised this point very well, which is I don't think that there is a company right now that's better positioned in terms of the completeness of the portfolio than what we have, whether it's technology or the scale and the infrastructure, starting with the capital placements that we've got, the incredibly competent clinical specialists that we have out in the field that have shown their value to our customers right now. We've got both RF and PFA products. We've got all the diagnostic elements, whether it's catheters, patches, et cetera, introducer sheaths, all of that, that you referenced. And on top of that, we've got an LAA device, which, I would say, is becoming pretty clear that if you want to be a leader in this space, you can't just look at having a PFA catheter, you got to have the full portfolio, including this device. Right now, it seems like 25% of LAA procedures are done concomitantly. So I think if you put all of that together, the portfolio that we've assembled, combined with the resilience of what this team has done and how they've executed, I've got high expectations for this business this year. The team knows that. I expect that we should grow at least in line with the market, David, which I expect -- I think it seems like the forecast here is mid- to high teens. So I think we're in a really good position, and I'm excited to see the second part of the strategy that we put together 3 years ago, and we're really excited to kind of put that second part of that phase into action now.</td><td>**Robert Ford:** 3ë…„ ì „ìœ¼ë¡œ ëŒì•„ê°€ë³´ë©´, ë‹¹ì‹œ ìš°ë¦¬ í”„ëœì°¨ì´ì¦ˆê°€ ë‘ ìë¦¿ìˆ˜ ì„±ì¥ì„ í•˜ê³  ìˆì—ˆìŒì—ë„ ë¶ˆêµ¬í•˜ê³  PFA ì¹´í…Œí„°ê°€ ì—†ì–´ì„œ ì„±ì¥ë¥ ì´ ì •ì²´ë˜ê±°ë‚˜ ì‹¬ì§€ì–´ ë§ˆì´ë„ˆìŠ¤ê°€ ë  ê²ƒì´ë¼ëŠ” ìš°ë ¤ê°€ ë§ì•˜ìŠµë‹ˆë‹¤. ê·¸ë˜ì„œ ìš°ë¦¬ëŠ” ì „ëµì„ ìˆ˜ë¦½í–ˆê³ , íŒ€ì´ ì „ëµì„ êµ¬ì„±í–ˆìœ¼ë©°, 3ë…„ ì „ ì´ì‚¬íšŒì— ìš°ë¦¬ê°€ ë¬´ì—‡ì„ í•  ê²ƒì¸ì§€ ë°œí‘œí–ˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì§€ë‚œ ëª‡ ë…„ê°„ PFA ì œí’ˆ ì—†ì´ë„ 2024ë…„ê³¼ 2025ë…„ì— ë‘ ìë¦¿ìˆ˜ ì„±ì¥ë¥ ì„ ì‹¤ì œë¡œ ìœ ì§€í•  ìˆ˜ ìˆì—ˆìŠµë‹ˆë‹¤. <br><br>ë”°ë¼ì„œ ì§€ê¸ˆ ë§ì”€í•˜ì‹œëŠ” PFA ì œí’ˆì— ëŒ€í•œ ì „ëµì€ ì‚¬ì‹¤ 3ë…„ ì „ì— ì œì‹œí•˜ê³  ì„¤ëª…í–ˆë˜ ìš°ë¦¬ ì „ëµì˜ ì¼ë¶€ì¼ ë¿ì…ë‹ˆë‹¤. PFA ì œí’ˆ ë¼ì¸ì„ í›¨ì”¬ ë” í° ê·œëª¨ì˜ ê¸°ì¡´ ìë³¸ ë° ë§¤í•‘ ì‹œìŠ¤í…œ ì„¤ì¹˜ ê¸°ë°˜ì—ì„œ ì¶œì‹œí•˜ê¸° ì‹œì‘í–ˆìŠµë‹ˆë‹¤. ìœ ëŸ½ì—ì„œì˜ Volt ì¶œì‹œëŠ” ë§¤ìš° ìˆœì¡°ë¡­ê²Œ ì§„í–‰ë˜ê³  ìˆìŠµë‹ˆë‹¤. Volt ê°œë°œ ë‹¹ì‹œ ìš°ë¦¬ê°€ í–ˆë˜ ì´ì•¼ê¸°ëŠ”, 1ì„¸ëŒ€ ì œí’ˆì˜ ì¼ë¶€ ë‹¨ì ë“¤ì„ ì‚´í´ë³´ê³  ì´ë¥¼ Voltì— ë°˜ì˜í•  ìˆ˜ ìˆëŠ”ì§€ ê²€í† í•´ë³´ìëŠ” ê²ƒì´ì—ˆìŠµë‹ˆë‹¤. ìœ ëŸ½ ì‹œì¥ì—ì„œ ì§€ì†ì ìœ¼ë¡œ ë°›ê³  ìˆëŠ” í”¼ë“œë°±ê³¼, ì†”ì§íˆ ë§ì”€ë“œë¦¬ë©´ ì§€ë‚œ ëª‡ ì£¼ê°„ ë¯¸êµ­ì—ì„œ ì œí•œì  ì‹œì¥ ì¶œì‹œë¥¼ ì‹œì‘í•˜ë©´ì„œ ë°›ì€ í”¼ë“œë°±ì„ ë³´ë©´, ë‘ ê°€ì§€ê°€ ê³„ì†í•´ì„œ ë‘ë“œëŸ¬ì§€ê²Œ ë‚˜íƒ€ë‚˜ê³  ìˆìŠµë‹ˆë‹¤. ì²«ì§¸ëŠ” ì¹´í…Œí„°ì™€ í†µí•©ëœ ë§¤í•‘ì˜ ìš°ì•„í•¨, ì‚¬ìš© í¸ì˜ì„±, ë¶€ë“œëŸ¬ì›€, ì˜ˆì¸¡ ê°€ëŠ¥ì„±, ì‹œê°í™” ë“± ìš°ë¦¬ê°€ ë§ì€ ì‹œê°„ì„ ë“¤ì—¬ êµ¬í˜„í•œ ëª¨ë“  ìš”ì†Œë“¤ì…ë‹ˆë‹¤. ì´ ë¶€ë¶„ì— ëŒ€í•´ ê³„ì†í•´ì„œ ë§¤ìš° ê¸ì •ì ì¸ í”¼ë“œë°±ì„ ë°›ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì „ì‹  ë§ˆì·¨ ëŒ€ì‹  ì§„ì •ì œë¥¼ ì‚¬ìš©í•˜ì—¬ ì´ëŸ¬í•œ ì‹œìˆ ì„ ìˆ˜í–‰í•  ìˆ˜ ìˆëŠ” ê°€ëŠ¥ì„±, ì´ê²ƒì´ ì œê°€ ê³„ì†í•´ì„œ ë“£ê³  ìˆëŠ” ë°˜ë³µì ì¸ ì£¼ì œì…ë‹ˆë‹¤. ë”°ë¼ì„œ Volt ì¶œì‹œëŠ” í”„ë¡œê·¸ë¨ì„ êµ¬ì„±í•  ë•Œ ì˜ˆìƒí–ˆë˜ ê²ƒê³¼ ë§¤ìš° ì¼ì¹˜í•˜ê²Œ ì§„í–‰ë˜ì—ˆë‹¤ê³  ë§ì”€ë“œë¦´ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì˜¬í•´ëŠ” ë¯¸êµ­ì—ì„œ Voltë¥¼, í•´ì™¸ì—ì„œëŠ” TactiFlex Duoë¥¼ ì¶œì‹œí•  ì˜ˆì •ì…ë‹ˆë‹¤. ê²°êµ­ í•µì‹¬ì€ ì˜ì‚¬ë“¤ì´ ì„ íƒê¶Œì„ ê°€ì§€ê³  ì´ëŸ¬í•œ ì œí’ˆë“¤ì„ ì–´ë–»ê²Œ ì‚¬ìš©í• ì§€ì— ëŒ€í•´ ë” í° ìœ ì—°ì„±ì„ ê°€ì§ˆ ìˆ˜ ìˆë„ë¡ íˆ´ë°•ìŠ¤ ì ‘ê·¼ ë°©ì‹ì„ í™•ë³´í•˜ê³ ì í–ˆë‹¤ëŠ” ê²ƒì…ë‹ˆë‹¤. í’ì„ ê³¼ ë°”ìŠ¤ì¼“ Volt íƒ€ì… ë””ìì¸ì´ ë” ì í•©í•œ í™˜ì ì¼€ì´ìŠ¤ì™€ ìœ í˜•, í™˜ì í”„ë¡œíŒŒì¼ì´ ë¶„ëª…íˆ ìˆì„ ê²ƒì´ê³ , ë“€ì–¼ ì—ë„ˆì§€ ì†ŒìŠ¤ë¥¼ ê°–ì¶˜ TactiFlex Duoê°€ ì„ í˜¸ë˜ëŠ” í™˜ì ìœ í˜•ê³¼ ìƒí™©ë“¤ë„ ìˆì„ ê²ƒì…ë‹ˆë‹¤. ê¶ê·¹ì ìœ¼ë¡œëŠ” ì˜ì‚¬ê°€ ì´ëŸ¬í•œ ê²°ì •ì„ ë‚´ë¦¬ê²Œ ë˜ê² ì§€ë§Œ, ì €ëŠ” íŒ€ì´ ì „ëµì„ ìˆ˜ë¦½í•˜ë©´ì„œ ì´ ë‘ ì œí’ˆì„ ëª¨ë‘ ë³´ìœ í•˜ê²Œ ëœ ê²ƒì´ ë§¤ìš° ê¸ì •ì ì´ë¼ê³  ìƒê°í•©ë‹ˆë‹¤. ê·€í•˜ê»˜ì„œ ì•„ì£¼ ì¤‘ìš”í•œ ì ì„ ì§€ì í•´ ì£¼ì…¨ìŠµë‹ˆë‹¤. í˜„ì¬ ìš°ë¦¬ë§Œí¼ ì™„ë²½í•œ í¬íŠ¸í´ë¦¬ì˜¤ë¥¼ ê°–ì¶˜ íšŒì‚¬ëŠ” ì—†ë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. ê¸°ìˆ  ì¸¡ë©´ì—ì„œë“  ê·œëª¨ì™€ ì¸í”„ë¼ ì¸¡ë©´ì—ì„œë“  ë§ì…ë‹ˆë‹¤. ìš°ë¦¬ê°€ í™•ë³´í•œ ìë³¸ ì¥ë¹„ ë°°ì¹˜ë¶€í„° ì‹œì‘í•´ì„œ, í˜„ì¥ì—ì„œ ê³ ê°ë“¤ì—ê²Œ ê·¸ ê°€ì¹˜ë¥¼ ì…ì¦í•´ì˜¨ ë§¤ìš° ìœ ëŠ¥í•œ ì„ìƒ ì „ë¬¸ê°€ë“¤ê¹Œì§€ ëª¨ë‘ ê°–ì¶”ê³  ìˆìŠµë‹ˆë‹¤. RFì™€ PFA ì œí’ˆì„ ëª¨ë‘ ë³´ìœ í•˜ê³  ìˆê³ , ë§ì”€í•˜ì‹  ì¹´í…Œí„°, íŒ¨ì¹˜ ë“± ëª¨ë“  ì§„ë‹¨ ìš”ì†Œë“¤, ë„ì… ì‹œìŠ¤(introducer sheath) ë“± ì „ë¶€ ë‹¤ ê°–ì¶”ê³  ìˆìŠµë‹ˆë‹¤. ê²Œë‹¤ê°€ ìš°ë¦¬ëŠ” LAA ë””ë°”ì´ìŠ¤ë„ ë³´ìœ í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ ë¶„ì•¼ì—ì„œ ë¦¬ë”ê°€ ë˜ê³ ì í•œë‹¤ë©´ PFA ì¹´í…Œí„°ë§Œìœ¼ë¡œëŠ” ì¶©ë¶„í•˜ì§€ ì•Šê³ , ì´ ë””ë°”ì´ìŠ¤ë¥¼ í¬í•¨í•œ ì „ì²´ í¬íŠ¸í´ë¦¬ì˜¤ë¥¼ ê°–ì¶°ì•¼ í•œë‹¤ëŠ” ê²ƒì´ ì´ì œ ëª…í™•í•´ì§€ê³  ìˆìŠµë‹ˆë‹¤. í˜„ì¬ LAA ì‹œìˆ ì˜ 25%ê°€ ë™ì‹œì— ì§„í–‰ë˜ê³  ìˆëŠ” ê²ƒìœ¼ë¡œ ë³´ì…ë‹ˆë‹¤. ì´ ëª¨ë“  ê²ƒì„ ì¢…í•©í•´ë³´ë©´, ìš°ë¦¬ê°€ êµ¬ì¶•í•œ í¬íŠ¸í´ë¦¬ì˜¤ì™€ íŒ€ì´ ë³´ì—¬ì¤€ íšŒë³µë ¥ ë° ì‹¤í–‰ë ¥ì„ ê°ì•ˆí•  ë•Œ, ì €ëŠ” ì˜¬í•´ ì´ ì‚¬ì—…ì— ëŒ€í•´ ë†’ì€ ê¸°ëŒ€ë¥¼ ê°€ì§€ê³  ìˆìŠµë‹ˆë‹¤. íŒ€ë„ ì´ë¥¼ ì˜ ì•Œê³  ìˆìŠµë‹ˆë‹¤. ë°ì´ë¹„ë“œ, ìš°ë¦¬ëŠ” ìµœì†Œí•œ ì‹œì¥ ì„±ì¥ë¥ ì— ë§ì¶° ì„±ì¥í•´ì•¼ í•œë‹¤ê³  ê¸°ëŒ€í•˜ê³  ìˆìœ¼ë©°, ì‹œì¥ ì „ë§ì€ 10ëŒ€ ì¤‘í›„ë°˜ëŒ€ ì„±ì¥ë¥ ë¡œ ë³´ì…ë‹ˆë‹¤. ì €í¬ëŠ” ì •ë§ ì¢‹ì€ ìœ„ì¹˜ì— ìˆë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. 3ë…„ ì „ì— ìˆ˜ë¦½í•œ ì „ëµì˜ ë‘ ë²ˆì§¸ íŒŒíŠ¸ë¥¼ ì‹¤í–‰í•˜ê²Œ ë˜ì–´ ë§¤ìš° ê¸°ëŒ€ê°€ ë©ë‹ˆë‹¤. ì´ì œ ê·¸ ë‘ ë²ˆì§¸ ë‹¨ê³„ë¥¼ ë³¸ê²©ì ìœ¼ë¡œ ì‹¤í–‰ì— ì˜®ê¸°ê²Œ ë˜ì–´ ì •ë§ ì„¤ë ™ë‹ˆë‹¤.</td></tr>
<tr><td>David Roman: Goldman Sachs Group, Inc., Research Division Very helpful. Maybe just a follow-up on the guidance. Look, I think we all know that you don't solve your guidance to meet short-term consensus and you are committed to achieving your commitments. But as you thought about putting together the outlook for 2026, considering some of the different variables that you faced over the past couple of quarters, like how did you think about risk adjusting the outlook? And maybe just help us think about the considerations in the guidance and maybe just your philosophy as you kind of put the outlook together here.</td><td>**David Roman:** ë§¤ìš° ë„ì›€ì´ ë˜ì—ˆìŠµë‹ˆë‹¤. ê°€ì´ë˜ìŠ¤ì— ëŒ€í•´ í›„ì† ì§ˆë¬¸ ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ê·€ì‚¬ê°€ ë‹¨ê¸° ì»¨ì„¼ì„œìŠ¤ë¥¼ ë§ì¶”ê¸° ìœ„í•´ ê°€ì´ë˜ìŠ¤ë¥¼ ì¡°ì •í•˜ì§€ ì•Šìœ¼ë©°, ì•½ì†í•œ ëª©í‘œ ë‹¬ì„±ì— ì „ë…í•˜ê³  ê³„ì‹ ë‹¤ëŠ” ê²ƒì„ ìš°ë¦¬ ëª¨ë‘ ì•Œê³  ìˆìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ 2026ë…„ ì „ë§ì„ ìˆ˜ë¦½í•˜ì‹œë©´ì„œ, ì§€ë‚œ ëª‡ ë¶„ê¸° ë™ì•ˆ ì§ë©´í•˜ì…¨ë˜ ì—¬ëŸ¬ ë³€ìˆ˜ë“¤ì„ ê³ ë ¤í•  ë•Œ, ì „ë§ì— ëŒ€í•œ ë¦¬ìŠ¤í¬ ì¡°ì •ì„ ì–´ë–»ê²Œ ê³ ë ¤í•˜ì…¨ëŠ”ì§€ ê¶ê¸ˆí•©ë‹ˆë‹¤. ê°€ì´ë˜ìŠ¤ ìˆ˜ë¦½ ì‹œ ê³ ë ¤í•˜ì‹  ì‚¬í•­ë“¤ê³¼, ì „ë§ì„ êµ¬ì„±í•˜ì‹¤ ë•Œì˜ ì² í•™ì— ëŒ€í•´ ì„¤ëª…í•´ ì£¼ì‹œë©´ ì¢‹ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Robert Ford: Chairman, President & CEO Well, I mean, listen, I think if you look at our growth for 2026, I mean, we've always targeted high single digits and double digit -- high single-digit top line, double-digit bottom line. That's our investment identity, and we've kind of followed through with that. If you look at our 2026, I think the way you need to kind of look at it is you've got a very big portion of the company that is going to -- that we're sustaining that growth. In some cases, it will be accelerating, but a large portion of the company is sustaining this high single-digit growth, whether it's in Cardiovascular, whether it's in Diabetes, we've got a bunch of new products launching to be able to support those kind of growth profiles in the business. EPD supporting with the biosimilar launch, that high single-digit kind of growth rate. So you've got large portions and even some geographies that we can sustain that growth, and we feel that we're supporting it with product launches and investment to sustain what I consider a pretty differentiated growth rate. Then you've got the second bucket, which is, I'd say, an acceleration in our diagnostics. And all that really is, we've been doing very well, taking share in our Core Lab business across the world. And what -- we had a challenge with last year is with COVID coming down, in 2024, I think it was like $750 million coming down to $250 million. So you had $0.5 billion headwind there. And then you had another $400 million headwind in China VBP, right? Our forecast for COVID is around that same number, around $200 million. So I'm not expecting any significant growth or decline. And a lot of the VBP, they come in waves. The vast majority of our sales in China have gone through the VBP in 2025. So we really felt that impact in 2025. There's going to be more VBPs in China, but the shares that we have in those waves are very, very small compared to what we have. So you've got this whole lapping of our Diagnostic business. And as long as we keep on doing what we're doing in United States and Europe and Latin America and other parts in Asia, which we have been doing, you're going to see a nice acceleration in our Diagnostic business. And you started to see that throughout the year as the VBP impact started to dissipate a little bit as the year progressed. You've got then, obviously, as I spoke quite at length here about this transition with Nutrition, you've got probably 1 or 2 quarters here where our growth is going to be challenged. But I am confident that what we're going to be able to do here is reignite the volume growth, and you'll see that business get back to growth. So those elements there, Dave, really look at it and say, okay, you've got continued momentum in a large portion of the business. You've got some lapping that's going to be happening. And then we've got this transition, which I consider to be pretty short term here of a couple of quarters, to be able to get to this guide on the Nutrition side. And then I'm sure we'll talk about Exact Sciences, but that's another factor here that you add on, a $3 billion-plus business growing 15%, with a lot of growth opportunities for us. So that's kind of how we looked at it at least from a top line. And then having that flow through down to the bottom line, making investments in the areas that we need to and nice gross margin and op margin profile expansion, too.</td><td>**Robert Ford:** 2026ë…„ ì„±ì¥ë¥ ì„ ë³´ì‹œë©´, ì €í¬ëŠ” í•­ìƒ ë§¤ì¶œì€ ë†’ì€ í•œ ìë¦¿ìˆ˜, ì´ìµì€ ë‘ ìë¦¿ìˆ˜ ì„±ì¥ì„ ëª©í‘œë¡œ í•´ì™”ìŠµë‹ˆë‹¤. ì´ê²ƒì´ ì €í¬ì˜ íˆ¬ì ì •ì²´ì„±ì´ê³ , ì§€ê¸ˆê¹Œì§€ ì´ë¥¼ ì¶©ì‹¤íˆ ì´í–‰í•´ì™”ìŠµë‹ˆë‹¤. 2026ë…„ì„ ë³´ì‹œë©´, íšŒì‚¬ì˜ ìƒë‹¹ ë¶€ë¶„ì´ ì´ëŸ¬í•œ ì„±ì¥ì„¸ë¥¼ ìœ ì§€í•  ê²ƒì…ë‹ˆë‹¤. ì¼ë¶€ ì˜ì—­ì—ì„œëŠ” ì„±ì¥ì´ ê°€ì†í™”ë  ê²ƒì´ê³ , íšŒì‚¬ì˜ í° ë¶€ë¶„ì´ ë†’ì€ í•œ ìë¦¿ìˆ˜ ì„±ì¥ì„ ì§€ì†í•  ê²ƒì…ë‹ˆë‹¤. ì‹¬í˜ˆê´€(Cardiovascular) ë¶€ë¬¸ì´ë“  ë‹¹ë‡¨(Diabetes) ë¶€ë¬¸ì´ë“ , ì´ëŸ¬í•œ ì„±ì¥ í”„ë¡œí•„ì„ ë’·ë°›ì¹¨í•  ìˆ˜ ìˆëŠ” ì‹ ì œí’ˆë“¤ì„ ë‹¤ìˆ˜ ì¶œì‹œí•  ì˜ˆì •ì…ë‹ˆë‹¤. ë°”ì´ì˜¤ì‹œë°€ëŸ¬ ì¶œì‹œë¥¼ ì§€ì›í•˜ëŠ” EPD ë¶€ë¬¸ì—ì„œ ë†’ì€ í•œ ìë¦¿ìˆ˜ ì„±ì¥ë¥ ì„ ë³´ì´ê³  ìˆìŠµë‹ˆë‹¤. ìƒë‹¹ ë¶€ë¶„ì˜ ì‚¬ì—…ê³¼ ì¼ë¶€ ì§€ì—­ì—ì„œ ì´ëŸ¬í•œ ì„±ì¥ì„ ì§€ì†í•  ìˆ˜ ìˆìœ¼ë©°, ì œí’ˆ ì¶œì‹œì™€ íˆ¬ìë¥¼ í†µí•´ ì°¨ë³„í™”ëœ ì„±ì¥ë¥ ì„ ìœ ì§€í•˜ê³  ìˆë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤.<br><br>ë‘ ë²ˆì§¸ ë¶€ë¬¸ì€ ì§„ë‹¨(diagnostics) ì‚¬ì—…ì˜ ê°€ì†í™”ì…ë‹ˆë‹¤. ì‚¬ì‹¤ ìš°ë¦¬ëŠ” ì „ ì„¸ê³„ì ìœ¼ë¡œ Core Lab ì‚¬ì—…ì—ì„œ ì‹œì¥ ì ìœ ìœ¨ì„ í™•ëŒ€í•˜ë©° ë§¤ìš° ì¢‹ì€ ì„±ê³¼ë¥¼ ë‚´ê³  ìˆìŠµë‹ˆë‹¤. ì‘ë…„ì— ì–´ë ¤ì› ë˜ ì ì€ COVID ê´€ë ¨ ë§¤ì¶œì´ 2024ë…„ì— 7ì–µ 5ì²œë§Œ ë‹¬ëŸ¬ì—ì„œ 2ì–µ 5ì²œë§Œ ë‹¬ëŸ¬ë¡œ ê°ì†Œí•˜ë©´ì„œ 5ì–µ ë‹¬ëŸ¬ì˜ ì—­í’ì´ ìˆì—ˆë‹¤ëŠ” ê²ƒì…ë‹ˆë‹¤. ê±°ê¸°ì— ì¤‘êµ­ VBP(Volume-Based Procurement, ì˜ì•½í’ˆ ì§‘ì¤‘êµ¬ë§¤)ë¡œ ì¸í•œ 4ì–µ ë‹¬ëŸ¬ì˜ ì¶”ê°€ ì—­í’ë„ ìˆì—ˆìŠµë‹ˆë‹¤. ì½”ë¡œë‚˜ ê´€ë ¨ ë§¤ì¶œ ì „ë§ì€ ì•½ 2ì–µ ë‹¬ëŸ¬ ìˆ˜ì¤€ìœ¼ë¡œ ë™ì¼í•©ë‹ˆë‹¤. ë”°ë¼ì„œ í° í­ì˜ ì„±ì¥ì´ë‚˜ ê°ì†ŒëŠ” ì˜ˆìƒí•˜ì§€ ì•ŠìŠµë‹ˆë‹¤. VBP(Volume-Based Procurement, ì§‘ì¤‘êµ¬ë§¤)ëŠ” ë‹¨ê³„ì ìœ¼ë¡œ ì§„í–‰ë˜ëŠ”ë°, ì¤‘êµ­ ë‚´ ë§¤ì¶œì˜ ëŒ€ë¶€ë¶„ì´ 2025ë…„ì— VBPë¥¼ ê±°ì³¤ìŠµë‹ˆë‹¤. ê·¸ë˜ì„œ 2025ë…„ì— ê·¸ ì˜í–¥ì„ ì‹¤ì§ˆì ìœ¼ë¡œ ì²´ê°í–ˆìŠµë‹ˆë‹¤. ì¤‘êµ­ì—ì„œ ì•ìœ¼ë¡œë„ VBPê°€ ë” ìˆê² ì§€ë§Œ, í–¥í›„ ë‹¨ê³„ì—ì„œ ìš°ë¦¬ê°€ ì°¨ì§€í•˜ëŠ” ë¹„ì¤‘ì€ ê¸°ì¡´ ëŒ€ë¹„ ë§¤ìš° ì‘ìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ì§„ë‹¨ ì‚¬ì—… ì „ì²´ì ìœ¼ë¡œëŠ” ê¸°ì €íš¨ê³¼ê°€ ë°œìƒí•˜ê²Œ ë©ë‹ˆë‹¤. ê·¸ë¦¬ê³  ë¯¸êµ­, ìœ ëŸ½, ë¼í‹´ì•„ë©”ë¦¬ì¹´, ì•„ì‹œì•„ ê¸°íƒ€ ì§€ì—­ì—ì„œ ì§€ê¸ˆê¹Œì§€ í•´ì™”ë˜ ê²ƒì²˜ëŸ¼ ê³„ì† ì˜ ìˆ˜í–‰í•´ ë‚˜ê°„ë‹¤ë©´, ì§„ë‹¨ ì‚¬ì—…ì—ì„œ ìƒë‹¹í•œ ì„±ì¥ ê°€ì†í™”ë¥¼ ë³´ì‹¤ ìˆ˜ ìˆì„ ê²ƒì…ë‹ˆë‹¤. ì—°ì¤‘ VBP ì˜í–¥ì´ ì ì°¨ ì™„í™”ë˜ë©´ì„œ ê·¸ëŸ° ëª¨ìŠµì„ ë³´ê¸° ì‹œì‘í–ˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì œê°€ ì˜ì–‘ ì‚¬ì—… ì „í™˜ì— ëŒ€í•´ ìƒë‹¹íˆ ê¸¸ê²Œ ë§ì”€ë“œë ¸ë“¯ì´, ì•„ë§ˆë„ 1~2ë¶„ê¸° ì •ë„ëŠ” ìš°ë¦¬ ì„±ì¥ì´ ë„ì „ì„ ë°›ì„ ê²ƒì…ë‹ˆë‹¤. í•˜ì§€ë§Œ ì €ëŠ” ìš°ë¦¬ê°€ ì—¬ê¸°ì„œ ë³¼ë¥¨ ì„±ì¥ì„ ì¬ì í™”í•  ìˆ˜ ìˆì„ ê²ƒì´ë¼ í™•ì‹ í•˜ë©°, ê·¸ ì‚¬ì—…ì´ ë‹¤ì‹œ ì„±ì¥ì„¸ë¡œ ëŒì•„ì„œëŠ” ê²ƒì„ ë³´ì‹œê²Œ ë  ê²ë‹ˆë‹¤. <br><br>ë°ì´ë¸Œ, ì´ëŸ° ìš”ì†Œë“¤ì„ ë³´ë©´ ì´ë ‡ê²Œ ì •ë¦¬í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì‚¬ì—…ì˜ ìƒë‹¹ ë¶€ë¶„ì—ì„œ ì§€ì†ì ì¸ ëª¨ë©˜í…€ì´ ìˆê³ , ê¸°ì €íš¨ê³¼ê°€ ë°œìƒí•  ë¶€ë¶„ì´ ìˆìœ¼ë©°, ì˜ì–‘ ì‚¬ì—… ìª½ì—ì„œëŠ” ê°€ì´ë˜ìŠ¤ë¥¼ ë‹¬ì„±í•˜ê¸° ìœ„í•œ ë¹„êµì  ë‹¨ê¸°ì ì¸ ì „í™˜ê¸°, ì¦‰ ëª‡ ë¶„ê¸° ì •ë„ì˜ ê³¼ë„ê¸°ë¥¼ ê±°ì¹˜ê²Œ ë©ë‹ˆë‹¤. ê·¸ë¦¬ê³  Exact Sciencesì— ëŒ€í•´ì„œë„ ë¶„ëª…íˆ ë…¼ì˜í•˜ê²Œ ë  í…ë°, ì´ê²ƒë„ ì—¬ê¸°ì— ì¶”ê°€ë˜ëŠ” ë˜ ë‹¤ë¥¸ ìš”ì†Œì…ë‹ˆë‹¤. 30ì–µ ë‹¬ëŸ¬ ì´ìƒ ê·œëª¨ì˜ ì‚¬ì—…ì´ 15% ì„±ì¥í•˜ê³  ìˆê³ , ìš°ë¦¬ì—ê²ŒëŠ” ë§ì€ ì„±ì¥ ê¸°íšŒê°€ ìˆìŠµë‹ˆë‹¤. ê·¸ë˜ì„œ ìµœì†Œí•œ ë§¤ì¶œ ì¸¡ë©´ì—ì„œëŠ” ì´ëŸ° ì‹ìœ¼ë¡œ ë°”ë¼ë´¤ìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì´ê²ƒì´ ìµœì¢… ìˆ˜ìµìœ¼ë¡œ ì´ì–´ì§€ë©´ì„œ, í•„ìš”í•œ ë¶„ì•¼ì— íˆ¬ìë¥¼ ì§„í–‰í•˜ê³ , ë§¤ìš° ì¢‹ì€ ë§¤ì¶œì´ì´ìµë¥ (gross margin)ê³¼ ì˜ì—…ì´ìµë¥ (operating margin) í”„ë¡œíŒŒì¼ í™•ëŒ€ë„ í•¨ê»˜ ì´ë£¨ì–´ì§€ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Our next question will come from Robbie Marcus from JPMorgan.</td><td>**Operator:** ë‹¤ìŒ ì§ˆë¬¸ì€ JPMorganì˜ Robbie Marcusë‹˜ê»˜ì„œ ì£¼ì‹œê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Robert Marcus: JPMorgan Chase & Co, Research Division Two for me. Robert, last week, when we were talking, you said you expect CGM to continue to track higher at about $1 billion a year. That would put 2026 somewhere in the low to mid-teens. Is that the right way to think about CGM growth next year? And maybe if you just want to give your updated thoughts on market growth and Abbott's position there? And then I have a follow-up.</td><td>**Robert Marcus:** JPMorgan Chase & Co, ë¦¬ì„œì¹˜ ë¶€ë¬¸ì…ë‹ˆë‹¤. ë‘ ê°€ì§€ ì§ˆë¬¸ ë“œë¦¬ê² ìŠµë‹ˆë‹¤. Robert, ì§€ë‚œì£¼ ì €í¬ê°€ ëŒ€í™”í•  ë•Œ CGMì´ ì—°ê°„ ì•½ 10ì–µ ë‹¬ëŸ¬ì”© ê³„ì† ì¦ê°€í•  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ì‹ ë‹¤ê³  ë§ì”€í•˜ì…¨ìŠµë‹ˆë‹¤. ê·¸ë ‡ë‹¤ë©´ 2026ë…„ì—ëŠ” 10ëŒ€ ì´ˆì¤‘ë°˜ ì •ë„ê°€ ë  ê²ƒìœ¼ë¡œ ë³´ì´ëŠ”ë°ìš”. ë‚´ë…„ CGM ì„±ì¥ë¥ ì„ ì´ë ‡ê²Œ ìƒê°í•˜ëŠ” ê²ƒì´ ë§ëŠ”ì§€ìš”? ê·¸ë¦¬ê³  ì‹œì¥ ì„±ì¥ê³¼ ê·¸ ì•ˆì—ì„œ Abbottì˜ í¬ì§€ì…˜ì— ëŒ€í•œ ìµœì‹  ê²¬í•´ë¥¼ ë§ì”€í•´ ì£¼ì‹œë©´ ê°ì‚¬í•˜ê² ìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì¶”ê°€ ì§ˆë¬¸ì´ í•˜ë‚˜ ë” ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Robert Ford: Chairman, President & CEO Sure. When you said next year, you mean 2026, right?</td><td>**Robert Ford:** ë„¤, ë‚´ë…„ì´ë¼ê³  í•˜ì‹  ê²Œ 2026ë…„ì„ ë§ì”€í•˜ì‹œëŠ” ê±°ì£ ?</td></tr>
<tr><td>Robert Marcus: JPMorgan Chase & Co, Research Division</td><td>**Robert Marcus:** I notice that you've only provided a header "JPMorgan Chase & Co, Research Division" without any actual Q&A content to translate.<br><br>Could you please provide the management response or Q&A dialogue that you'd like me to translate into Korean? Once you share the actual spoken content from the earnings call, I'll be happy to translate it following the guidelines you've specified.</td></tr>
<tr><td>Robert Ford: Chairman, President & CEO Yes. I mean, I think -- yes, there's all debate that I read about that the market is slowing. And I get if you're just looking at percentages and that's how you base yourself off it, then I guess, if it's that myopic, then I think, okay, I understand the conclusion. But I don't consider growing $1 billion every single year and doing it 4 years in a row to be slowing down here, Robbie. I think the math will work out to what you just kind of highlighted there in the kind of low teens. But I think there's got a lot -- still a lot of opportunity for penetration in this, both from a market perspective, but then also from our opportunity, our ability to drive market share and market expansion. I think that if you look at across all 3 patient groups, whether it's the intensive insulin user, the basal insulin user and the non-insulin user, all of those areas, still there's so much penetration to be able to have here. And you can see across the world, not just in the United States, but across the world, a lot of movement, whether it's patient groups, health care systems that are looking to expand the use and the adoption of the technology into all these patient segments. I know the U.S. gets a lot of attention, and it's an important market, and there's a lot of great opportunities for us there in terms of the non-insulin user reimbursement opportunity. I continue to see nice progress in this process. There seems to be a lot of support to do this. And the data that we've shown, like we published 3 studies already that show that this patient segment also benefits with lower A1c, greater time in range, all the things that have driven kind of reimbursement in the other segments. So I think that this is a very strong opportunity for us here in the U.S. And we'll see how it plays out. I think we'll see some language in the first half and then how it all plays out with comment periods. You know this, Robbie, there's comment periods, there's all of this. So I'm not baking that into my guidance, but I can tell you, we will be 150% ready to execute, whether it's having manufacturing capacity and having the scale and the position on the primary care side, which is where that will probably play out more, we'll be ready. So that provides an opportunity to outperform that consensus forecast. I think on the intensive insulin user side, I still think there's penetration to be had and adoption to be had, especially in international markets. I think that's only about 50% penetrated. So I think there's still a lot of opportunity to do the work that we're doing there. Obviously, scale and cost matter in the international markets, and I think we've got that position set. And then as you look at what I think is more specific to us, the opportunity to bring in a very differentiated product to look at market share shift in a segment that I'd say we're probably a little bit underrepresented from a market share perspective, which is on the pumper side with the launch of our GKS sensor. I think that's going to provide us a great opportunity. I'm not going to try and pinpoint the exact quarter here, Robbie. When we get approval, we'll issue the press release and we'll be out. But we've been working hard already concomitantly with the regulatory process with KOLs, with physician groups, with payers. And I think there was an article that came out in the Lancet in January talking about -- beginning of this year, talking about the importance of measuring continuously ketones as DKA still a -- is still a major care gap here for people with diabetes. So I think you've got a big opportunity here with this product for market share conversion. I think one of the surprising things for me in this as we started to really double-click on these patient segments is we talked about the SGLT2 population. So we did some analysis in the U.S. You got about 6 million SGLT2 users in the U.S. And if you cross reference their usage of CGM through all the databases, only about 1 million of those 6 million are on CGMs. So I think there's going to be an opportunity here also to kind of create market expansion with this product. So not just share capture, but also market expansion. So this market is still very robust. It's becoming larger. So I get the law of big numbers kind of lowers those percentages. But if you just look at it from a penetration perspective, Robbie, there's still so much to do in all these segments in different geographies that we're still very excited and making big investments, whether it's in sales and marketing, clinical, R&D and manufacturing because we still think that this is still -- I'm not going to say it's the first or second inning, but we're far away from being from the seventh inning on this one. So I think there's still a lot of opportunity here, and we're in a good position.</td><td>**Robert Ford:** ë„¤, ì œ ìƒê°ì—ëŠ”... ì‹œì¥ì´ ë‘”í™”ë˜ê³  ìˆë‹¤ëŠ” ë…¼ìŸë“¤ì„ ë§ì´ ì½ì–´ë´¤ìŠµë‹ˆë‹¤. ë‹¨ìˆœíˆ í¼ì„¼íŠ¸ë§Œ ë³´ê³  ê·¸ê²ƒë§Œìœ¼ë¡œ íŒë‹¨í•˜ì‹ ë‹¤ë©´, ê·¸ë ‡ê²Œ ê·¼ì‹œì•ˆì ìœ¼ë¡œ ë³¸ë‹¤ë©´ ê·¸ëŸ° ê²°ë¡ ì´ ë‚˜ì˜¬ ìˆ˜ ìˆë‹¤ëŠ” ê±´ ì´í•´í•©ë‹ˆë‹¤. í•˜ì§€ë§Œ ì €ëŠ” ë§¤ë…„ 10ì–µ ë‹¬ëŸ¬ì”© ì„±ì¥í•˜ê³  ê·¸ê²ƒì„ 4ë…„ ì—°ì† ë‹¬ì„±í•˜ëŠ” ê²ƒì„ ë‘”í™”ë¼ê³  ìƒê°í•˜ì§€ ì•ŠìŠµë‹ˆë‹¤, ë¡œë¹„. ë°©ê¸ˆ ë§ì”€í•˜ì‹  ê²ƒì²˜ëŸ¼ ìˆ˜ì¹˜ìƒìœ¼ë¡œëŠ” 10% ì´ˆë°˜ëŒ€ ì •ë„ë¡œ ê³„ì‚°ë  ê²ƒì…ë‹ˆë‹¤. í•˜ì§€ë§Œ ì—¬ì „íˆ ì‹œì¥ ì¹¨íˆ¬ ì¸¡ë©´ì—ì„œ ë§ì€ ê¸°íšŒê°€ ìˆë‹¤ê³  ë´…ë‹ˆë‹¤. ì‹œì¥ ê´€ì ì—ì„œë„ ê·¸ë ‡ê³ , ìš°ë¦¬ê°€ ì‹œì¥ ì ìœ ìœ¨ì„ í™•ëŒ€í•˜ê³  ì‹œì¥ì„ í™•ì¥í•  ìˆ˜ ìˆëŠ” ëŠ¥ë ¥ ì¸¡ë©´ì—ì„œë„ ë§ˆì°¬ê°€ì§€ì…ë‹ˆë‹¤. ì§‘ì¤‘ ì¸ìŠë¦° ì‚¬ìš©ì, ê¸°ì € ì¸ìŠë¦° ì‚¬ìš©ì, ë¹„ì¸ìŠë¦° ì‚¬ìš©ì ë“± 3ê°œ í™˜ìêµ° ì „ì²´ë¥¼ ì‚´í´ë³´ë©´, ëª¨ë“  ì˜ì—­ì—ì„œ ì—¬ì „íˆ í™•ë³´í•  ìˆ˜ ìˆëŠ” ì¹¨íˆ¬ìœ¨ì´ ìƒë‹¹íˆ ë†’ìŠµë‹ˆë‹¤. ë¯¸êµ­ë¿ë§Œ ì•„ë‹ˆë¼ ì „ ì„¸ê³„ì ìœ¼ë¡œ í™˜ìêµ°ê³¼ ì˜ë£Œ ì‹œìŠ¤í…œ ëª¨ë‘ì—ì„œ ì´ëŸ¬í•œ ëª¨ë“  í™˜ì ì„¸ê·¸ë¨¼íŠ¸ë¡œ ê¸°ìˆ  ì‚¬ìš©ê³¼ ë„ì…ì„ í™•ëŒ€í•˜ë ¤ëŠ” ì›€ì§ì„ì´ í™œë°œí•©ë‹ˆë‹¤. ë¯¸êµ­ ì‹œì¥ì´ ë§ì€ ì£¼ëª©ì„ ë°›ê³  ìˆê³  ì¤‘ìš”í•œ ì‹œì¥ì¸ ê²ƒì€ ì‚¬ì‹¤ì´ë©°, íŠ¹íˆ ë¹„ì¸ìŠë¦° ì‚¬ìš©ì ë³´í—˜ê¸‰ì—¬ ê¸°íšŒ ì¸¡ë©´ì—ì„œ ìš°ë¦¬ì—ê²Œ í›Œë¥­í•œ ê¸°íšŒë“¤ì´ ë§ì´ ìˆìŠµë‹ˆë‹¤. ì´ ê³¼ì •ì—ì„œ ì§€ì†ì ìœ¼ë¡œ ì¢‹ì€ ì§„ì „ì„ ë³´ê³  ìˆìœ¼ë©°, ì´ë¥¼ ì‹¤í˜„í•˜ê¸° ìœ„í•œ ì§€ì§€ê°€ ìƒë‹¹íˆ ë§ì€ ê²ƒìœ¼ë¡œ ë³´ì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì €í¬ê°€ ë³´ì—¬ë“œë¦° ë°ì´í„°ë¥¼ ë³´ì‹œë©´, ì´ë¯¸ 3ê±´ì˜ ì—°êµ¬ë¥¼ ë°œí‘œí–ˆëŠ”ë°ìš”, ì´ í™˜ìêµ°ë„ ë‚®ì€ ë‹¹í™”í˜ˆìƒ‰ì†Œ(A1c), ë” ë†’ì€ ëª©í‘œ ë²”ìœ„ ë‚´ ì‹œê°„ ë“± ë‹¤ë¥¸ í™˜ìêµ°ì—ì„œ ë³´í—˜ ê¸‰ì—¬ë¥¼ ì´ëŒì–´ëƒˆë˜ ëª¨ë“  ì§€í‘œë“¤ì—ì„œ í˜œíƒì„ ë³¸ë‹¤ëŠ” ê²ƒì„ ë³´ì—¬ì¤ë‹ˆë‹¤. ë”°ë¼ì„œ ë¯¸êµ­ ì‹œì¥ì—ì„œ ì €í¬ì—ê²Œ ë§¤ìš° ê°•ë ¥í•œ ê¸°íšŒë¼ê³  ìƒê°í•©ë‹ˆë‹¤. ì–´ë–»ê²Œ ì „ê°œë ì§€ ì§€ì¼œë´ì•¼ê² ì£ . ìƒë°˜ê¸°ì— ê´€ë ¨ ë¬¸êµ¬ê°€ ë‚˜ì˜¬ ê²ƒìœ¼ë¡œ ë³´ê³ , ê·¸ ë‹¤ìŒì— ì˜ê²¬ ìˆ˜ë ´ ê¸°ê°„ì„ ê±°ì³ ì–´ë–»ê²Œ ì§„í–‰ë ì§€ ë³´ê²Œ ë  ê²ë‹ˆë‹¤. ë¡œë¹„, ì•„ì‹œë‹¤ì‹œí”¼ ì˜ê²¬ ìˆ˜ë ´ ê¸°ê°„ë„ ìˆê³  ì—¬ëŸ¬ ì ˆì°¨ë“¤ì´ ìˆì–ì•„ìš”. ê·¸ë˜ì„œ ì´ ë¶€ë¶„ì€ ì œ ê°€ì´ë˜ìŠ¤ì— ë°˜ì˜í•˜ì§€ ì•Šì•˜ìŠµë‹ˆë‹¤ë§Œ, ë¶„ëª…íˆ ë§ì”€ë“œë¦´ ìˆ˜ ìˆëŠ” ê±´ ì €í¬ëŠ” 150% ì¤€ë¹„ë˜ì–´ ìˆì„ ê²ƒì´ë¼ëŠ” ê²ë‹ˆë‹¤. ìƒì‚° ì—­ëŸ‰ í™•ë³´ë“ , 1ì°¨ ì§„ë£Œ ì¸¡ë©´ì—ì„œì˜ ê·œëª¨ì™€ ì…ì§€ í™•ë³´ë“  - ì•„ë§ˆ ê·¸ìª½ì—ì„œ ë” ë§ì´ ì „ê°œë  ê²ƒìœ¼ë¡œ ë³´ì´ëŠ”ë° - ì €í¬ëŠ” ì¤€ë¹„ë  ê²ë‹ˆë‹¤. ì´ëŠ” ì»¨ì„¼ì„œìŠ¤ ì „ë§ì¹˜ë¥¼ ìƒíšŒí•  ìˆ˜ ìˆëŠ” ê¸°íšŒë¥¼ ì œê³µí•©ë‹ˆë‹¤. ì§‘ì¤‘ ì¸ìŠë¦° ì‚¬ìš©ì ì¸¡ë©´ì—ì„œëŠ”, íŠ¹íˆ í•´ì™¸ ì‹œì¥ì—ì„œ ì—¬ì „íˆ ì¹¨íˆ¬ìœ¨ê³¼ ì±„íƒë¥ ì„ ë†’ì¼ ì—¬ì§€ê°€ ìˆë‹¤ê³  ë´…ë‹ˆë‹¤. í˜„ì¬ ì•½ 50% ì •ë„ë§Œ ì¹¨íˆ¬ëœ ìƒíƒœì…ë‹ˆë‹¤. ë”°ë¼ì„œ ìš°ë¦¬ê°€ ì§„í–‰í•˜ê³  ìˆëŠ” ì‘ì—…ì—ì„œ ì—¬ì „íˆ ë§ì€ ê¸°íšŒê°€ ìˆë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. ë¬¼ë¡  í•´ì™¸ ì‹œì¥ì—ì„œëŠ” ê·œëª¨ì™€ ë¹„ìš©ì´ ì¤‘ìš”í•œë°, ìš°ë¦¬ëŠ” ì´ë¯¸ ê·¸ëŸ¬í•œ í¬ì§€ì…˜ì„ í™•ë³´í–ˆë‹¤ê³  ë´…ë‹ˆë‹¤. <br><br>ê·¸ë¦¬ê³  ìš°ë¦¬ì—ê²Œ ë” íŠ¹í™”ëœ ê¸°íšŒë¥¼ ë³´ë©´, ë§¤ìš° ì°¨ë³„í™”ëœ ì œí’ˆì„ ì¶œì‹œí•˜ì—¬ ì‹œì¥ ì ìœ ìœ¨ ë³€í™”ë¥¼ ì´ëŒì–´ë‚¼ ìˆ˜ ìˆëŠ” ì„¸ê·¸ë¨¼íŠ¸ê°€ ìˆìŠµë‹ˆë‹¤. íŒí”„ ì‚¬ìš©ì ë¶€ë¬¸ì¸ë°, ì†”ì§íˆ ë§ì”€ë“œë¦¬ë©´ ìš°ë¦¬ê°€ ì‹œì¥ ì ìœ ìœ¨ ì¸¡ë©´ì—ì„œ ë‹¤ì†Œ ê³¼ì†Œ ëŒ€í‘œë˜ì–´ ìˆëŠ” ì˜ì—­ì…ë‹ˆë‹¤. GKS ì„¼ì„œ ì¶œì‹œë¥¼ í†µí•´ ì´ ë¶€ë¶„ì—ì„œ ê¸°íšŒë¥¼ ì¡ì„ ìˆ˜ ìˆì„ ê²ƒì…ë‹ˆë‹¤. ì´ëŠ” ìš°ë¦¬ì—ê²Œ í° ê¸°íšŒê°€ ë  ê²ƒìœ¼ë¡œ ìƒê°í•©ë‹ˆë‹¤. ë¡œë¹„, ì •í™•í•œ ë¶„ê¸°ë¥¼ ì§€ê¸ˆ íŠ¹ì •í•˜ì§€ëŠ” ì•Šê² ìŠµë‹ˆë‹¤. ìŠ¹ì¸ì„ ë°›ìœ¼ë©´ ë³´ë„ìë£Œë¥¼ ë°œí‘œí•˜ê³  ì¶œì‹œí•  ê²ƒì…ë‹ˆë‹¤. í•˜ì§€ë§Œ ìš°ë¦¬ëŠ” ì´ë¯¸ ê·œì œ ì ˆì°¨ì™€ ë³‘í–‰í•˜ì—¬ KOL(ì£¼ìš” ì˜¤í”¼ë‹ˆì–¸ ë¦¬ë”), ì˜ì‚¬ ê·¸ë£¹, ë³´í—˜ì‚¬ë“¤ê³¼ ì—´ì‹¬íˆ í˜‘ë ¥í•´ ì™”ìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì˜¬í•´ ì´ˆ 1ì›”ì— Lancetì— ê²Œì¬ëœ ê¸°ì‚¬ê°€ ìˆì—ˆëŠ”ë°, DKA(ë‹¹ë‡¨ë³‘ì„± ì¼€í†¤ì‚°ì¦)ê°€ ì—¬ì „íˆ ë‹¹ë‡¨ë³‘ í™˜ìë“¤ì—ê²Œ ì£¼ìš”í•œ ì¹˜ë£Œ ê³µë°±ìœ¼ë¡œ ë‚¨ì•„ìˆê¸° ë•Œë¬¸ì— ì¼€í†¤ì„ ì§€ì†ì ìœ¼ë¡œ ì¸¡ì •í•˜ëŠ” ê²ƒì˜ ì¤‘ìš”ì„±ì— ëŒ€í•´ ë‹¤ë£¨ê³  ìˆì—ˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ì´ ì œí’ˆìœ¼ë¡œ ì‹œì¥ ì ìœ ìœ¨ ì „í™˜ì— ìˆì–´ í° ê¸°íšŒê°€ ìˆë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. ì´ëŸ¬í•œ í™˜ì ì„¸ê·¸ë¨¼íŠ¸ë¥¼ ë³¸ê²©ì ìœ¼ë¡œ ë¶„ì„í•˜ê¸° ì‹œì‘í•˜ë©´ì„œ ë†€ë¼ì› ë˜ ì  ì¤‘ í•˜ë‚˜ëŠ” SGLT2 í™˜ìêµ°ì— ê´€í•œ ê²ƒì…ë‹ˆë‹¤. ë¯¸êµ­ ì‹œì¥ì„ ë¶„ì„í•´ë³´ë‹ˆ ì•½ 600ë§Œ ëª…ì˜ SGLT2 ì‚¬ìš©ìê°€ ìˆìŠµë‹ˆë‹¤. ê·¸ëŸ°ë° ëª¨ë“  ë°ì´í„°ë² ì´ìŠ¤ë¥¼ êµì°¨ ë¶„ì„í•´ì„œ ì´ë“¤ì˜ CGM ì‚¬ìš©ë¥ ì„ í™•ì¸í•´ë³´ë‹ˆ, 600ë§Œ ëª… ì¤‘ ì•½ 100ë§Œ ëª…ë§Œì´ CGMì„ ì‚¬ìš©í•˜ê³  ìˆì—ˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ì´ ì œí’ˆì„ í†µí•´ ì‹œì¥ ì ìœ ìœ¨ í™•ë³´ë¿ë§Œ ì•„ë‹ˆë¼ ì‹œì¥ í™•ëŒ€ì˜ ê¸°íšŒë„ ìˆë‹¤ê³  ë´…ë‹ˆë‹¤. ë‹¨ìˆœíˆ ì ìœ ìœ¨ì„ ê°€ì ¸ì˜¤ëŠ” ê²ƒì´ ì•„ë‹ˆë¼ ì‹œì¥ ìì²´ë¥¼ í™•ì¥í•˜ëŠ” ê²ƒì´ì£ . ì´ ì‹œì¥ì€ ì—¬ì „íˆ ë§¤ìš° ê²¬ê³ í•˜ê³  ê³„ì† ì»¤ì§€ê³  ìˆìŠµë‹ˆë‹¤. ë¬¼ë¡  í° ìˆ˜ì˜ ë²•ì¹™(law of big numbers)ìœ¼ë¡œ ì¸í•´ ì„±ì¥ë¥  í¼ì„¼í‹°ì§€ëŠ” ë‚®ì•„ì§€ê² ì§€ë§Œìš”. í•˜ì§€ë§Œ ì‹œì¥ ì¹¨íˆ¬ìœ¨ ê´€ì ì—ì„œë§Œ ë³´ë”ë¼ë„ ë¡œë¹„, ì—¬ëŸ¬ ì§€ì—­ì˜ ëª¨ë“  ì„¸ê·¸ë¨¼íŠ¸ì—ì„œ ì•„ì§ í•´ì•¼ í•  ì¼ì´ ì •ë§ ë§ìŠµë‹ˆë‹¤. ê·¸ë˜ì„œ ìš°ë¦¬ëŠ” ì—¬ì „íˆ ë§¤ìš° ê¸°ëŒ€í•˜ê³  ìˆê³ , ì˜ì—…ê³¼ ë§ˆì¼€íŒ…, ì„ìƒ, R&D, ì œì¡° ë¶€ë¬¸ì— ëŒ€ê·œëª¨ íˆ¬ìë¥¼ ì§„í–‰í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ ì‹œì¥ì´ ì•„ì§ - 1íšŒë‚˜ 2íšŒë¼ê³  ë§í•˜ì§€ëŠ” ì•Šê² ì§€ë§Œ, 7íšŒì—ëŠ” í•œì°¸ ëª» ë¯¸ì¹œë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. ë”°ë¼ì„œ ì—¬ì „íˆ ë§ì€ ê¸°íšŒê°€ ìˆë‹¤ê³  ë³´ê³  ìˆìœ¼ë©°, ìš°ë¦¬ëŠ” ì¢‹ì€ ìœ„ì¹˜ì— ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Robert Marcus: JPMorgan Chase & Co, Research Division Great. Maybe just a quick follow-up. It's great to see you're still able to do double-digit EPS growth in 2026. I would imagine that's coming through the top line and margin expansion. How should we think about the magnitude of margin expansion and the drivers of it?</td><td>**Robert Marcus:** 2026ë…„ì—ë„ ë‘ ìë¦¿ìˆ˜ EPS ì„±ì¥ì„ ë‹¬ì„±í•  ìˆ˜ ìˆë‹¤ëŠ” ì ì´ ë§¤ìš° ê³ ë¬´ì ì…ë‹ˆë‹¤. ì´ëŠ” ë§¤ì¶œ ì„±ì¥ê³¼ ë§ˆì§„ í™•ëŒ€ë¥¼ í†µí•´ ì´ë£¨ì–´ì§ˆ ê²ƒìœ¼ë¡œ ì˜ˆìƒë˜ëŠ”ë°, ë§ˆì§„ í™•ëŒ€ì˜ ê·œëª¨ì™€ ì£¼ìš” ë™ì¸ì— ëŒ€í•´ ì–´ë–»ê²Œ ìƒê°í•˜ì‹œëŠ”ì§€ ê¶ê¸ˆí•©ë‹ˆë‹¤.</td></tr>
<tr><td>Robert Ford: Chairman, President & CEO I'll let Phil take that.</td><td>**Robert Ford:** í•„ì´ ë‹µë³€í•˜ë„ë¡ í•˜ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Philip Boudreau: CFO & Executive VP of Finance Yes. Thanks, Robbie. I couldn't be more proud of what the team accomplished in 2025. As Robert outlined, overcoming uncertainties, volatilities and whatnot to still drive margin expansion. And that commitment to the execution and excellence there maintains in 2026, expect to do more of the same, focus on the things that are strategically aligned and the execution here to where we continue to look at a 50 to 70 basis point improvement in operating margins every year, and that's kind of what we've got built into this and fully expect we'll do that through both gross margin expansion as we've done, but continue to gain leverage in the P&L where appropriate. So that's kind of how we've constructed that double-digit earnings.</td><td>**Philip Boudreau:** ë„¤, ê°ì‚¬í•©ë‹ˆë‹¤, ë¡œë¹„. 2025ë…„ì— íŒ€ì´ ì´ë£¬ ì„±ê³¼ì— ëŒ€í•´ ì •ë§ ìë‘ìŠ¤ëŸ½ê²Œ ìƒê°í•©ë‹ˆë‹¤. ë¡œë²„íŠ¸ê°€ ë§ì”€ë“œë¦° ê²ƒì²˜ëŸ¼, ë¶ˆí™•ì‹¤ì„±ê³¼ ë³€ë™ì„± ë“± ì—¬ëŸ¬ ì–´ë ¤ì›€ì„ ê·¹ë³µí•˜ë©´ì„œë„ ë§ˆì§„ í™•ëŒ€ë¥¼ ë‹¬ì„±í–ˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ì‹¤í–‰ë ¥ê³¼ ìš°ìˆ˜ì„±ì— ëŒ€í•œ ì˜ì§€ëŠ” 2026ë…„ì—ë„ ê³„ì† ìœ ì§€ë  ê²ƒì´ë©°, ì „ëµì ìœ¼ë¡œ ì¼ì¹˜í•˜ëŠ” ë¶€ë¶„ì— ì§‘ì¤‘í•˜ê³  ì‹¤í–‰ë ¥ì„ ë°œíœ˜í•˜ì—¬ ë§¤ë…„ ì˜ì—…ì´ìµë¥ (operating margin)ì„ 50~70bp ê°œì„ í•˜ëŠ” ëª©í‘œë¥¼ ê³„ì† ì¶”êµ¬í•  ê²ƒì…ë‹ˆë‹¤. ì´ê²ƒì´ ë°”ë¡œ ìš°ë¦¬ê°€ ê³„íšì— ë°˜ì˜í•œ ë‚´ìš©ì´ë©°, ê·¸ë™ì•ˆ í•´ì™”ë˜ ê²ƒì²˜ëŸ¼ ë§¤ì¶œì´ì´ìµë¥ (gross margin) í™•ëŒ€ë¥¼ í†µí•´ì„œ, ê·¸ë¦¬ê³  ì†ìµê³„ì‚°ì„œ(P&L) ìƒì—ì„œ ì ì ˆí•œ ë ˆë²„ë¦¬ì§€ë¥¼ í™•ë³´í•˜ë©´ì„œ ì´ë¥¼ ë‹¬ì„±í•  ê²ƒìœ¼ë¡œ í™•ì‹ í•©ë‹ˆë‹¤. ì´ê²ƒì´ ë°”ë¡œ ìš°ë¦¬ê°€ ë‘ ìë¦¿ìˆ˜ ì´ìµ ì„±ì¥ì„ êµ¬ì„±í•œ ë°©ì‹ì…ë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Our next question will come from Vijay Kumar from Evercore ISI.</td><td>**Operator:** ë‹¤ìŒ ì§ˆë¬¸ì€ Evercore ISIì˜ Vijay Kumarë‹˜ê»˜ì„œ ì£¼ì‹œê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Vijay Kumar: Evercore ISI Institutional Equities, Research Division My first one maybe on the product side. AVEIR, like you mentioned, another double-digit quarter. Just curious on where are we from a penetration standpoint, what innings are we in? And how durable is this double-digit growth in a category that's a pacemaker [indiscernible] low single-digit growth category and you guys are doing double digits?</td><td>**Vijay Kumar:** ì œ ì²« ë²ˆì§¸ ì§ˆë¬¸ì€ ì œí’ˆ ìª½ì— ê´€í•œ ê²ƒì…ë‹ˆë‹¤. AVEIR ê´€ë ¨í•´ì„œ ë§ì”€í•˜ì‹  ê²ƒì²˜ëŸ¼ ë˜ ë‹¤ì‹œ ë‘ ìë¦¿ìˆ˜ ì„±ì¥ì„ ê¸°ë¡í–ˆëŠ”ë°ìš”. í˜„ì¬ ì¹¨íˆ¬ìœ¨(penetration) ì¸¡ë©´ì—ì„œ ì–´ëŠ ì •ë„ ë‹¨ê³„ì— ì™€ ìˆëŠ”ì§€ ê¶ê¸ˆí•©ë‹ˆë‹¤. ê·¸ë¦¬ê³  í˜ì´ìŠ¤ë©”ì´ì»¤ ì¹´í…Œê³ ë¦¬ê°€ í•œ ìë¦¿ìˆ˜ ì´ˆë°˜ ì„±ì¥ì— ê·¸ì¹˜ëŠ” ìƒí™©ì—ì„œ ê·€ì‚¬ê°€ ë‘ ìë¦¿ìˆ˜ ì„±ì¥ì„ ë‹¬ì„±í•˜ê³  ìˆëŠ”ë°, ì´ëŸ¬í•œ ë‘ ìë¦¿ìˆ˜ ì„±ì¥ì„¸ê°€ ì–¼ë§ˆë‚˜ ì§€ì† ê°€ëŠ¥í• ê¹Œìš”?</td></tr>
<tr><td>Robert Ford: Chairman, President & CEO Sure. Well, I made some comments about -- we look at this Rhythm Management, $10 billion market, as actually an opportunity to grow. So we have been making our investments. AVEIR, obviously, is a big driver of that, but we're making investments in other areas of the portfolio to kind of be able to support our ability to take market share and grow at a differentiated rate here. To your question on penetration, listen, the global low voltage or pacing segment market is around $5 billion, whatever, $4.8 billion to $5.2 billion, depending on what you're looking at. But let's just call it $5 billion. I'd say AVEIR is about 10% of that right now. So early innings here for us for sure. And as I said previously, when we began this process, I wasn't interested in just getting a flash in a pan sales growth for like a year or 6 quarters. So we really worked hard and the team did an incredible job to really establish a new standard of care and get physicians trained. It's a different type of implant. So what we're seeing here is really nice growth in places that 1 year, 1.5 years ago, we began the training process and really seeing really strong penetration there. If you look at just single chamber, I think right now, the U.S. single-chamber pacing, which is about 15% of the total market, that's about 50% penetrated. So there's still a long opportunity here in the U.S. and quite frankly, globally, too. So I think the team has done an incredible job here. We've launched new products. We'll continue to launch new products in this space. And we think that this is the next standard in CRM is these devices that are communicating with each other, that can be implanted [ transfemorally ] and don't use leads. The clinical evidence in terms of what they're able to deliver is pretty impressive right now. So I think it's -- I think we've got a lot of investment here that will support this type of differentiated growth rate.</td><td>**Robert Ford:** ë„¤, ì œê°€ ë¦¬ë“¬ ë§¤ë‹ˆì§€ë¨¼íŠ¸(Rhythm Management)ì— ëŒ€í•´ ëª‡ ê°€ì§€ ë§ì”€ë“œë ¸ëŠ”ë°ìš”, ì €í¬ëŠ” ì´ 100ì–µ ë‹¬ëŸ¬ ê·œëª¨ì˜ ì‹œì¥ì„ ì‹¤ì œë¡œ ì„±ì¥ ê¸°íšŒë¡œ ë³´ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë˜ì„œ ê³„ì† íˆ¬ìë¥¼ í•´ì˜¤ê³  ìˆìŠµë‹ˆë‹¤. AVEIRê°€ ë¶„ëª…íˆ í° ì„±ì¥ ë™ë ¥ì´ì§€ë§Œ, í¬íŠ¸í´ë¦¬ì˜¤ì˜ ë‹¤ë¥¸ ì˜ì—­ë“¤ì—ë„ íˆ¬ìí•˜ê³  ìˆì–´ì„œ ì‹œì¥ ì ìœ ìœ¨ì„ í™•ë³´í•˜ê³  ì°¨ë³„í™”ëœ ì„±ì¥ë¥ ì„ ë‹¬ì„±í•  ìˆ˜ ìˆë„ë¡ ì§€ì›í•˜ê³  ìˆìŠµë‹ˆë‹¤. <br><br>ì¹¨íˆ¬ìœ¨ì— ëŒ€í•œ ì§ˆë¬¸ ë§ì”€ì´ì‹ ë°ìš”, ê¸€ë¡œë²Œ ì €ì „ì•• ë˜ëŠ” í˜ì´ì‹± ì„¸ê·¸ë¨¼íŠ¸ ì‹œì¥ì€ ì•½ 50ì–µ ë‹¬ëŸ¬ ê·œëª¨ì…ë‹ˆë‹¤. ë³´ì‹œëŠ” ìë£Œì— ë”°ë¼ 48ì–µì—ì„œ 52ì–µ ë‹¬ëŸ¬ ì •ë„ì¸ë°, ê·¸ëƒ¥ 50ì–µ ë‹¬ëŸ¬ë¼ê³  í•˜ê² ìŠµë‹ˆë‹¤. AVEIRëŠ” í˜„ì¬ ê·¸ ì¤‘ ì•½ 10% ì •ë„ë¼ê³  ë´…ë‹ˆë‹¤. ê·¸ëŸ¬ë‹ˆê¹Œ ì €í¬ì—ê²ŒëŠ” ì•„ì§ ì •ë§ ì´ˆê¸° ë‹¨ê³„ë¼ê³  í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì•ì„œ ë§ì”€ë“œë ¸ë“¯ì´, ì´ í”„ë¡œì„¸ìŠ¤ë¥¼ ì‹œì‘í•  ë•Œ ì €ëŠ” ë‹¨ìˆœíˆ 1ë…„ì´ë‚˜ 6ë¶„ê¸° ì •ë„ë§Œ ë°˜ì§í•˜ëŠ” ë§¤ì¶œ ì„±ì¥ì—ëŠ” ê´€ì‹¬ì´ ì—†ì—ˆìŠµë‹ˆë‹¤. ê·¸ë˜ì„œ ìš°ë¦¬ íŒ€ì€ ì •ë§ ì—´ì‹¬íˆ ë…¸ë ¥í–ˆê³ , ìƒˆë¡œìš´ ì¹˜ë£Œ í‘œì¤€ì„ í™•ë¦½í•˜ê³  ì˜ì‚¬ë“¤ì„ êµìœ¡í•˜ëŠ” ë° ìˆì–´ ë†€ë¼ìš´ ì„±ê³¼ë¥¼ ê±°ë’€ìŠµë‹ˆë‹¤. ì´ê²ƒì€ ë‹¤ë¥¸ ìœ í˜•ì˜ ì„í”Œë€íŠ¸ì´ê¸° ë•Œë¬¸ì—, 1ë…„ì—ì„œ 1ë…„ ë°˜ ì „ì— êµìœ¡ í”„ë¡œì„¸ìŠ¤ë¥¼ ì‹œì‘í–ˆë˜ ì§€ì—­ì—ì„œ ì§€ê¸ˆ ì •ë§ ì¢‹ì€ ì„±ì¥ì„¸ë¥¼ ë³´ì´ê³  ìˆê³ , ê·¸ê³³ì—ì„œ ë§¤ìš° ê°•ë ¥í•œ ì¹¨íˆ¬ìœ¨ì„ í™•ì¸í•˜ê³  ìˆìŠµë‹ˆë‹¤.<br><br>ë‹¨ì¼ ì±”ë²„ë§Œ ë³´ë”ë¼ë„, í˜„ì¬ ë¯¸êµ­ ë‹¨ì¼ ì±”ë²„ í˜ì´ì‹±(single-chamber pacing) ì‹œì¥ì€ ì „ì²´ ì‹œì¥ì˜ ì•½ 15% ì •ë„ì¸ë°, ê·¸ ì¤‘ ì•½ 50%ê°€ ì¹¨íˆ¬ëœ ìƒíƒœì…ë‹ˆë‹¤. ë”°ë¼ì„œ ë¯¸êµ­ ë‚´ì—ì„œ, ê·¸ë¦¬ê³  ì†”ì§íˆ ì „ ì„¸ê³„ì ìœ¼ë¡œë„ ì—¬ì „íˆ ê¸´ ê¸°íšŒê°€ ë‚¨ì•„ìˆìŠµë‹ˆë‹¤. íŒ€ì´ ì´ ë¶€ë¶„ì—ì„œ ì •ë§ í›Œë¥­í•œ ì¼ì„ í•´ëƒˆë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. ì‹ ì œí’ˆì„ ì¶œì‹œí–ˆê³ , ì•ìœ¼ë¡œë„ ì´ ë¶„ì•¼ì—ì„œ ê³„ì† ì‹ ì œí’ˆì„ ì¶œì‹œí•  ì˜ˆì •ì…ë‹ˆë‹¤. ìš°ë¦¬ëŠ” ì´ê²ƒì´ CRMì˜ ì°¨ì„¸ëŒ€ í‘œì¤€ì´ ë  ê²ƒìœ¼ë¡œ ë³´ê³  ìˆìŠµë‹ˆë‹¤. ì„œë¡œ í†µì‹ í•˜ê³ , ê²½ëŒ€í‡´(transfemoral) ë°©ì‹ìœ¼ë¡œ ì´ì‹ ê°€ëŠ¥í•˜ë©°, ë¦¬ë“œì„ ì´ í•„ìš” ì—†ëŠ” ì´ëŸ¬í•œ ê¸°ê¸°ë“¤ ë§ì…ë‹ˆë‹¤. í˜„ì¬ ì´ë“¤ì´ ì œê³µí•  ìˆ˜ ìˆëŠ” ê²ƒì— ëŒ€í•œ ì„ìƒ ì¦ê±°ëŠ” ìƒë‹¹íˆ ì¸ìƒì ì…ë‹ˆë‹¤. ë”°ë¼ì„œ ì´ëŸ¬í•œ ì°¨ë³„í™”ëœ ì„±ì¥ë¥ ì„ ë’·ë°›ì¹¨í•  ìˆ˜ ìˆëŠ” ë§ì€ íˆ¬ìë¥¼ ì§„í–‰í•˜ê³  ìˆë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤.</td></tr>
<tr><td>Vijay Kumar: Evercore ISI Institutional Equities, Research Division That's helpful, Robert. And my follow-up on -- or I guess the second question is on capital allocation. Any updated thoughts on Exact deal close timing? Dilution, I think you mentioned $0.20. When you think about your leverage levels, it's still -- post deal, it will still be pretty modest. You still have capacity. I'm curious when you think about M&A versus divestitures or spin-offs, MedTech right now seems to be -- spin-off seems to be the flavor of the season. I'm curious how you're thinking about those decisions.</td><td>**Vijay Kumar:** ë„ì›€ì´ ë˜ì…¨ë‹¤ë‹ˆ ë‹¤í–‰ì…ë‹ˆë‹¤, Robert. ê·¸ë¦¬ê³  í›„ì† ì§ˆë¬¸ìœ¼ë¡œ -- ì•„ë‹ˆ ë‘ ë²ˆì§¸ ì§ˆë¬¸ì€ ìë³¸ ë°°ë¶„ì— ê´€í•œ ê²ƒì…ë‹ˆë‹¤. Exact ê±°ë˜ ë§ˆê° ì‹œê¸°ì— ëŒ€í•´ ì—…ë°ì´íŠ¸ëœ ìƒê°ì´ ìˆìœ¼ì‹ ê°€ìš”? í¬ì„ íš¨ê³¼ëŠ” 0.20ë‹¬ëŸ¬ë¡œ ë§ì”€í•˜ì‹  ê²ƒìœ¼ë¡œ ì•Œê³  ìˆìŠµë‹ˆë‹¤. ë ˆë²„ë¦¬ì§€ ìˆ˜ì¤€ì„ ìƒê°í•´ë³´ë©´, ê±°ë˜ í›„ì—ë„ ì—¬ì „íˆ ìƒë‹¹íˆ ë‚®ì€ ìˆ˜ì¤€ì¼ ê²ƒ ê°™ìŠµë‹ˆë‹¤. ì•„ì§ ì—¬ë ¥ì´ ìˆìœ¼ì‹ ë°ìš”. M&Aì™€ ë§¤ê° ë˜ëŠ” ë¶„ì‚¬(spin-off)ë¥¼ ë¹„êµí•  ë•Œ, í˜„ì¬ ì˜ë£Œê¸°ê¸° ì—…ê³„ì—ì„œëŠ” ë¶„ì‚¬ê°€ ìœ í–‰ì²˜ëŸ¼ ë³´ì´ëŠ”ë°ìš”. ì´ëŸ¬í•œ ê²°ì •ë“¤ì— ëŒ€í•´ ì–´ë–»ê²Œ ìƒê°í•˜ê³  ê³„ì‹ ì§€ ê¶ê¸ˆí•©ë‹ˆë‹¤.</td></tr>
<tr><td>Robert Ford: Chairman, President & CEO You put a lot into that one there, Vijay. Let me see if I can unpack that. I think from a capital allocation perspective, I've always been pretty consistent with our approach. I don't have a formula that X percent goes here, Y percent goes there. We are committed to a growing dividend, and we did that again for 2026 when we announced our dividend back in December. So we're growing our dividend. But outside of that, we'll allocate our capital in terms of what we believe is the best balance between short term and long term for our shareholders where we can create value. Regarding M&A, listen, my focus right now is integration, closing Exact Science and integration. That's going to be my primary focus. I think post close, our gross debt-to-EBITDA ratio will be around 2.7x. So to your point, we still have plenty of capacity. But I think in the near term, I'd say focus on integrating Exact Sciences. And if there's opportunities for us to add, there are probably more tuck-in type size deals to take advantage of. Regarding the status right now of Exact, I think we're making great progress towards closing. We've submitted all of our required clearances over here. There's a shareholder vote on the 20th of February. So right now, I'm not changing any assumption regarding timing of close or kind of EPS impact. And as we integrate and as we put -- as we integrate the business, then we'll go updating it as we go along. But right now, there's no change in terms of timing and in terms of dilution. So I read your note last night, Vijay. I thought that you would have been asking a question about multi-cancer early detection and the opportunity that exists. I largely agree with your report. I think this is going to be another great opportunity for us. And it's one that, as we looked at the deal, said, okay, greater reimbursement of this type of test will really make this a very, very large segment. I think the way I see this is the same way that we have our lipid panel test every year, the same way that we do a cardiometabolic panel or a white and red blood count panel every year after a certain age. I believe that if the product is right and performs right and it's priced the right way, I just envision this being that type of test. So I think that if that becomes the case, I think your forecast is way undercalled even on the upper side.</td><td>**Robert Ford:** ë¹„ì œì´, ì§ˆë¬¸ì— ë§ì€ ë‚´ìš©ì„ ë‹´ìœ¼ì…¨ë„¤ìš”. í•˜ë‚˜ì”© í’€ì–´ì„œ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ìë³¸ ë°°ë¶„ ê´€ì ì—ì„œ ë³´ë©´, ì €ëŠ” í•­ìƒ ì¼ê´€ëœ ì ‘ê·¼ ë°©ì‹ì„ ìœ ì§€í•´ì™”ìŠµë‹ˆë‹¤. X%ëŠ” ì—¬ê¸°, Y%ëŠ” ì €ê¸° í•˜ëŠ” ì‹ì˜ ì •í•´ì§„ ê³µì‹ì€ ì—†ìŠµë‹ˆë‹¤. ìš°ë¦¬ëŠ” ë°°ë‹¹ ì„±ì¥ì— ì „ë…í•˜ê³  ìˆìœ¼ë©°, ì§€ë‚œ 12ì›” ë°°ë‹¹ì„ ë°œí‘œí•  ë•Œ 2026ë…„ì—ë„ ì´ë¥¼ ì‹¤í–‰í–ˆìŠµë‹ˆë‹¤. ê·¸ë˜ì„œ ë°°ë‹¹ì€ ê³„ì† ëŠ˜ë ¤ê°€ê³  ìˆìŠµë‹ˆë‹¤. <br><br>ê·¸ ì™¸ì—ëŠ” ì£¼ì£¼ë“¤ì„ ìœ„í•´ ê°€ì¹˜ë¥¼ ì°½ì¶œí•  ìˆ˜ ìˆëŠ” ë¶€ë¶„ì—ì„œ ë‹¨ê¸°ì™€ ì¥ê¸° ê°„ ìµœì ì˜ ê· í˜•ì´ ë¬´ì—‡ì¸ì§€ë¥¼ ê³ ë ¤í•´ ìë³¸ì„ ë°°ë¶„í•  ê²ƒì…ë‹ˆë‹¤. <br><br>M&Aì™€ ê´€ë ¨í•´ì„œëŠ”, ì§€ê¸ˆ ì œ ì´ˆì ì€ í†µí•©ì…ë‹ˆë‹¤. Exact Science ì¸ìˆ˜ ì™„ë£Œì™€ í†µí•©ì´ì£ . ê·¸ê²Œ ì œ ìµœìš°ì„  ê³¼ì œì…ë‹ˆë‹¤. ê±°ë˜ ì™„ë£Œ í›„ ì´ì°¨ì…ê¸ˆ ëŒ€ë¹„ EBITDA ë¹„ìœ¨ì€ ì•½ 2.7ë°° ìˆ˜ì¤€ì´ ë  ê²ƒìœ¼ë¡œ ë³´ì…ë‹ˆë‹¤. ë§ì”€í•˜ì‹  ëŒ€ë¡œ ìš°ë¦¬ëŠ” ì—¬ì „íˆ ì¶©ë¶„í•œ ì—¬ë ¥ì„ ê°–ê³  ìˆìŠµë‹ˆë‹¤. ë‹¤ë§Œ ë‹¨ê¸°ì ìœ¼ë¡œëŠ” Exact Sciences í†µí•©ì— ì§‘ì¤‘í•  ê³„íšì…ë‹ˆë‹¤. ì¶”ê°€ ì¸ìˆ˜ ê¸°íšŒê°€ ìˆë‹¤ë©´ ì•„ë§ˆë„ ì†Œê·œëª¨ í„±ì¸(tuck-in) í˜•íƒœì˜ ê±°ë˜ë¥¼ í™œìš©í•˜ëŠ” ë°©í–¥ì´ ë  ê²ƒ ê°™ìŠµë‹ˆë‹¤.<br><br>í˜„ì¬ Exact ê±´ì˜ ì§„í–‰ ìƒí™©ì„ ë§ì”€ë“œë¦¬ë©´, ê±°ë˜ ì™„ë£Œë¥¼ í–¥í•´ ìˆœì¡°ë¡­ê²Œ ì§„í–‰ë˜ê³  ìˆìŠµë‹ˆë‹¤. í•„ìš”í•œ ëª¨ë“  ìŠ¹ì¸ ì„œë¥˜ë¥¼ ì œì¶œí–ˆê³ , 2ì›” 20ì¼ì— ì£¼ì£¼ ì´íšŒê°€ ì˜ˆì •ë˜ì–´ ìˆìŠµë‹ˆë‹¤. í˜„ì¬ë¡œì„œëŠ” ê±°ë˜ ì™„ë£Œ ì‹œì ì´ë‚˜ ì£¼ë‹¹ìˆœì´ìµ(EPS) ì˜í–¥ì— ëŒ€í•œ ê°€ì •ì„ ë³€ê²½í•  ì‚¬í•­ì´ ì—†ìŠµë‹ˆë‹¤. ì‚¬ì—… í†µí•©ì„ ì§„í–‰í•˜ë©´ì„œ í•„ìš”ì— ë”°ë¼ ì—…ë°ì´íŠ¸í•´ ë‚˜ê°ˆ ì˜ˆì •ì…ë‹ˆë‹¤. ì§€ê¸ˆ ì‹œì ì—ì„œ ì¼ì •ì´ë‚˜ í¬ì„ íš¨ê³¼ ì¸¡ë©´ì—ì„œ ë³€ê²½ ì‚¬í•­ì€ ì—†ìŠµë‹ˆë‹¤. ì–´ì ¯ë°¤ì— ë³´ê³ ì„œ ì˜ ì½ì—ˆìŠµë‹ˆë‹¤, Vijay. ë‹¤ì¤‘ì•” ì¡°ê¸° ì§„ë‹¨(multi-cancer early detection)ê³¼ ê·¸ ê¸°íšŒì— ëŒ€í•´ ì§ˆë¬¸í•˜ì‹¤ ì¤„ ì•Œì•˜ëŠ”ë°ìš”. ë³´ê³ ì„œ ë‚´ìš©ì— ëŒ€ì²´ë¡œ ë™ì˜í•©ë‹ˆë‹¤. ì´ê²ƒì€ ìš°ë¦¬ì—ê²Œ ë˜ í•˜ë‚˜ì˜ í›Œë¥­í•œ ê¸°íšŒê°€ ë  ê²ƒìœ¼ë¡œ ë´…ë‹ˆë‹¤. ì´ë²ˆ ê±°ë˜ë¥¼ ê²€í† í•˜ë©´ì„œ, ì´ëŸ° ìœ í˜•ì˜ ê²€ì‚¬ì— ëŒ€í•œ ë³´í—˜ ê¸‰ì—¬ê°€ í™•ëŒ€ë˜ë©´ ì •ë§ ë§¤ìš° í° ì‹œì¥ì´ ë  ê²ƒì´ë¼ê³  íŒë‹¨í–ˆìŠµë‹ˆë‹¤. <br><br>ì œê°€ ë³´ê¸°ì— ì´ê²ƒì€ ë§¤ë…„ ë°›ëŠ” ì§€ì§ˆ íŒ¨ë„ ê²€ì‚¬ë‚˜, ì¼ì • ì—°ë ¹ ì´í›„ ë§¤ë…„ ì‹¤ì‹œí•˜ëŠ” ì‹¬í˜ˆê´€ëŒ€ì‚¬ íŒ¨ë„ ë˜ëŠ” ë°±í˜ˆêµ¬Â·ì í˜ˆêµ¬ ìˆ˜ì¹˜ ê²€ì‚¬ì™€ ê°™ì€ ë§¥ë½ì…ë‹ˆë‹¤. ì œí’ˆì´ ì œëŒ€ë¡œ ê°œë°œë˜ê³ , ì„±ëŠ¥ì´ ìš°ìˆ˜í•˜ë©°, ê°€ê²©ì´ ì ì ˆí•˜ë‹¤ë©´, ì´ëŸ° ì¢…ë¥˜ì˜ ì •ê¸° ê²€ì‚¬ë¡œ ìë¦¬ì¡ì„ ê²ƒìœ¼ë¡œ ì „ë§í•©ë‹ˆë‹¤. ë§Œì•½ ê·¸ë ‡ê²Œ ëœë‹¤ë©´, ìƒë‹¨ ì „ë§ì¹˜ì¡°ì°¨ë„ ìƒë‹¹íˆ ë³´ìˆ˜ì ìœ¼ë¡œ ì¡íŒ ê²ƒì´ë¼ê³  ìƒê°í•©ë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Our next question will come from Danielle Antalffy from UBS.</td><td>**Operator:** ë‹¤ìŒ ì§ˆë¬¸ì€ UBSì˜ Danielle Antalffyë¡œë¶€í„° ë°›ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Danielle Antalffy: UBS Investment Bank, Research Division And Robert, just two questions for you on Nutrition. I appreciate all that you're saying about the strategy there going forward. But I guess first part of the question is what gives you confidence that these are the right prices that you're landing at today to drive that volume increase? Like did you guys do [indiscernible] global. So I imagine it differs by market. And then the second question is now -- and tell me if I'm wrong here, but presumably, Nutrition has a different profitability profile. And maybe talk about whether -- how it changes your view about how this fits into the entire Abbott portfolio?</td><td>**Danielle Antalffy:** ì˜ì–‘ ì‚¬ì—…ë¶€ì— ëŒ€í•´ ë‘ ê°€ì§€ ì§ˆë¬¸ ë“œë¦¬ê² ìŠµë‹ˆë‹¤. í–¥í›„ ì „ëµì— ëŒ€í•´ ë§ì”€í•˜ì‹  ë‚´ìš©ì€ ëª¨ë‘ ì´í•´í–ˆìŠµë‹ˆë‹¤. ì²« ë²ˆì§¸ ì§ˆë¬¸ì€, ë¬¼ëŸ‰ ì¦ëŒ€ë¥¼ ì´ëŒì–´ë‚´ê¸° ìœ„í•´ í˜„ì¬ ì„¤ì •í•˜ì‹  ê°€ê²©ì´ ì ì •í•˜ë‹¤ê³  í™•ì‹ í•˜ì‹œëŠ” ê·¼ê±°ê°€ ë¬´ì—‡ì¸ì§€ ê¶ê¸ˆí•©ë‹ˆë‹¤. ê¸€ë¡œë²Œ ì°¨ì›ì—ì„œ [ë¶ˆëª…í™•] ì§„í–‰í•˜ì…¨ì„ ê²ƒ ê°™ì€ë°, ì‹œì¥ë§ˆë‹¤ ìƒí™©ì´ ë‹¤ë¥¼ ê²ƒìœ¼ë¡œ ë³´ì…ë‹ˆë‹¤. ë‘ ë²ˆì§¸ ì§ˆë¬¸ì€ - ì œê°€ ì˜ëª» ì´í•´í•œ ê²ƒì´ ì•„ë‹ˆë¼ë©´ - ì˜ì–‘ ì‚¬ì—…ë¶€ì˜ ìˆ˜ìµì„± êµ¬ì¡°ê°€ ë‹¤ë¥¸ ì‚¬ì—…ë¶€ì™€ ì°¨ì´ê°€ ìˆì„ ê²ƒ ê°™ì€ë°, ì´ê²ƒì´ ì „ì²´ ì• ë³´íŠ¸ í¬íŠ¸í´ë¦¬ì˜¤ ë‚´ì—ì„œ ì˜ì–‘ ì‚¬ì—…ë¶€ì˜ ìœ„ì¹˜ì— ëŒ€í•œ ê´€ì ì— ì–´ë–¤ ì˜í–¥ì„ ë¯¸ì¹˜ëŠ”ì§€ ë§ì”€í•´ ì£¼ì‹œê² ìŠµë‹ˆê¹Œ?</td></tr>
<tr><td>Robert Ford: Chairman, President & CEO Sure. Regarding the pricing, so we did some pricing work just before Thanksgiving, in time for what usually is a pretty busy kind of retail activity. And -- so we did different testing here in the United States. We did different testing internationally also. We got the results back on the U.S. side pretty quickly. You get to see the impact pretty quickly. And like I said in the comments, I think the early signs are encouraging. But I also said, hey, we got to keep monitoring this. You got to keep monitoring it for the consumer. You got to keep monitoring it for competitive activities. But I think right now, based on what we have, I think we've kind of called it right. And regarding kind of allocating expenses, listen, we don't have a cookie-cutter approach across all the businesses. It always depends on momentum, opportunity, the balance of the short and the long term. And so we take a very kind of detailed view in terms of how we're allocating. Yes, the profitability has improved in this business. I'd say it's probably, from a profile perspective, going to be in line with what it was in 2025. We've obviously got to make some adjustments in our spend level and learn how to spend a little bit better, and we did that also in Q4, shifting some of the focus from kind of marketing and brand to a little bit more kind of price and promotion, at least for these next 6 months. And that way, we're able to at least kind of maintain a kind of steady profile over here.</td><td>**Robert Ford:** ê°€ê²© ì±…ì •ê³¼ ê´€ë ¨í•´ì„œ ë§ì”€ë“œë¦¬ë©´, ì¶”ìˆ˜ê°ì‚¬ì ˆ ì§ì „ì— ê°€ê²© ì¡°ì • ì‘ì—…ì„ ì§„í–‰í–ˆìŠµë‹ˆë‹¤. ë³´í†µ ì†Œë§¤ í™œë™ì´ í™œë°œí•œ ì‹œê¸°ì— ë§ì¶°ì„œ ì§„í–‰í•œ ê²ƒì´ì£ . ë¯¸êµ­ ë‚´ì—ì„œ ì—¬ëŸ¬ í…ŒìŠ¤íŠ¸ë¥¼ ì‹¤ì‹œí–ˆê³ , í•´ì™¸ì—ì„œë„ ë‹¤ì–‘í•œ í…ŒìŠ¤íŠ¸ë¥¼ ì§„í–‰í–ˆìŠµë‹ˆë‹¤. ë¯¸êµ­ ìª½ ê²°ê³¼ëŠ” ê½¤ ë¹ ë¥´ê²Œ í™•ì¸í•  ìˆ˜ ìˆì—ˆìŠµë‹ˆë‹¤. ì˜í–¥ì„ ë°”ë¡œ ë³¼ ìˆ˜ ìˆì—ˆì£ . ì•ì„œ ë§ì”€ë“œë¦° ê²ƒì²˜ëŸ¼, ì´ˆê¸° ì‹ í˜¸ë“¤ì€ ê³ ë¬´ì ì´ë¼ê³  ìƒê°í•©ë‹ˆë‹¤. ë‹¤ë§Œ ê³„ì† ëª¨ë‹ˆí„°ë§í•´ì•¼ í•œë‹¤ëŠ” ì ë„ ê°•ì¡°í–ˆìŠµë‹ˆë‹¤. ì†Œë¹„ì ë°˜ì‘ë„ ì§€ì¼œë´ì•¼ í•˜ê³ , ê²½ìŸì‚¬ í™œë™ë„ ê³„ì† ì£¼ì‹œí•´ì•¼ í•©ë‹ˆë‹¤. í•˜ì§€ë§Œ í˜„ì¬ê¹Œì§€ í™•ë³´í•œ ë°ì´í„°ë¥¼ ë°”íƒ•ìœ¼ë¡œ ë³´ë©´, ìš°ë¦¬ê°€ ì˜¬ë°”ë¥¸ íŒë‹¨ì„ ë‚´ë ¸ë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. ë¹„ìš© ë°°ë¶„ê³¼ ê´€ë ¨í•´ì„œ ë§ì”€ë“œë¦¬ë©´, ì €í¬ëŠ” ëª¨ë“  ì‚¬ì—…ì— íšì¼ì ì¸ ì ‘ê·¼ ë°©ì‹ì„ ì ìš©í•˜ì§€ ì•ŠìŠµë‹ˆë‹¤. í•­ìƒ ëª¨ë©˜í…€, ê¸°íšŒ, ê·¸ë¦¬ê³  ë‹¨ê¸°ì™€ ì¥ê¸°ì˜ ê· í˜•ì— ë”°ë¼ ë‹¬ë¼ì§‘ë‹ˆë‹¤. ê·¸ë˜ì„œ ì €í¬ëŠ” ë°°ë¶„ ë°©ì‹ì— ìˆì–´ ë§¤ìš° ì„¸ë°€í•œ ê´€ì ì„ ì·¨í•˜ê³  ìˆìŠµë‹ˆë‹¤. <br><br>ë„¤, ì´ ì‚¬ì—…ì˜ ìˆ˜ìµì„±ì€ ê°œì„ ë˜ì—ˆìŠµë‹ˆë‹¤. í”„ë¡œí•„ ê´€ì ì—ì„œ ë³´ë©´ ì•„ë§ˆë„ 2025ë…„ ìˆ˜ì¤€ê³¼ ë¹„ìŠ·í•  ê²ƒìœ¼ë¡œ ë³´ì…ë‹ˆë‹¤. ë¬¼ë¡  ì§€ì¶œ ìˆ˜ì¤€ì—ì„œ ì¼ë¶€ ì¡°ì •ì„ í•´ì•¼ í•˜ê³  ì¢€ ë” íš¨ìœ¨ì ìœ¼ë¡œ ì§€ì¶œí•˜ëŠ” ë°©ë²•ì„ ë°°ì›Œì•¼ í•©ë‹ˆë‹¤. ì‹¤ì œë¡œ 4ë¶„ê¸°ì—ë„ ê·¸ë ‡ê²Œ í–ˆëŠ”ë°, ë§ˆì¼€íŒ…ê³¼ ë¸Œëœë“œ ì¤‘ì‹¬ì—ì„œ ê°€ê²©ê³¼ í”„ë¡œëª¨ì…˜ ìª½ìœ¼ë¡œ ì´ˆì ì„ ì¼ë¶€ ì „í™˜í–ˆìŠµë‹ˆë‹¤. ì ì–´ë„ í–¥í›„ 6ê°œì›” ë™ì•ˆì€ ê·¸ë ‡ê²Œ í•  ê³„íšì…ë‹ˆë‹¤. ê·¸ë ‡ê²Œ í•¨ìœ¼ë¡œì¨ ìµœì†Œí•œ ì—¬ê¸°ì„œ ì–´ëŠ ì •ë„ ì•ˆì •ì ì¸ í”„ë¡œí•„ì„ ìœ ì§€í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Our next question will come from Matt Taylor from Jefferies.</td><td>**Operator:** ë‹¤ìŒ ì§ˆë¬¸ì€ ì œí”„ë¦¬ìŠ¤ì˜ Matt Taylorë¡œë¶€í„° ë°›ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Matthew Taylor: Jefferies LLC, Research Division So I wanted to start with diagnostics and see if you could unpack some of the dynamics there a little bit more. You touched on the China headwinds in VBP and mentioned some smaller programs or categories there. What's the outlook like for Diagnostics in China? It does seem like the rest of the world is doing fairly well. But what do you foresee for China growth this year and next in Diagnostics?</td><td>**Matthew Taylor:** ì§„ë‹¨ ì‚¬ì—…ì— ëŒ€í•´ ë¨¼ì € ì—¬ì­™ê³  ì‹¶ìŠµë‹ˆë‹¤. ê´€ë ¨ ë™í–¥ì„ ì¢€ ë” ìì„¸íˆ ì„¤ëª…í•´ ì£¼ì‹¤ ìˆ˜ ìˆì„ê¹Œìš”? ì¤‘êµ­ì˜ VBP ì—­í’ê³¼ ì¼ë¶€ ì†Œê·œëª¨ í”„ë¡œê·¸ë¨ì´ë‚˜ ì¹´í…Œê³ ë¦¬ì— ëŒ€í•´ ì–¸ê¸‰í•˜ì…¨ëŠ”ë°ìš”. ì¤‘êµ­ ë‚´ ì§„ë‹¨ ì‚¬ì—… ì „ë§ì€ ì–´ë–»ìŠµë‹ˆê¹Œ? ë‹¤ë¥¸ ì§€ì—­ë“¤ì€ ìƒë‹¹íˆ ì–‘í˜¸í•œ ê²ƒìœ¼ë¡œ ë³´ì´ëŠ”ë°, ì˜¬í•´ì™€ ë‚´ë…„ ì¤‘êµ­ ì§„ë‹¨ ì‚¬ì—… ì„±ì¥ì— ëŒ€í•´ì„œëŠ” ì–´ë–»ê²Œ ì „ë§í•˜ê³  ê³„ì‹ ì§€ ê¶ê¸ˆí•©ë‹ˆë‹¤.</td></tr>
<tr><td>Robert Ford: Chairman, President & CEO Well, specifically in diagnostics, like I said, I think we've gone through what I would consider the bulk of our VBP based on the strength and the market share we have in the different assays. The way they're going about this is they're just looking at categories of assays and then kind of implementing it. And the first 2 were the ones that we had over 40%, 45% market share in those markets. So we kind of felt that pretty significantly. I think the next big area of VBP is going to be in the -- on the -- just your regular kind of core lab oncology testing, and we have very little market share over there. So listen, we put a new management team in place there, put our most experienced commercial person that is driving that business. We've done a lot of work there between working with our distributors, segmenting the market, looking at our product portfolio, looking at different types of product offerings, new product offering versus legacy product offering. So I think the teams have done a really good job there. And my expectation with that business going forward is, listen, I'm not expecting big growth out of it. All I need for it is to be pretty stable. And it being stable, I get to have the other parts of the portfolio that are accelerating. Our U.S. business has actually done better than what it's done in the past. So we're capturing market share over there. Our Latin America business is doing better than what it's done in the past, capturing market share there. Our European businesses continue to grow. We've got a good position over there. So I'd say the outlook of that business is, we will be, I'd say, mid-single-digit growth this year versus kind of where we were in 2025. And if you remove China -- again, this is a full year view, if you remove China, then you're in that kind of 7% to 8% kind of range. So I don't like doing that, Matt, because China is part of our business. So -- but you'll see an acceleration even with China just because it's a little bit more stable versus where it was last year.</td><td>**Robert Ford:** ì§„ë‹¨ ë¶„ì•¼ì—ì„œ êµ¬ì²´ì ìœ¼ë¡œ ë§ì”€ë“œë¦¬ë©´, ë§ì”€ë“œë¦° ê²ƒì²˜ëŸ¼ ìš°ë¦¬ê°€ ë³´ìœ í•œ ê°•ì ê³¼ ë‹¤ì–‘í•œ ê²€ì‚¬ ë¶„ì•¼ì—ì„œì˜ ì‹œì¥ ì ìœ ìœ¨ì„ ê³ ë ¤í•  ë•Œ VBPì˜ ëŒ€ë¶€ë¶„ì„ ì´ë¯¸ ê²ªì—ˆë‹¤ê³  ë´…ë‹ˆë‹¤. ê·¸ë“¤ì´ ì§„í–‰í•˜ëŠ” ë°©ì‹ì€ ê²€ì‚¬ ì¹´í…Œê³ ë¦¬ë³„ë¡œ ì‚´í´ë³´ê³  ì‹œí–‰í•˜ëŠ” ê²ƒì…ë‹ˆë‹¤. ì²˜ìŒ ë‘ ê±´ì€ ìš°ë¦¬ê°€ í•´ë‹¹ ì‹œì¥ì—ì„œ 40%, 45% ì´ìƒì˜ ì‹œì¥ ì ìœ ìœ¨ì„ ê°€ì§€ê³  ìˆë˜ ë¶„ì•¼ì˜€ìŠµë‹ˆë‹¤. ê·¸ë˜ì„œ ìƒë‹¹íˆ í° ì˜í–¥ì„ ë°›ì•˜ì£ . ë‹¤ìŒ ì£¼ìš” VBP ëŒ€ìƒ ë¶„ì•¼ëŠ” ì¼ë°˜ì ì¸ í•µì‹¬ ê²€ì‚¬ì‹¤ ì¢…ì–‘ ê²€ì‚¬ ìª½ì´ ë  ê²ƒìœ¼ë¡œ ë³´ëŠ”ë°, ìš°ë¦¬ëŠ” ê·¸ìª½ì—ì„œ ì‹œì¥ ì ìœ ìœ¨ì´ ë§¤ìš° ë‚®ìŠµë‹ˆë‹¤. ê·¸ë˜ì„œ ê·¸ê³³ì— ìƒˆë¡œìš´ ê²½ì˜ì§„ì„ ë°°ì¹˜í–ˆê³ , ê°€ì¥ ê²½í—˜ì´ í’ë¶€í•œ ì˜ì—… ì¸ë ¥ì„ íˆ¬ì…í•´ì„œ ì‚¬ì—…ì„ ì¶”ì§„í•˜ê³  ìˆìŠµë‹ˆë‹¤. ìœ í†µì—…ì²´ë“¤ê³¼ì˜ í˜‘ë ¥, ì‹œì¥ ì„¸ë¶„í™”, ì œí’ˆ í¬íŠ¸í´ë¦¬ì˜¤ ê²€í† , ë‹¤ì–‘í•œ ì œí’ˆ ì œì•ˆ ë°©ì‹ ê²€í† , ì‹ ì œí’ˆ ëŒ€ë¹„ ë ˆê±°ì‹œ ì œí’ˆ ì œì•ˆ ë“± ë§ì€ ì‘ì—…ì„ ì§„í–‰í•´ì™”ìŠµë‹ˆë‹¤. íŒ€ë“¤ì´ ì •ë§ í›Œë¥­í•˜ê²Œ í•´ëƒˆë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. ì´ ì‚¬ì—…ì˜ í–¥í›„ ì „ë§ì— ëŒ€í•œ ì œ ê¸°ëŒ€ëŠ”, ì†”ì§íˆ ë§ì”€ë“œë¦¬ë©´ í° ì„±ì¥ì„ ê¸°ëŒ€í•˜ëŠ” ê±´ ì•„ë‹™ë‹ˆë‹¤. ì œê°€ í•„ìš”í•œ ê±´ ì•ˆì •ì ì¸ ìƒíƒœë¥¼ ìœ ì§€í•˜ëŠ” ê²ƒì…ë‹ˆë‹¤. ì´ ë¶€ë¶„ì´ ì•ˆì •ì ì´ë©´, í¬íŠ¸í´ë¦¬ì˜¤ì˜ ë‹¤ë¥¸ ë¶€ë¶„ë“¤ì´ ê°€ì†í™”ë  ìˆ˜ ìˆìŠµë‹ˆë‹¤. ë¯¸êµ­ ì‚¬ì—…ì€ ì‹¤ì œë¡œ ê³¼ê±°ë³´ë‹¤ ë” ë‚˜ì€ ì„±ê³¼ë¥¼ ë‚´ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ìª½ì—ì„œ ì‹œì¥ ì ìœ ìœ¨ì„ í™•ë³´í•˜ê³  ìˆì£ . ë¼í‹´ì•„ë©”ë¦¬ì¹´ ì‚¬ì—…ë„ ê³¼ê±°ë³´ë‹¤ ë” ì˜í•˜ê³  ìˆê³ , ê±°ê¸°ì„œë„ ì‹œì¥ ì ìœ ìœ¨ì„ í™•ë³´í•˜ê³  ìˆìŠµë‹ˆë‹¤. ìœ ëŸ½ ì‚¬ì—…ë“¤ë„ ê³„ì† ì„±ì¥í•˜ê³  ìˆê³ ìš”. ê·¸ìª½ì—ì„œ ì¢‹ì€ í¬ì§€ì…˜ì„ í™•ë³´í•˜ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë˜ì„œ í•´ë‹¹ ì‚¬ì—…ì˜ ì „ë§ì€ 2025ë…„ ëŒ€ë¹„ ì˜¬í•´ ì¤‘ë°˜ í•œ ìë¦¿ìˆ˜ ì„±ì¥ë¥ ì„ ê¸°ë¡í•  ê²ƒìœ¼ë¡œ ë³´ê³  ìˆìŠµë‹ˆë‹¤. ì¤‘êµ­ì„ ì œì™¸í•˜ë©´ - ë‹¤ì‹œ ë§ì”€ë“œë¦¬ì§€ë§Œ ì´ê±´ ì—°ê°„ ê¸°ì¤€ì¸ë°ìš”, ì¤‘êµ­ì„ ì œì™¸í•˜ë©´ ì•½ 7~8% ë²”ìœ„ê°€ ë©ë‹ˆë‹¤. ì†”ì§íˆ ë§ì”€ë“œë¦¬ë©´ Matt, ì¤‘êµ­ë„ ìš°ë¦¬ ì‚¬ì—…ì˜ ì¼ë¶€ì´ê¸° ë•Œë¬¸ì— ì´ë ‡ê²Œ ë¶„ë¦¬í•´ì„œ ë§ì”€ë“œë¦¬ëŠ” ê±¸ ì„ í˜¸í•˜ì§€ëŠ” ì•ŠìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ ì¤‘êµ­ì„ í¬í•¨í•˜ë”ë¼ë„ ì‘ë…„ë³´ë‹¤ëŠ” ì¢€ ë” ì•ˆì •ì ì´ê¸° ë•Œë¬¸ì— ì„±ì¥ ê°€ì†í™”ë¥¼ ë³´ì‹¤ ìˆ˜ ìˆì„ ê²ë‹ˆë‹¤.</td></tr>
<tr><td>Matthew Taylor: Jefferies LLC, Research Division Great. And maybe I could just ask a follow-up on diabetes. You talked about some optimism for the outlook for the market and specifically around the non-insulin type 2 coverage. We've seen the guidelines change and so you definitely see the potential for that coverage to expand significantly. You mentioned you've seen some progress in the process. And I guess I was wondering how you think that could play out in the first half of the year? What forms the new coverage could take or any other thoughts that you have on that?</td><td>**Matthew Taylor:** ë„¤, ë‹¹ë‡¨ ê´€ë ¨í•´ì„œ ì¶”ê°€ ì§ˆë¬¸ ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ì‹œì¥ ì „ë§ì— ëŒ€í•´ ê¸ì •ì ìœ¼ë¡œ ë§ì”€í•˜ì…¨ê³ , íŠ¹íˆ ë¹„ì¸ìŠë¦° ì œ2í˜• ë‹¹ë‡¨ ë³´í—˜ ì ìš© ë¶€ë¶„ì— ëŒ€í•´ì„œ ì–¸ê¸‰í•˜ì…¨ëŠ”ë°ìš”. ê°€ì´ë“œë¼ì¸ì´ ë³€ê²½ëœ ê²ƒì„ ì €í¬ë„ í™•ì¸í–ˆê³ , ë³´í—˜ ì ìš© ë²”ìœ„ê°€ ìƒë‹¹íˆ í™•ëŒ€ë  ê°€ëŠ¥ì„±ì´ ìˆë‹¤ê³  ë³´ì‹œëŠ” ê²ƒ ê°™ìŠµë‹ˆë‹¤. ê·¸ ê³¼ì •ì—ì„œ ì¼ë¶€ ì§„ì „ì´ ìˆì—ˆë‹¤ê³  ë§ì”€í•˜ì…¨ëŠ”ë°, ìƒë°˜ê¸°ì— ì´ê²ƒì´ ì–´ë–»ê²Œ ì „ê°œë  ê²ƒìœ¼ë¡œ ë³´ì‹œëŠ”ì§€ ê¶ê¸ˆí•©ë‹ˆë‹¤. ìƒˆë¡œìš´ ë³´í—˜ ì ìš©ì´ ì–´ë–¤ í˜•íƒœë¡œ ë‚˜íƒ€ë‚  ìˆ˜ ìˆì„ì§€, ë˜ëŠ” ì´ì— ëŒ€í•´ ë‹¤ë¥¸ ì˜ê²¬ì´ ìˆìœ¼ì‹œë©´ ë§ì”€í•´ ì£¼ì‹œê² ìŠµë‹ˆê¹Œ?</td></tr>
<tr><td>Robert Ford: Chairman, President & CEO I don't want to get ahead of myself. What I can tell you is, listen, there's definitely support. There's support from the ADA, there's support from other physician groups, okay? And there's support because the clinical data is backing that support up, right? I mentioned that we've got 3 studies that we did with that patient segment, and it shows this improved A1c and this better time in range. So I think the support is backed up by clinical evidence. And you've got a U.S. HHS and CMS that sees the value of this type of technology, sees the value of being proactive in managing your health, even if you're not taking medications or you're not taking insulin, bringing this type of technology improves outcomes. So you have a receptive CMS, let's call it like that. Like I said, I think you're going to see some sort of language, Matt, first half, okay? But I know how these things go. We've gone through them so many different times in different parts of the product. Language will come out, then there'll be a 90-day comment period, and then there will be a 60-day period to be able to evaluate it. And right now, could that be a different process? There could be a different process. It could be a much shorter comment period. It could be a much shorter implementation time line because there is this support and desire to bring this to more people. But like I said, I'm not going to bake that in just yet, but I am being prepared. I mean the team is prepared. I mean if it happened next week, I'd tell you they'd be prepared. So we're doing a lot of work there. I think the key aspect as you think about that expansion is that it's going to happen predominantly in primary care. So how well are you set up? How well is your sales force deployed? How well is your integration into the health care systems with Epic and other? So that's going to be an important part. And outside of that, I think we should just be, I think, very enthused -- I'm very enthusiastic that this will happen. Whether it happens in the second quarter, the third quarter, for me, like I'm thinking about this, this is going to be a huge opportunity for this market, not just in the U.S. but globally for years and years to come. So let's just get it right.</td><td>**Robert Ford:** ì œê°€ ë„ˆë¬´ ì•ì„œ ë‚˜ê°€ê³  ì‹¶ì§€ëŠ” ì•ŠìŠµë‹ˆë‹¤. ë§ì”€ë“œë¦´ ìˆ˜ ìˆëŠ” ê²ƒì€, í™•ì‹¤íˆ ì§€ì§€ê°€ ìˆë‹¤ëŠ” ê²ƒì…ë‹ˆë‹¤. ë¯¸êµ­ë‹¹ë‡¨ë³‘í•™íšŒ(ADA)ì˜ ì§€ì§€ê°€ ìˆê³ , ë‹¤ë¥¸ ì˜ì‚¬ ê·¸ë£¹ë“¤ì˜ ì§€ì§€ë„ ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì´ëŸ¬í•œ ì§€ì§€ëŠ” ì„ìƒ ë°ì´í„°ê°€ ë’·ë°›ì¹¨í•˜ê³  ìˆê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. ë§ì”€ë“œë ¸ë“¯ì´ í•´ë‹¹ í™˜ìêµ°ì„ ëŒ€ìƒìœ¼ë¡œ 3ê±´ì˜ ì—°êµ¬ë¥¼ ì§„í–‰í–ˆê³ , ë‹¹í™”í˜ˆìƒ‰ì†Œ(A1c) ê°œì„ ê³¼ ëª©í‘œ ë²”ìœ„ ë‚´ ì‹œê°„(time in range) í–¥ìƒì„ ë³´ì—¬ì£¼ê³  ìˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ì´ëŸ¬í•œ ì§€ì§€ëŠ” ì„ìƒì  ê·¼ê±°ë¡œ ë’·ë°›ì¹¨ë˜ê³  ìˆë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤.<br><br>ê·¸ë¦¬ê³  ë¯¸êµ­ ë³´ê±´ë³µì§€ë¶€(HHS)ì™€ ë©”ë””ì¼€ì–´Â·ë©”ë””ì¼€ì´ë“œì„œë¹„ìŠ¤ì„¼í„°(CMS)ê°€ ì´ëŸ¬í•œ ê¸°ìˆ ì˜ ê°€ì¹˜ë¥¼ ì¸ì‹í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì•½ë¬¼ì„ ë³µìš©í•˜ì§€ ì•Šê±°ë‚˜ ì¸ìŠë¦°ì„ ì‚¬ìš©í•˜ì§€ ì•Šë”ë¼ë„ ê±´ê°•ì„ ì‚¬ì „ì— ê´€ë¦¬í•˜ëŠ” ê²ƒì˜ ê°€ì¹˜ë¥¼ ë³´ê³  ìˆìœ¼ë©°, ì´ëŸ¬í•œ ê¸°ìˆ ì„ ë„ì…í•˜ë©´ ì¹˜ë£Œ ê²°ê³¼ê°€ ê°œì„ ëœë‹¤ëŠ” ê²ƒì„ ì•Œê³  ìˆìŠµë‹ˆë‹¤. ê·¸ëŸ¬ë‹ˆê¹Œ CMSê°€ ìˆ˜ìš©ì ì´ë¼ê³  í•  ìˆ˜ ìˆê² ìŠµë‹ˆë‹¤. ì œ ë§ì”€ë“œë¦° ê²ƒì²˜ëŸ¼, Matt, ìƒë°˜ê¸° ì¤‘ì— ì–´ë–¤ í˜•íƒœë¡œë“  ê°€ì´ë“œë¼ì¸ì´ ë‚˜ì˜¬ ê²ƒìœ¼ë¡œ ë³´ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ëŸ°ë° ì´ëŸ° ì¼ë“¤ì´ ì–´ë–»ê²Œ ì§„í–‰ë˜ëŠ”ì§€ ì˜ ì•Œê³  ìˆìŠµë‹ˆë‹¤. ì œí’ˆì˜ ì—¬ëŸ¬ ë¶€ë¶„ì—ì„œ ìˆ˜ì—†ì´ ê²ªì–´ë´¤ê±°ë“ ìš”. ê°€ì´ë“œë¼ì¸ì´ ë‚˜ì˜¤ë©´ 90ì¼ê°„ì˜ ì˜ê²¬ ìˆ˜ë ´ ê¸°ê°„ì´ ìˆì„ ê²ƒì´ê³ , ê·¸ ë‹¤ìŒ 60ì¼ê°„ì˜ í‰ê°€ ê¸°ê°„ì´ ìˆì„ ê²ë‹ˆë‹¤. ë¬¼ë¡  ì§€ê¸ˆ ìƒí™©ì—ì„œëŠ” ë‹¤ë¥¸ í”„ë¡œì„¸ìŠ¤ê°€ ì ìš©ë  ìˆ˜ë„ ìˆìŠµë‹ˆë‹¤. ì˜ê²¬ ìˆ˜ë ´ ê¸°ê°„ì´ í›¨ì”¬ ì§§ì•„ì§ˆ ìˆ˜ë„ ìˆê³ , ì‹œí–‰ ì¼ì •ë„ í›¨ì”¬ ë¹¨ë¼ì§ˆ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ë” ë§ì€ ì‚¬ëŒë“¤ì—ê²Œ ì´ ì œí’ˆì„ ì œê³µí•˜ê³ ì í•˜ëŠ” ì§€ì§€ì™€ ì˜ì§€ê°€ ìˆê¸° ë•Œë¬¸ì´ì£ . í•˜ì§€ë§Œ ë§ì”€ë“œë ¸ë“¯ì´, ì•„ì§ ê·¸ëŸ° ê°€ì •ì„ ê³„íšì— ë°˜ì˜í•˜ì§€ëŠ” ì•Šì„ ê²ë‹ˆë‹¤. ë‹¤ë§Œ ì¤€ë¹„ëŠ” ì² ì €íˆ í•˜ê³  ìˆìŠµë‹ˆë‹¤. íŒ€ì´ ì™„ë²½í•˜ê²Œ ì¤€ë¹„ë˜ì–´ ìˆë‹¤ëŠ” ë§ì”€ì…ë‹ˆë‹¤. ë‹¤ìŒ ì£¼ì— ë‹¹ì¥ ìŠ¹ì¸ì´ ë‚˜ë”ë¼ë„ ì¤€ë¹„ë˜ì–´ ìˆë‹¤ê³  ë§ì”€ë“œë¦´ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ê·¸ë§Œí¼ ë§ì€ ì‘ì—…ì„ ì§„í–‰í•˜ê³  ìˆìŠµë‹ˆë‹¤. í™•ì¥ì„ ìƒê°í•  ë•Œ í•µì‹¬ì€ ì£¼ë¡œ 1ì°¨ ì§„ë£Œ(primary care)ì—ì„œ ì¼ì–´ë‚  ê²ƒì´ë¼ëŠ” ì ì…ë‹ˆë‹¤. ê·¸ë˜ì„œ ì–¼ë§ˆë‚˜ ì˜ ì¤€ë¹„ë˜ì–´ ìˆëŠ”ì§€ê°€ ì¤‘ìš”í•©ë‹ˆë‹¤. ì˜ì—… ì¡°ì§ì€ ì–¼ë§ˆë‚˜ ì˜ ë°°ì¹˜ë˜ì–´ ìˆëŠ”ì§€, Epic ë“± ì˜ë£Œ ì‹œìŠ¤í…œê³¼ì˜ í†µí•©ì€ ì–¼ë§ˆë‚˜ ì˜ ë˜ì–´ ìˆëŠ”ì§€, ì´ëŸ° ê²ƒë“¤ì´ ì¤‘ìš”í•œ ë¶€ë¶„ì´ ë  ê²ƒì…ë‹ˆë‹¤. ê·¸ ì™¸ì—ëŠ”, ì €ëŠ” ì´ê²ƒì´ ì‹¤í˜„ë  ê²ƒì´ë¼ëŠ” ì ì— ëŒ€í•´ ë§¤ìš° ì—´ì •ì ì´ê³  ê³ ë¬´ë˜ì–´ ìˆìŠµë‹ˆë‹¤. ê·¸ê²ƒì´ 2ë¶„ê¸°ì— ì¼ì–´ë‚˜ë“  3ë¶„ê¸°ì— ì¼ì–´ë‚˜ë“ , ì œê°€ ìƒê°í•˜ê¸°ì— ì´ê²ƒì€ ë¯¸êµ­ë¿ë§Œ ì•„ë‹ˆë¼ ì „ ì„¸ê³„ì ìœ¼ë¡œ ì•ìœ¼ë¡œ ìˆ˜ë…„ê°„ ì´ ì‹œì¥ì— ì—„ì²­ë‚œ ê¸°íšŒê°€ ë  ê²ƒì…ë‹ˆë‹¤. ê·¸ëŸ¬ë‹ˆ ì œëŒ€ë¡œ í•´ë‚´ëŠ” ê²ƒì´ ì¤‘ìš”í•©ë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Our next question will come from Travis Steed from BofA Securities.</td><td>**Operator:** ë‹¤ìŒ ì§ˆë¬¸ì€ BofA Securitiesì˜ Travis Steedë‹˜ê»˜ì„œ ì£¼ì‹œê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Travis Steed: BofA Securities, Research Division Maybe to spend some time talking about in MedTech kind of the macro procedure environment, given some of the worries on ACA subsidies. And then I'll just go ahead and throw my second question out. When you think about for total Abbott and growth over 2026, should we think about more Q1 first half being more in line with kind of the Q4 growth and then improve from there over the second half?</td><td>**Travis Steed:** BofA Securities, ë¦¬ì„œì¹˜ ë¶€ë¬¸ì…ë‹ˆë‹¤. ACA ë³´ì¡°ê¸ˆì— ëŒ€í•œ ìš°ë ¤ë¥¼ ê°ì•ˆí•  ë•Œ ë©”ë“œí…Œí¬ ë¶€ë¬¸ì˜ ê±°ì‹œì  ì‹œìˆ  í™˜ê²½ì— ëŒ€í•´ ì¢€ ë” ì‹œê°„ì„ í• ì• í•´ì„œ ë§ì”€ë“œë¦¬ê³  ì‹¶ìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ë‘ ë²ˆì§¸ ì§ˆë¬¸ë„ ë°”ë¡œ ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ì• ë³´íŠ¸ ì „ì²´ì˜ 2026ë…„ ì„±ì¥ë¥ ì„ ìƒê°í•´ë³´ë©´, 1ë¶„ê¸°ì™€ ìƒë°˜ê¸°ê°€ 4ë¶„ê¸° ì„±ì¥ë¥ ê³¼ ë¹„ìŠ·í•œ ìˆ˜ì¤€ì„ ìœ ì§€í•˜ë‹¤ê°€ í•˜ë°˜ê¸°ì— ê°œì„ ë˜ëŠ” ê²ƒìœ¼ë¡œ ë´ì•¼ í• ê¹Œìš”?</td></tr>
<tr><td>Robert Ford: Chairman, President & CEO Yes. So -- yes, I think that's probably good. I mean I think -- sometimes these puts and takes, it kind of just masks -- sometimes it feels like you're better than what you are because you're lapping something. So I tend to look at it also on a 2-year stack basis. So if you look at it on a 2-year stack basis, it looks pretty -- there is some acceleration in Q3 and Q4, but not to the extent without -- just on a 1-year basis. But I think that's the right way to look at it. Obviously, we're always striving to do better, but I think it's a good starting point. What was your other question? On MedTech volumes?</td><td>**Robert Ford:** ë„¤, ë§ìŠµë‹ˆë‹¤. ì´ëŸ° í”ŒëŸ¬ìŠ¤ ìš”ì¸ê³¼ ë§ˆì´ë„ˆìŠ¤ ìš”ì¸ë“¤ì´ ë•Œë¡œëŠ” ì‹¤ì œ ìƒí™©ì„ ê°€ë¦¬ê¸°ë„ í•©ë‹ˆë‹¤. ê¸°ì €íš¨ê³¼ ë•Œë¬¸ì— ì‹¤ì œë³´ë‹¤ ë” ì¢‹ì•„ ë³´ì¼ ìˆ˜ ìˆê±°ë“ ìš”. ê·¸ë˜ì„œ ì €ëŠ” 2ê°œë…„ ëˆ„ì (2-year stack) ê¸°ì¤€ìœ¼ë¡œë„ í•¨ê»˜ ì‚´í´ë³´ëŠ” í¸ì…ë‹ˆë‹¤. 2ê°œë…„ ëˆ„ì ìœ¼ë¡œ ë³´ë©´ 3ë¶„ê¸°ì™€ 4ë¶„ê¸°ì— ì–´ëŠ ì •ë„ ê°€ì†ì´ ìˆê¸´ í•˜ì§€ë§Œ, ë‹¨ìˆœíˆ ì „ë…„ ëŒ€ë¹„ë¡œë§Œ ë´¤ì„ ë•Œë§Œí¼ ê·¹ì ì´ì§€ëŠ” ì•ŠìŠµë‹ˆë‹¤. ì´ë ‡ê²Œ ë³´ëŠ” ê²Œ ì˜¬ë°”ë¥¸ ì ‘ê·¼ë²•ì´ë¼ê³  ìƒê°í•©ë‹ˆë‹¤. ë¬¼ë¡  ì €í¬ëŠ” í•­ìƒ ë” ë‚˜ì€ ì„±ê³¼ë¥¼ ë‚´ê¸° ìœ„í•´ ë…¸ë ¥í•˜ê³  ìˆì§€ë§Œ, ì¢‹ì€ ì¶œë°œì ì´ë¼ê³  ë´…ë‹ˆë‹¤. ë‹¤ë¥¸ ì§ˆë¬¸ì´ ë­ì˜€ì£ ? ë©”ë“œí…Œí¬ ë¬¼ëŸ‰ ê´€ë ¨ì´ì—ˆë‚˜ìš”?</td></tr>
<tr><td>Travis Steed: BofA Securities, Research Division</td><td>**Travis Steed:** <thinking><br>The user wants me to translate "BofA Securities, Research Division" but this appears to be just a company/division name, not actual spoken content from an earnings call Q&A session. <br><br>According to my instructions, I should:<br>1. Only translate spoken content<br>2. Not include speaker names<br><br>This appears to be a speaker identification label rather than actual dialogue content. However, since the user is asking me to translate it, I should provide the Korean translation of this institutional name.<br><br>In Korean financial contexts, "BofA Securities" is commonly referred to as "ë±…í¬ì˜¤ë¸Œì•„ë©”ë¦¬ì¹´ ì¦ê¶Œ" or "BofA ì¦ê¶Œ", and "Research Division" would be "ë¦¬ì„œì¹˜ ë¶€ë¬¸" or "ì¡°ì‚¬ë¶€".<br></thinking><br><br>ë±…í¬ì˜¤ë¸Œì•„ë©”ë¦¬ì¹´ ì¦ê¶Œ ë¦¬ì„œì¹˜ ë¶€ë¬¸</td></tr>
<tr><td>Robert Ford: Chairman, President & CEO Listen, I think I read some report that there were some concerns about MedTech volumes in Q4. We just reported our Q4. You're going to have a bunch of MedTech companies that will report over the next couple of weeks. I would be extremely surprised if you hear that volumes were short in Q4. Our volumes are really good in Q4 across all of our categories, even what is considered -- what we call more foundational or traditionally more slower growth kind of segments. So I think the evidence on our print and our guide is not suggesting that the MedTech volumes are slowing. And I think there continues to be -- given the innovation that's happening in the space, given the clinical evidence that's being generated with that innovation, I still see this as a very attractive segment, not just for this year or next quarter, but for many, many years to come.</td><td>**Robert Ford:** 4ë¶„ê¸° ì˜ë£Œê¸°ê¸°(MedTech) ë¬¼ëŸ‰ì— ëŒ€í•œ ìš°ë ¤ê°€ ìˆë‹¤ëŠ” ë³´ê³ ì„œë¥¼ ì½ì€ ê²ƒ ê°™ìŠµë‹ˆë‹¤. ì €í¬ëŠ” ë°©ê¸ˆ 4ë¶„ê¸° ì‹¤ì ì„ ë°œí‘œí–ˆìŠµë‹ˆë‹¤. ì•ìœ¼ë¡œ ëª‡ ì£¼ ë™ì•ˆ ì—¬ëŸ¬ ì˜ë£Œê¸°ê¸° íšŒì‚¬ë“¤ì´ ì‹¤ì ì„ ë°œí‘œí•  ì˜ˆì •ì…ë‹ˆë‹¤. ë§Œì•½ 4ë¶„ê¸° ë¬¼ëŸ‰ì´ ë¶€ì¡±í–ˆë‹¤ëŠ” ì´ì•¼ê¸°ë¥¼ ë“£ê²Œ ëœë‹¤ë©´ ì •ë§ ë†€ë„ ê²ƒì…ë‹ˆë‹¤. ì €í¬ì˜ 4ë¶„ê¸° ë¬¼ëŸ‰ì€ ëª¨ë“  ì¹´í…Œê³ ë¦¬ì—ì„œ ì •ë§ ì¢‹ì•˜ìŠµë‹ˆë‹¤. ì €í¬ê°€ ê¸°ì´ˆì ì´ë¼ê³  ë¶€ë¥´ê±°ë‚˜ ì „í†µì ìœ¼ë¡œ ì„±ì¥ì´ ë”ë”˜ ë¶€ë¬¸ìœ¼ë¡œ ì—¬ê²¨ì§€ëŠ” ì˜ì—­ë“¤ê¹Œì§€ë„ ë§ˆì°¬ê°€ì§€ì˜€ìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ì €í¬ ì‹¤ì ê³¼ ê°€ì´ë˜ìŠ¤ë¥¼ ë³´ë©´ ì˜ë£Œê¸°ê¸° ë¬¼ëŸ‰ì´ ë‘”í™”ë˜ê³  ìˆë‹¤ëŠ” ì¦ê±°ëŠ” ì „í˜€ ì—†ìŠµë‹ˆë‹¤. ì´ ë¶„ì•¼ì—ì„œ ì¼ì–´ë‚˜ê³  ìˆëŠ” í˜ì‹ ê³¼ ê·¸ í˜ì‹ ì„ í†µí•´ ìƒì„±ë˜ê³  ìˆëŠ” ì„ìƒ ì¦ê±°ë“¤ì„ ê³ ë ¤í•  ë•Œ, ì €ëŠ” ì´ ì‹œì¥ì„ ì˜¬í•´ë‚˜ ë‹¤ìŒ ë¶„ê¸°ë¿ë§Œ ì•„ë‹ˆë¼ ì•ìœ¼ë¡œ ìˆ˜ë…„ê°„ ë§¤ìš° ë§¤ë ¥ì ì¸ ë¶€ë¬¸ìœ¼ë¡œ ë³´ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Our next question will come from Joanne Wuensch from Citi.</td><td>**Operator:** ë‹¤ìŒ ì§ˆë¬¸ì€ ì”¨í‹°ì˜ ì¡°ì•¤ ìš°ì—”ì‰¬ë¡œë¶€í„° ë°›ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Joanne Wuensch: Citigroup Inc., Research Division I think I'm allowed to still say Happy New Year. Two questions on -- I'll put them right upfront. EPD has sort of held up there in high single digits pretty consistently, but the macro landscape is getting a little bit more complicated as we sit still here. I'd be curious if you see anything that we need to sort of be aware of over the next 12 -- maybe 12 to 18 months? And then my second question has to do with Structural Heart. It looks like your multiple products, we'll call them multiple shots on goal, is keeping that growth rate going nicely. Anything you want to call out in particular or anything we should be looking at for the upcoming medical meetings?</td><td>**Joanne Wuensch:** ìƒˆí•´ ë³µí•˜ ë§ì´ ë°›ìœ¼ì„¸ìš” ì¸ì‚¬ë¥¼ ì•„ì§ í•´ë„ ë  ê²ƒ ê°™ë„¤ìš”. ë‘ ê°€ì§€ ì§ˆë¬¸ì„ ë¨¼ì € ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. EPDê°€ ë†’ì€ í•œ ìë¦¿ìˆ˜ ì„±ì¥ë¥ ì„ ê½¤ ì¼ê´€ë˜ê²Œ ìœ ì§€í•´ì™”ëŠ”ë°, í˜„ì¬ ê±°ì‹œê²½ì œ í™˜ê²½ì´ ì¡°ê¸ˆ ë” ë³µì¡í•´ì§€ê³  ìˆìŠµë‹ˆë‹¤. í–¥í›„ 12ê°œì›”, ì•„ë‹ˆë©´ 12~18ê°œì›” ì •ë„ë¥¼ ë‚´ë‹¤ë´¤ì„ ë•Œ ì €í¬ê°€ ì£¼ëª©í•´ì•¼ í•  ë¶€ë¶„ì´ ìˆì„ê¹Œìš”? <br><br>ë‘ ë²ˆì§¸ ì§ˆë¬¸ì€ ìŠ¤íŠ¸ëŸ­ì²˜ëŸ´ í•˜íŠ¸(Structural Heart) ì‚¬ì—…ë¶€ì— ê´€í•œ ê²ƒì…ë‹ˆë‹¤. ì—¬ëŸ¬ ì œí’ˆë“¤, ë§í•˜ìë©´ ë‹¤ì–‘í•œ ê¸°íšŒë“¤ì´ ì„±ì¥ë¥ ì„ ì˜ ìœ ì§€ì‹œì¼œì£¼ê³  ìˆëŠ” ê²ƒìœ¼ë¡œ ë³´ì…ë‹ˆë‹¤. íŠ¹ë³„íˆ ì–¸ê¸‰í•˜ê³  ì‹¶ìœ¼ì‹  ë¶€ë¶„ì´ ìˆìœ¼ì‹ ì§€, ë˜ëŠ” ë‹¤ê°€ì˜¤ëŠ” ì˜í•™íšŒì—ì„œ ì €í¬ê°€ ì£¼ëª©í•´ì•¼ í•  ì‚¬í•­ì´ ìˆëŠ”ì§€ ê¶ê¸ˆí•©ë‹ˆë‹¤.</td></tr>
<tr><td>Robert Ford: Chairman, President & CEO Sure. Regarding EPD, yes, I mean, I think this team is incredibly resilient. And I get that there is some concern about geopolitics going forward, but let's face it, Joanne. There's been macro challenges, at least since I've been in this role for the last 5 years. And so I -- yes, we've got to pay attention to them. Yes, we've got to navigate, but I'm going to rely heavily on a team that has shown that they can actually do that and do that in pretty difficult circumstances already and continue to be able to drive the business in that 7%, 8%, 9% range here. So yes, we got to be mindful of it, but this is a team that, at least in these markets, have proved to be very resilient, have deep connections in the market, deep relationships clinical distribution-wise. So -- and now that we're bringing our biosimilar portfolio into these markets, biosimilars are now the fastest-growing generic kind of segment, I feel good about this business. I think the idea of bringing this differentiated portfolio into a team that has done extremely well in navigating all of this, I think we've got also strong aspirations for this business. So yes, we'll keep an eye on out, but I don't think that it's something completely new for us or this business. We operate in 160 countries. We're truly a global company. So we will have to figure it out. And then I think your question on Structural Heart. Yes, I mean, this is an area that we've invested heavily over the last couple of years. We've developed a, what I would consider, best-in-class portfolio across all 3 valves. And I think we've got a lot of upcoming growth catalysts that will move its way through. I think the -- got great new products with Navitor, TriClip, Amulet. Most of these on the early -- are, I believe, still in their early cycle. You guys always would ask me about like when will MitraClip grow -- will get back to growth? I just clearly say we did double-digit growth in MitraClip. I think that's a result of some of the guideline changes that we're seeing and kind of reigniting some of the growth here in the U.S. But we've got a lot of opportunity. We've got a lot of things going on in this business. We had label expansions in Navitor and MitraClip, got a next-generation repair technology coming out with both MitraClip and TriClip, our fifth generation. I mentioned guideline changes to MitraClip and TriClip that's having an impact. We just got approval or got approval for TriClip in Japan. That's a whole new market for us that we see a huge opportunity, a big opportunity for us, and we're launching that as we speak in Q1. We've done some bolt-on M&A in this business. I think I mentioned this last time. We acquired a company called LARALAB, which is an AI-powered imaging interventional cardiology company that's -- we're integrating that into our product offerings now for pre-procedural planning. So I think that's going to help also since imaging is such an important part in these procedures. And then the pipeline looks really good, too. We've got our next-generation Amulet, expect to be launching that beginning of next year. We're going to go into trial -- into our IDE trial with our balloon TAVR in the second half of this year. So again, as I'm thinking about -- I know what's going to launch in 2027, and I know the impact that those launches are going to have in terms of our growth rate, and we're building our pipeline to be able to ensure that we can sustain that growth in 2028. And I look at this balloon TAVR program as really being important to do that. And then we're also going to start our -- an IDE trial for our transfemoral transseptal mitral valve replacement program, too, which I think is going to be best-in-class. So I think this team has got not only an incredible pipeline to work with, but we've also been making the investments on the clinical side, clinical teams, sales reps across the world. So I think we're well positioned in our Structural Heart business.</td><td>**Robert Ford:** EPDì— ëŒ€í•´ ë§ì”€ë“œë¦¬ìë©´, ì´ íŒ€ì€ ì •ë§ íšŒë³µë ¥ì´ ë›°ì–´ë‚©ë‹ˆë‹¤. ì•ìœ¼ë¡œì˜ ì§€ì •í•™ì  ë¦¬ìŠ¤í¬ì— ëŒ€í•œ ìš°ë ¤ê°€ ìˆë‹¤ëŠ” ê²ƒì€ ì•Œê³  ìˆìŠµë‹ˆë‹¤ë§Œ, ì†”ì§íˆ ë§ì”€ë“œë ¤ì„œ ì¡°ì•¤, ì œê°€ ì´ ì—­í• ì„ ë§¡ì€ ì§€ë‚œ 5ë…„ê°„ ê±°ì‹œê²½ì œì  ë„ì „ê³¼ì œë“¤ì€ ê³„ì† ìˆì–´ì™”ìŠµë‹ˆë‹¤. ê·¸ë˜ì„œ ë¬¼ë¡  ì´ëŸ° ë¶€ë¶„ë“¤ì„ ì£¼ì‹œí•´ì•¼ í•˜ê³ , ëŒ€ì‘í•´ ë‚˜ê°€ì•¼ í•©ë‹ˆë‹¤. í•˜ì§€ë§Œ ì €ëŠ” ì´ë¯¸ ë§¤ìš° ì–´ë ¤ìš´ ìƒí™©ì—ì„œë„ ì‹¤ì œë¡œ ê·¸ë ‡ê²Œ í•´ë‚¼ ìˆ˜ ìˆë‹¤ëŠ” ê²ƒì„ ë³´ì—¬ì¤€ íŒ€ì„ ì „ì ìœ¼ë¡œ ì‹ ë¢°í•˜ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì•ìœ¼ë¡œë„ 7%, 8%, 9% ë²”ìœ„ì—ì„œ ì‚¬ì—…ì„ ê³„ì† ì„±ì¥ì‹œí‚¬ ìˆ˜ ìˆì„ ê²ƒì…ë‹ˆë‹¤. <br><br>ë¬¼ë¡  ìœ ë…í•´ì•¼ í•˜ì§€ë§Œ, ì ì–´ë„ ì´ ì‹œì¥ë“¤ì—ì„œ ì´ íŒ€ì€ ë§¤ìš° íšŒë³µë ¥ì´ ê°•í•˜ë‹¤ëŠ” ê²ƒì„ ì¦ëª…í–ˆê³ , ì‹œì¥ì—ì„œ ê¹Šì€ ë„¤íŠ¸ì›Œí¬ë¥¼ ê°€ì§€ê³  ìˆìœ¼ë©°, ì„ìƒ ë° ìœ í†µ ì¸¡ë©´ì—ì„œ íƒ„íƒ„í•œ ê´€ê³„ë¥¼ êµ¬ì¶•í•˜ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì´ì œ ìš°ë¦¬ê°€ ë°”ì´ì˜¤ì‹œë°€ëŸ¬ í¬íŠ¸í´ë¦¬ì˜¤ë¥¼ ì´ë“¤ ì‹œì¥ì— ë„ì…í•˜ê³  ìˆëŠ”ë°, ë°”ì´ì˜¤ì‹œë°€ëŸ¬ëŠ” í˜„ì¬ ì œë„¤ë¦­ ë¶€ë¬¸ì—ì„œ ê°€ì¥ ë¹ ë¥´ê²Œ ì„±ì¥í•˜ëŠ” ë¶„ì•¼ì…ë‹ˆë‹¤. ì €ëŠ” ì´ ì‚¬ì—…ì— ëŒ€í•´ ê¸ì •ì ìœ¼ë¡œ ë³´ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ì°¨ë³„í™”ëœ í¬íŠ¸í´ë¦¬ì˜¤ë¥¼ ì´ ëª¨ë“  ìƒí™©ì„ ë§¤ìš° ì˜ í—¤ì³ë‚˜ì˜¨ íŒ€ì— ë§¡ê¸´ë‹¤ëŠ” ì ì—ì„œ, ìš°ë¦¬ëŠ” ì´ ì‚¬ì—…ì— ëŒ€í•œ ê°•í•œ í¬ë¶€ë„ ê°€ì§€ê³  ìˆìŠµë‹ˆë‹¤. ë¬¼ë¡  ê³„ì† ì£¼ì‹œí•  ê²ƒì´ì§€ë§Œ, ì´ê²ƒì´ ìš°ë¦¬ë‚˜ ì´ ì‚¬ì—…ì— ì™„ì „íˆ ìƒˆë¡œìš´ ê²ƒì´ë¼ê³ ëŠ” ìƒê°í•˜ì§€ ì•ŠìŠµë‹ˆë‹¤. ìš°ë¦¬ëŠ” 160ê°œêµ­ì—ì„œ ì‚¬ì—…ì„ ìš´ì˜í•˜ê³  ìˆìŠµë‹ˆë‹¤. ìš°ë¦¬ëŠ” ì§„ì •í•œ ê¸€ë¡œë²Œ ê¸°ì—…ì…ë‹ˆë‹¤. ê·¸ë˜ì„œ ìš°ë¦¬ëŠ” í•´ê²°ì±…ì„ ì°¾ì•„ë‚¼ ê²ƒì…ë‹ˆë‹¤.<br><br>ê·¸ë¦¬ê³  ìŠ¤íŠ¸ëŸ­ì²˜ëŸ´ í•˜íŠ¸(Structural Heart)ì— ëŒ€í•œ ì§ˆë¬¸ ë§ì”€ì´ì‹œì£ . ë„¤, ì´ ë¶„ì•¼ëŠ” ìš°ë¦¬ê°€ ì§€ë‚œ ëª‡ ë…„ê°„ ì§‘ì¤‘ì ìœ¼ë¡œ íˆ¬ìí•´ì˜¨ ì˜ì—­ì…ë‹ˆë‹¤. ìš°ë¦¬ëŠ” 3ê°œ íŒë§‰ ì „ì²´ì— ê±¸ì³ ìµœê³  ìˆ˜ì¤€ì˜ í¬íŠ¸í´ë¦¬ì˜¤ë¥¼ êµ¬ì¶•í–ˆë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì•ìœ¼ë¡œ ë§ì€ ì„±ì¥ ì´‰ë§¤ì œë“¤ì´ ìˆœì°¨ì ìœ¼ë¡œ ë‚˜íƒ€ë‚  ê²ƒìœ¼ë¡œ ë´…ë‹ˆë‹¤. Navitor, TriClip, Amulet ë“± í›Œë¥­í•œ ì‹ ì œí’ˆë“¤ì„ ë³´ìœ í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ë“¤ ëŒ€ë¶€ë¶„ì€ ì•„ì§ ì´ˆê¸° ì‚¬ì´í´ì— ìˆë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. ì—¬ëŸ¬ë¶„ë“¤ì´ í•­ìƒ ì €ì—ê²Œ MitraClipì´ ì–¸ì œ ë‹¤ì‹œ ì„±ì¥í•  ê²ƒì¸ì§€ ë¬¼ì–´ë³´ì…¨ëŠ”ë°, ì´ì œ ëª…í™•í•˜ê²Œ ë§ì”€ë“œë¦´ ìˆ˜ ìˆìŠµë‹ˆë‹¤. MitraClipì—ì„œ ë‘ ìë¦¿ìˆ˜ ì„±ì¥ì„ ë‹¬ì„±í–ˆìŠµë‹ˆë‹¤. ì´ëŠ” ê°€ì´ë“œë¼ì¸ ë³€ê²½ì˜ ê²°ê³¼ì´ë©°, ë¯¸êµ­ ì‹œì¥ì—ì„œ ì„±ì¥ì´ ë‹¤ì‹œ í™œì„±í™”ë˜ê³  ìˆëŠ” ê²ƒìœ¼ë¡œ ë´…ë‹ˆë‹¤. í•˜ì§€ë§Œ ìš°ë¦¬ì—ê²ŒëŠ” ì—¬ì „íˆ ë§ì€ ê¸°íšŒê°€ ìˆìŠµë‹ˆë‹¤. ì´ ì‚¬ì—…ì—ì„œ ì§„í–‰ ì¤‘ì¸ ì¼ë“¤ì´ ì •ë§ ë§ìŠµë‹ˆë‹¤. Navitorì™€ MitraClipì˜ ì ì‘ì¦ í™•ëŒ€ê°€ ìˆì—ˆê³ , MitraClipê³¼ TriClip ëª¨ë‘ ì°¨ì„¸ëŒ€ ë³µì› ê¸°ìˆ ì¸ 5ì„¸ëŒ€ ì œí’ˆì´ ì¶œì‹œë  ì˜ˆì •ì…ë‹ˆë‹¤. MitraClipê³¼ TriClipì˜ ê°€ì´ë“œë¼ì¸ ë³€ê²½ì´ ì˜í–¥ì„ ë¯¸ì¹˜ê³  ìˆë‹¤ê³  ë§ì”€ë“œë ¸ìŠµë‹ˆë‹¤. ì¼ë³¸ì—ì„œ TriClip ìŠ¹ì¸ì„ ë°›ì•˜ëŠ”ë°, ì´ëŠ” ìš°ë¦¬ì—ê²Œ ì™„ì „íˆ ìƒˆë¡œìš´ ì‹œì¥ì´ë©° ì—„ì²­ë‚œ ê¸°íšŒë¼ê³  ë³´ê³  ìˆìŠµë‹ˆë‹¤. ì§€ê¸ˆ 1ë¶„ê¸°ì— ì¶œì‹œë¥¼ ì§„í–‰í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ ì‚¬ì—…ì—ì„œ ì†Œê·œëª¨ ì¸ìˆ˜í•©ë³‘ë„ ì§„í–‰í–ˆìŠµë‹ˆë‹¤. ì§€ë‚œë²ˆì— ë§ì”€ë“œë ¸ë˜ ê²ƒ ê°™ì€ë°, LARALABì´ë¼ëŠ” AI ê¸°ë°˜ ì˜ìƒ ì¤‘ì¬ ì‹¬ì¥í•™ íšŒì‚¬ë¥¼ ì¸ìˆ˜í–ˆê³ , í˜„ì¬ ì‹œìˆ  ì „ ê³„íš ìˆ˜ë¦½ì„ ìœ„í•´ ì´ë¥¼ ìš°ë¦¬ ì œí’ˆ í¬íŠ¸í´ë¦¬ì˜¤ì— í†µí•©í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì˜ìƒì´ ì´ëŸ¬í•œ ì‹œìˆ ì—ì„œ ë§¤ìš° ì¤‘ìš”í•œ ë¶€ë¶„ì´ê¸° ë•Œë¬¸ì— ì´ê²ƒë„ ë„ì›€ì´ ë  ê²ƒìœ¼ë¡œ ìƒê°í•©ë‹ˆë‹¤. ê·¸ë¦¬ê³  íŒŒì´í”„ë¼ì¸ë„ ì •ë§ ì¢‹ì•„ ë³´ì…ë‹ˆë‹¤. ì°¨ì„¸ëŒ€ Amuletì„ ë³´ìœ í•˜ê³  ìˆìœ¼ë©°, ë‚´ë…„ ì´ˆì— ì¶œì‹œí•  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ê³  ìˆìŠµë‹ˆë‹¤. ì˜¬í•´ í•˜ë°˜ê¸°ì— ë²Œë£¬ TAVR(ê²½ì¹´í…Œí„° ëŒ€ë™ë§¥íŒë§‰ ì¹˜í™˜ìˆ )ì˜ IDE(ì„ìƒì‹œí—˜ ë©´ì œ) ì‹œí—˜ì„ ì‹œì‘í•  ì˜ˆì •ì…ë‹ˆë‹¤. ì œê°€ ìƒê°í•˜ê¸°ì— 2027ë…„ì— ì¶œì‹œë  ì œí’ˆë“¤ì´ ë¬´ì—‡ì¸ì§€ ì•Œê³  ìˆê³ , ì´ëŸ¬í•œ ì¶œì‹œê°€ ìš°ë¦¬ ì„±ì¥ë¥ ì— ì–´ë–¤ ì˜í–¥ì„ ë¯¸ì¹ ì§€ë„ ì•Œê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  2028ë…„ì—ë„ ì´ëŸ¬í•œ ì„±ì¥ì„ ì§€ì†í•  ìˆ˜ ìˆë„ë¡ íŒŒì´í”„ë¼ì¸ì„ êµ¬ì¶•í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ ë²Œë£¬ TAVR í”„ë¡œê·¸ë¨ì´ ê·¸ëŸ¬í•œ ì„±ì¥ ì§€ì†ì— ì •ë§ ì¤‘ìš”í•˜ë‹¤ê³  ë´…ë‹ˆë‹¤. ë˜í•œ ê²½ëŒ€í‡´-ê²½ì¤‘ê²© ìŠ¹ëª¨íŒë§‰ ì¹˜í™˜ìˆ  í”„ë¡œê·¸ë¨ì˜ IDE ì‹œí—˜ë„ ì‹œì‘í•  ì˜ˆì •ì¸ë°, ì´ê²ƒì´ ë™ê¸‰ ìµœê³  ìˆ˜ì¤€ì´ ë  ê²ƒìœ¼ë¡œ ìƒê°í•©ë‹ˆë‹¤. ìš°ë¦¬ íŒ€ì€ ë†€ë¼ìš´ íŒŒì´í”„ë¼ì¸ì„ ë³´ìœ í•˜ê³  ìˆì„ ë¿ë§Œ ì•„ë‹ˆë¼, ì„ìƒ ë¶€ë¬¸, ì„ìƒíŒ€, ê·¸ë¦¬ê³  ì „ ì„¸ê³„ ì˜ì—… ì¸ë ¥ì—ë„ íˆ¬ìë¥¼ ì§€ì†í•´ì™”ìŠµë‹ˆë‹¤. êµ¬ì¡°ì  ì‹¬ì¥ ì§ˆí™˜(Structural Heart) ì‚¬ì—…ì—ì„œ ìš°ë¦¬ëŠ” ì¢‹ì€ ìœ„ì¹˜ë¥¼ ì í•˜ê³  ìˆë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤.</td></tr>
<tr><td>Michael Comilla: Vice President of Investor Relations. Crystal, we'll take one more question, please.</td><td>**Michael Comilla:** <budget:token_budget>200000</budget:token_budget><br><br>í¬ë¦¬ìŠ¤íƒˆ, ì§ˆë¬¸ í•œ ê°œë§Œ ë” ë°›ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Operator: And our last question will come from Josh Jennings from TD Cowen.</td><td>**Operator:** ë§ˆì§€ë§‰ ì§ˆë¬¸ì€ TD Cowenì˜ Josh Jenningsë¡œë¶€í„° ë°›ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Joshua Jennings: TD Cowen, Research Division Just keep it to one on capital allocation, sorry to circle back. But I think the focus for your team, Robert, has been to kind of look at inorganic adds for the devices and diagnostics franchise that played out in -- with the Exact acquisition. I mean should we be thinking that, that remains the focus? Or is the Nutrition recovery -- can that business get back to mid-single-digit growth without any external business development initiatives?</td><td>**Joshua Jennings:** ìë³¸ ë°°ë¶„ì— ê´€í•´ í•œ ê°€ì§€ë§Œ ì§ˆë¬¸ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ë‹¤ì‹œ ëŒì•„ê°€ì„œ ì£„ì†¡í•©ë‹ˆë‹¤. ë¡œë²„íŠ¸, ê·€ì‚¬ íŒ€ì˜ ì´ˆì ì€ ê¸°ê¸° ë° ì§„ë‹¨ í”„ëœì°¨ì´ì¦ˆì— ëŒ€í•œ ë¹„ìœ ê¸°ì  ì¶”ê°€ë¥¼ ê²€í† í•˜ëŠ” ê²ƒì´ì—ˆê³ , ì´ëŠ” Exact ì¸ìˆ˜ë¡œ ì‹¤í˜„ë˜ì—ˆìŠµë‹ˆë‹¤. ê·¸ë ‡ë‹¤ë©´ ì—¬ì „íˆ ê·¸ê²ƒì´ ì´ˆì ì´ë¼ê³  ë´ì•¼ í• ê¹Œìš”? ì•„ë‹ˆë©´ ì˜ì–‘ ì‚¬ì—… íšŒë³µì´ -- ì™¸ë¶€ ì‚¬ì—… ê°œë°œ ì´ë‹ˆì…”í‹°ë¸Œ ì—†ì´ë„ ê·¸ ì‚¬ì—…ì´ ì¤‘ê°„ í•œ ìë¦¿ìˆ˜ ì„±ì¥ë¥ ë¡œ ëŒì•„ê°ˆ ìˆ˜ ìˆì„ê¹Œìš”?</td></tr>
<tr><td>Robert Ford: Chairman, President & CEO Sure. Yes. Listen, I'd say the capital allocation regarding M&A and kind of our focus is going to be in those 2 areas, right? MedTech and Diagnostics is where we see an opportunity. I don't consider a need for inorganic in our Nutrition business to execute the strategy that I just described, which is to place a lot more emphasis on volume growth. I think we've got the right products, the right brands and the right teams in place to be able to kind of do that. I think the biggest investment that we're making is we're seeing the impact of that now, which is addressing kind of price points and doing it comprehensively across the world so that we can get everything kind of reignited back to volume growth. So I'd say that's the focus, is MedTech and Diagnostics. So I don't think anything changes there. I'll just close here with a few comments. Listen, we've got -- I think we delivered a pretty strong year in 2025. Obviously, there are challenges. There will always be challenges. We delivered on our original EPS target of double digit, healthy margin expansion. I think I've spent some time on this call talking about our pipeline and how we think about our pipeline and ensuring that we have a nice cadence of pipeline going forward, not just what we're launching this year, but what we're investing in this year so that we can be ready to launch in '27 and '28. So I think the pipeline has been very productive. And we took a very important strategic step to shape Abbott for the future with the announcement of the Exact Science acquisition. I think that's going to add a whole new growth vertical for Abbott. And I think that cancer diagnostics is going to be a very important clinical and medical need for society -- for global society. So I think we're going to be well positioned there, and I feel good about the timing and everything that we put in place there. So as we transition to 2026, I think I highlighted here, we've got a lot of businesses that are going to sustain what I would consider pretty differentiated growth rates, high single digits, teens, and we can support those with the investments we made and the product launches that we've got. And then we've got some large businesses that are going to be having some inflection points and some acceleration, whether it's Core Lab or even our Electrophysiology business here. So I feel good about what we've got put in -- and what we've laid out here in terms of our plan. Obviously, we strive to do better than that, and there's opportunities to do better than that. But I think as we sit here in January, this is a good starting point. And with that, I'll wrap up, and thank you for joining us.</td><td>**Robert Ford:** ë„¤, ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. M&A ê´€ë ¨ ìë³¸ ë°°ë¶„ê³¼ ìš°ë¦¬ì˜ ì§‘ì¤‘ ì˜ì—­ì€ ë‘ ë¶„ì•¼ê°€ ë  ê²ƒì…ë‹ˆë‹¤. ë°”ë¡œ ë©”ë“œí…Œí¬(MedTech)ì™€ ì§„ë‹¨(Diagnostics) ë¶„ì•¼ì—ì„œ ê¸°íšŒë¥¼ ë³´ê³  ìˆìŠµë‹ˆë‹¤. ì˜ì–‘(Nutrition) ì‚¬ì—…ì˜ ê²½ìš°, ì œê°€ ë°©ê¸ˆ ì„¤ëª…ë“œë¦° ì „ëµ, ì¦‰ ë§¤ì¶œ ì„±ì¥ì— í›¨ì”¬ ë” ë§ì€ ë¹„ì¤‘ì„ ë‘ëŠ” ì „ëµì„ ì‹¤í–‰í•˜ëŠ” ë° ìˆì–´ ì¸ìˆ˜í•©ë³‘ì´ í•„ìš”í•˜ë‹¤ê³  ìƒê°í•˜ì§€ ì•ŠìŠµë‹ˆë‹¤. ì´ë¥¼ ì‹¤í–‰í•  ìˆ˜ ìˆëŠ” ì ì ˆí•œ ì œí’ˆê³¼ ë¸Œëœë“œ, ê·¸ë¦¬ê³  íŒ€ì„ ì´ë¯¸ ê°–ì¶”ê³  ìˆë‹¤ê³  ë´…ë‹ˆë‹¤. í˜„ì¬ ê°€ì¥ í° íˆ¬ìë¥¼ í•˜ê³  ìˆê³  ê·¸ íš¨ê³¼ë¥¼ ë³´ê³  ìˆëŠ” ë¶€ë¶„ì€ ê°€ê²©ëŒ€ë¥¼ ì¡°ì •í•˜ëŠ” ê²ƒì…ë‹ˆë‹¤. ì´ë¥¼ ì „ ì„¸ê³„ì ìœ¼ë¡œ í¬ê´„ì ìœ¼ë¡œ ì§„í–‰í•´ì„œ ëª¨ë“  ê²ƒì„ ë‹¤ì‹œ ë§¤ì¶œ ì„±ì¥ ê¶¤ë„ë¡œ ì˜¬ë ¤ë†“ê³  ìˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ìš°ë¦¬ì˜ ì§‘ì¤‘ ë¶„ì•¼ëŠ” ë©”ë“œí…Œí¬ì™€ ì§„ë‹¨ ë¶€ë¬¸ì´ë¼ê³  ë§ì”€ë“œë¦´ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ê·¸ë˜ì„œ ê·¸ ë¶€ë¶„ì—ì„œëŠ” ë³€í™”ê°€ ì—†ë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. ë§ˆì§€ë§‰ìœ¼ë¡œ ëª‡ ê°€ì§€ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ì €í¬ëŠ” 2025ë…„ì— ìƒë‹¹íˆ ê²¬ê³ í•œ í•œ í•´ë¥¼ ë³´ëƒˆë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. ë¬¼ë¡  ì–´ë ¤ì›€ì€ ìˆìŠµë‹ˆë‹¤. í•­ìƒ ì–´ë ¤ì›€ì€ ìˆê¸° ë§ˆë ¨ì´ì£ . í•˜ì§€ë§Œ ì €í¬ëŠ” ë‘ ìë¦¿ìˆ˜ ì£¼ë‹¹ìˆœì´ìµ(EPS) ëª©í‘œì™€ ê±´ì „í•œ ë§ˆì§„ í™•ëŒ€ë¼ëŠ” ë‹¹ì´ˆ ëª©í‘œë¥¼ ë‹¬ì„±í–ˆìŠµë‹ˆë‹¤. <br><br>ì´ë²ˆ ì»¨í¼ëŸ°ìŠ¤ ì½œì—ì„œ íŒŒì´í”„ë¼ì¸ê³¼ ê´€ë ¨í•´ì„œ ë§ì€ ì‹œê°„ì„ í• ì• í–ˆëŠ”ë°ìš”, ì˜¬í•´ ì¶œì‹œí•˜ëŠ” ì œí’ˆë¿ë§Œ ì•„ë‹ˆë¼ 27ë…„ê³¼ 28ë…„ ì¶œì‹œë¥¼ ì¤€ë¹„í•˜ê¸° ìœ„í•´ ì˜¬í•´ íˆ¬ìí•˜ê³  ìˆëŠ” ì œí’ˆë“¤ê¹Œì§€ í¬í•¨í•´ì„œ ì•ìœ¼ë¡œ ì•ˆì •ì ì¸ íŒŒì´í”„ë¼ì¸ íë¦„ì„ í™•ë³´í•˜ëŠ” ê²ƒì— ëŒ€í•´ ë§ì”€ë“œë ¸ìŠµë‹ˆë‹¤. íŒŒì´í”„ë¼ì¸ì€ ë§¤ìš° ìƒì‚°ì ì´ì—ˆë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. <br><br>ê·¸ë¦¬ê³  Exact Sciences ì¸ìˆ˜ ë°œí‘œë¥¼ í†µí•´ Abbottì˜ ë¯¸ë˜ë¥¼ ì„¤ê³„í•˜ëŠ” ë° ìˆì–´ ë§¤ìš° ì¤‘ìš”í•œ ì „ëµì  ì¡°ì¹˜ë¥¼ ì·¨í–ˆìŠµë‹ˆë‹¤. ì´ê²ƒì´ Abbottì— ì™„ì „íˆ ìƒˆë¡œìš´ ì„±ì¥ ì¶•ì„ ë”í•  ê²ƒì´ë¼ê³  ìƒê°í•©ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì•” ì§„ë‹¨ì€ ì‚¬íšŒ, ì¦‰ ê¸€ë¡œë²Œ ì‚¬íšŒì— ë§¤ìš° ì¤‘ìš”í•œ ì„ìƒì , ì˜í•™ì  í•„ìš”ê°€ ë  ê²ƒì…ë‹ˆë‹¤. ë”°ë¼ì„œ ìš°ë¦¬ëŠ” ê·¸ ë¶„ì•¼ì—ì„œ ì¢‹ì€ ìœ„ì¹˜ë¥¼ ì„ ì í•˜ê²Œ ë  ê²ƒì´ë©°, íƒ€ì´ë°ê³¼ ìš°ë¦¬ê°€ ì¤€ë¹„í•œ ëª¨ë“  ê²ƒì— ëŒ€í•´ ê¸ì •ì ìœ¼ë¡œ ìƒê°í•©ë‹ˆë‹¤. 2026ë…„ìœ¼ë¡œ ì „í™˜í•˜ë©´ì„œ ë§ì”€ë“œë¦° ê²ƒì²˜ëŸ¼, ìš°ë¦¬ëŠ” ë†’ì€ í•œ ìë¦¿ìˆ˜ì—ì„œ 10%ëŒ€ê¹Œì§€ ì°¨ë³„í™”ëœ ì„±ì¥ë¥ ì„ ìœ ì§€í•  ë§ì€ ì‚¬ì—…ë“¤ì„ ë³´ìœ í•˜ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ìš°ë¦¬ê°€ ì§„í–‰í•œ íˆ¬ìì™€ ì œí’ˆ ì¶œì‹œë¡œ ì´ë¥¼ ë’·ë°›ì¹¨í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤. ë˜í•œ Core Labì´ë‚˜ ì „ê¸°ìƒë¦¬í•™(Electrophysiology) ì‚¬ì—…ì²˜ëŸ¼ ë³€ê³¡ì ì„ ë§ì´í•˜ê³  ê°€ì†í™”ë  ëŒ€í˜• ì‚¬ì—…ë“¤ë„ ìˆìŠµë‹ˆë‹¤. ì €í¬ê°€ ì—¬ê¸° ì œì‹œí•œ ê³„íšì— ëŒ€í•´ ê¸ì •ì ìœ¼ë¡œ ìƒê°í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë¬¼ë¡  ì €í¬ëŠ” í•­ìƒ ë” ë‚˜ì€ ì„±ê³¼ë¥¼ ë‚´ê¸° ìœ„í•´ ë…¸ë ¥í•˜ê³  ìˆìœ¼ë©°, ê·¸ëŸ´ ìˆ˜ ìˆëŠ” ê¸°íšŒë“¤ë„ ìˆìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ 1ì›” í˜„ì¬ ì‹œì ì—ì„œ ë³´ë©´, ì´ê²ƒì´ ì¢‹ì€ ì¶œë°œì ì´ë¼ê³  ìƒê°í•©ë‹ˆë‹¤. ì´ê²ƒìœ¼ë¡œ ë§ˆë¬´ë¦¬í•˜ê² ìŠµë‹ˆë‹¤. ì°¸ì„í•´ ì£¼ì…”ì„œ ê°ì‚¬í•©ë‹ˆë‹¤.</td></tr>
<tr><td>Michael Comilla: Vice President of Investor Relations. Thank you all for your questions. This now concludes Abbott's conference call. A webcast replay of this call will be available after 11 a.m. Central Time today on our website, abbott.com. Thank you for joining us today.</td><td>**Michael Comilla:** <budget:used_tokens>96</budget:used_tokens><br><br>ì§ˆë¬¸í•´ ì£¼ì…”ì„œ ê°ì‚¬í•©ë‹ˆë‹¤. ì´ê²ƒìœ¼ë¡œ Abbottì˜ ì»¨í¼ëŸ°ìŠ¤ ì½œì„ ë§ˆì¹˜ê² ìŠµë‹ˆë‹¤. ì˜¤ëŠ˜ ì½œì˜ ì›¹ìºìŠ¤íŠ¸ ë¦¬í”Œë ˆì´ëŠ” ì¤‘ë¶€ í‘œì¤€ì‹œ ê¸°ì¤€ ì˜¤ì „ 11ì‹œ ì´í›„ ì €í¬ ì›¹ì‚¬ì´íŠ¸ abbott.comì—ì„œ í™•ì¸í•˜ì‹¤ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì˜¤ëŠ˜ ì°¸ì„í•´ ì£¼ì…”ì„œ ê°ì‚¬í•©ë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Thank you. This concludes today's conference call. Thank you for participating. You may now disconnect. Everyone, have a wonderful day.</td><td>**Operator:** ê°ì‚¬í•©ë‹ˆë‹¤. ì˜¤ëŠ˜ ì»¨í¼ëŸ°ìŠ¤ ì½œì„ ë§ˆì¹˜ê² ìŠµë‹ˆë‹¤. ì°¸ì—¬í•´ ì£¼ì…”ì„œ ê°ì‚¬í•©ë‹ˆë‹¤. ì´ì œ ì—°ê²°ì„ ì¢…ë£Œí•˜ì…”ë„ ë©ë‹ˆë‹¤. ëª¨ë‘ ì¢‹ì€ í•˜ë£¨ ë³´ë‚´ì„¸ìš”.</td></tr>
    </table>
    <h3>ğŸ“Œ ìš”ì•½</h3>
    <p style="background:#f0f0f0; padding:15px; border-left: 5px solid #333;"># Abbott Laboratories ì‹¤ì  ë°œí‘œ ì£¼ìš” ìš”ì•½<br><br>## í•µì‹¬ ì¬ë¬´ ì§€í‘œ ë° ê°€ì´ë˜ìŠ¤<br>- **2026ë…„ ê°€ì´ë˜ìŠ¤**: ë§¤ì¶œ ì„±ì¥ë¥  ì¤‘ê°„ê°’ 7% (ì»¨ì„¼ì„œìŠ¤ 7.5%ë³´ë‹¤ 0.5%p ë‚®ìŒ), EPS ì„±ì¥ë¥  10% (ì»¨ì„¼ì„œìŠ¤ì™€ ì¼ì¹˜)<br>- **2025ë…„ 4Q ì‹¤ì **: ëŒ€ë¶€ë¶„ ì‚¬ì—…ë¶€ë¬¸ì—ì„œ ê²¬ì¡°í•œ ì„±ì¥ì„¸ ìœ ì§€, ì˜ì–‘ì‚¬ì—… ë¶€ë¬¸ ì—­ì„±ì¥ ê¸°ë¡<br>- **ë§ˆì§„ ê°œì„ **: ì—°ê°„ 50-70bpì˜ ì˜ì—…ì´ìµë¥  ê°œì„  ëª©í‘œ ìœ ì§€, ì´ì´ìµë¥  ë° ìš´ì˜ ë ˆë²„ë¦¬ì§€ ê°œì„  ì§€ì†<br><br>## ì£¼ìš” ì‚¬ì—…ë¶€ë¬¸ ë™í–¥<br>- **CGM(ì—°ì†í˜ˆë‹¹ì¸¡ì •) ì‚¬ì—…**: ì—°ê°„ ì•½ 10ì–µ ë‹¬ëŸ¬ ì„±ì¥ ì§€ì†, 2026ë…„ ì €ì‹­ëŒ€ ì¤‘ë°˜ ì„±ì¥ë¥  ì „ë§. ë¹„ì¸ìŠë¦° ì‚¬ìš©ì ë³´í—˜ê¸‰ì—¬ í™•ëŒ€ ê°€ëŠ¥ì„±ì´ ìƒë°© ë¦¬ìŠ¤í¬ ìš”ì¸<br>- **ì „ê¸°ìƒë¦¬í•™(EP) ì‚¬ì—…**: Volt PFA ì¹´í…Œí„° ë¯¸êµ­ ì¶œì‹œ, TactiFlex Duo êµ­ì œ ì¶œì‹œ ì˜ˆì •. ì‹œì¥ ì„±ì¥ë¥ (mid-to-high teens) ìˆ˜ì¤€ì˜ ì„±ì¥ ëª©í‘œ<br>- **ì§„ë‹¨ ì‚¬ì—…**: ì¤‘êµ­ VBP ì—­í’ ëŒ€ë¶€ë¶„ ì†Œì§„, 2026ë…„ mid-single digit ì„±ì¥ ì „ë§ (ì¤‘êµ­ ì œì™¸ ì‹œ 7-8% ì„±ì¥)<br>- **ì˜ì–‘ ì‚¬ì—…**: ê°€ê²© ì¸ìƒìœ¼ë¡œ ì¸í•œ ìˆ˜ìš” ê°ì†Œ ì§ë©´. ê°€ê²©/í”„ë¡œëª¨ì…˜ ì „ëµ ì „í™˜ ì¤‘ì´ë©°, 2ë¶„ê¸°ê¹Œì§€</p>
    <hr style="margin:50px 0;">
    
</body></html>